Inhibitors of fatty acid amide hydrolase

ABSTRACT

The present invention provides compounds, and pharmaceutically acceptable compositions thereof, encompassed by any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof. The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof.

BACKGROUND

Fatty acid amide hydrolase (FAAH), also referred to as oleamidehydrolase and anandamide amidohydrolase, is an integral membrane proteinthat degrades fatty acid primary amides and ethanolamides, includingoleamide and anandamide. FAAH degrades neuromodulating fatty acid amidesat their sites of action and is intimately involved in their regulation.

FAAH has been demonstrated to be involved in a number of biologicalprocesses and its inhibition has been shown to be effective in treatinga variety of conditions. For example, inhibiting FAAH has been shown tobe useful in treating chronic pain, acute pain, neuropathic pain,anxiety, depression, feeding behaviors, movement disorders, glaucoma,neuroprotection and cardiovascular disease. However, current inhibitorsof FAAH lack the target selectivity, biological activity and/orbioavailability needed for in vivo studies and therapeutic use. Thus, todate, the therapeutic potential of FAAH inhibitors remains essentiallyunexplored.

SUMMARY

Compounds described herein, and pharmaceutically acceptable compositionsthereof, are effective inhibitors of fatty acid amide hydrolase (FAAH).Such compounds are encompassed by formula (I):

or pharmaceutically acceptable salts or prodrugs thereof, wherein Z¹,Z², L¹, X, Ring A, R¹, R^(A) and n are as defined herein.

In certain embodiments, Ring A is a C₃₋₁₀ carbocyclyl or C₆₋₁₀ arylgroup. In some embodiments, Ring A is phenyl. In other embodiments, RingA is a 3-10 membered heterocyclyl group or a 5-10 membered heteroarylgroup. In some embodiments, Ring A is monocyclic, while in otherembodiments Ring A is bicyclic.

In certain embodiments, R^(A) is Ring B, i.e., providing compounds whichare encompassed by formula (II):

or pharmaceutically acceptable salts or prodrugs thereof, wherein Z¹,Z², L¹, X, Ring A, Ring B, R¹, R², n and m are as defined herein. Incertain embodiments, Ring B is a 3-10 membered heterocyclyl group or a5-10 membered heteroaryl group. In some embodiments, Ring B ismonocyclic, while in other embodiments Ring B is bicyclic.

Also provided are methods for treating conditions associated withexcessive FAAH activity by administering a therapeutically effectiveamount of a compound provided herein, or a pharmaceutical compositionthereof, to a patient in need thereof.

Also provided are methods for inhibiting FAAH in a patient byadministering a therapeutically effective amount of a compound providedherein, or a pharmaceutically acceptable composition thereof, to apatient in need thereof.

Sequence Identification Numbers SEQ ID NO. 1: Homo Sapiens FAAH AminoAcid Sequence:

MVQYELWAALPGASGVALACCFVAAAVALRWSGRRTARGAVVRARQRQRAGLENMDRAAQRFRLQNPDLDSEALLALPLPQLVQKLHSRELAPEAVLFTYVGKAWEVNKGTNCVTSYLADCETQLSQAPRQGLLYGVPVSLKECFTYVKGQDSTLGLSLNEGVPAECDSVVVHLKLQGAVPFVHTNVPQSMFSYDCSNPLFGQTVNPWKSSKSPGGSSGGEGALIGSGGSPLGLGTDIGGSIRFPSSFCGICGLKPTGNRLSKSGLKGCVYGQEAVRLSVGPMARDVESLALCLRALLCEDMFRLDPTVPPLPFREEVYTSSQPLRVGYYETDNYTMPSPAMRRAVLETKQSLEAAGHTLVPFLPSNIPHALETLSTGGLFSDGGHTFLQNFKGDFVDPCLGDLVSILKLPQWLKGLLAFLVKPLLPRLSAFLSNMKSRSAGKLWELQHEIEVYRKTVIAQWRALDLDVVLTPMLAPALDLNAPGRATGAVSYTMLYNCLDFPAGVVPVTTVTAEDEAQMEHYRGYFGDIWDKMLQKGMKKSVGLPVAVQCVALPWQEELCLRFMREVERLMTPEKQSS

DETAILED DESCRIPTION 1. General Description of Compounds

Provided are inhibitors of FAAH that contain at least one Lewis acidicboron head group, such as, for example, a boronic acid, boronic ester,borinic acid or borinic ester head group. Such compounds includecompounds of formula (I):

or a pharmaceutically acceptable salt or prodrug thereof;wherein:

(i) Z¹ is —OH or —OR³; and Z² is —OH, —OR⁴, an optionally substitutedC₁₋₈ alkyl, optionally substituted C₂₋₈ alkenyl, optionally substitutedC₂₋₈ alkynyl, optionally substituted C₁₋₈ heteroalkyl, optionallysubstituted C₂₋₈ heteroalkenyl, optionally substituted C₂₋₈heteroalkynyl, optionally substituted C₃₋₁₀ carbocyclyl, optionallysubstituted 3-10 membered heterocyclyl, optionally substituted C₆₋₁₀aryl, or optionally substituted 5-10 membered heteroaryl group;

(ii) Z¹ and Z² taken together with the boron atom to which they arebound, form a 5- to 8-membered ring having at least one O, S, N or NR⁵atom directly bonded to the boron atom;

(iii) Z¹ is —OH or —OR³; and Z² and Ring A taken together form anoptionally substituted 5- to 7-membered ring;

L¹ is a covalent bond, an optionally substituted straight or branchedC₁₋₆ alkylene, or an optionally substituted straight or branched C₂₋₆alkenylene moiety;

Ring A is optionally substituted C₃₋₁₀ carbocyclyl, optionallysubstituted 3-10 membered heterocyclyl, optionally substituted C₆₋₁₀aryl, or optionally substituted 5-10 membered heteroaryl;

X is a covalent bond, —O—, —N═N—, —C═N—, —NR⁶—, —C(NR⁶)—, —S—, —C(O)—,—S(O)—, —S(O)₂—, or optionally substituted C₁₋₆ alkylene, wherein one,two or three methylene units of the C₁₋₆ alkylene are optionally andindependently replaced with one or more groups selected from —O—, —N═N—,—C═N—, —NR⁶—, —C(NR⁶)—, —S—, —C(O)—, —S(O)—, and —S(O)₂—;

R^(A) is hydrogen, halogen, —OR⁷, —CF₃, —CN, —NO₂, —SO₂R⁷, —SOR⁷,—C(O)R⁷, —CO₂R⁷, —C(O)N(R⁷)₂, —N₃, —N₂R⁷, —N(R⁷)₂, or Ring B havingformula:

wherein Ring B is optionally substituted C₃₋₁₀ carbocyclyl, optionallysubstituted 3-10 membered heterocyclyl, optionally substituted C₆₋₁₀aryl, or optionally substituted 5-10 membered heteroaryl;

each instance of R¹ is, independently, halogen, —OR⁸, —CF₃, —CN, —NO₂,—SO₂R⁸, —SOR⁸, —C(O)R⁸, —CO₂R⁸, —C(O)N(R⁸)₂, —N₃, —N₂R⁸, —N(R⁸)₂,—B(OH₂), optionally substituted C₁₋₈ alkyl, optionally substituted C₂₋₈alkenyl, optionally substituted C₂₋₈ alkynyl, optionally substitutedC₁₋₈ heteroalkyl, optionally substituted C₂₋₈ heteroalkenyl, optionallysubstituted C₂₋₈ heteroalkynyl, optionally substituted C₃₋₁₀carbocyclyl, optionally substituted 3-10 membered heterocyclyl,optionally substituted C₆₋₁₀ aryl, or optionally substituted 5-10membered heteroaryl;

each instance of R² is, independently, halogen, —OR⁹, —CF₃, —CN, —NO₂,—SO₂R⁹, —SOR⁹, —C(O)R⁹, —CO₂R⁹, —C(O)N(R⁹)₂, —N₃, —N₂R⁹, —N(R⁹)₂,optionally substituted C₁₋₈ alkyl, optionally substituted C₂₋₈ alkenyl,optionally substituted C₂₋₈ alkynyl, optionally substituted C₁₋₈heteroalkyl, optionally substituted C₂₋₈ heteroalkenyl, optionallysubstituted C₂₋₈ heteroalkynyl, optionally substituted C₃₋₁₀carbocyclyl, optionally substituted 3-10 membered heterocyclyl,optionally substituted C₆₋₁₀ aryl, or optionally substituted 5-10membered heteroaryl;

each instance of R³ and R⁴ is, independently, optionally substitutedC₁₋₈ alkyl, optionally substituted C₂₋₈ alkenyl, optionally substitutedC₂₋₈ alkynyl, optionally substituted C₁₋₈ heteroalkyl, optionallysubstituted C₂₋₈ heteroalkenyl, optionally substituted C₂₋₈heteroalkynyl, optionally substituted C₃₋₁₀ carbocyclyl, optionallysubstituted 3-10 membered heterocyclyl, optionally substituted C₆₋₁₀aryl, or optionally substituted 5-10 membered heteroaryl;

each instance of R⁵, R⁶, R⁷, R⁸, R⁹, and R¹⁰ is, independently,hydrogen, —SO₂R¹¹, —SOR¹¹, —C(O)R¹¹, —CO₂R¹¹, —C(O)N(R¹¹)₂,—C(O)NH(R¹¹), —C(O)NH₂, optionally substituted C₁₋₈ alkyl, optionallysubstituted C₂₋₈ alkenyl, optionally substituted C₂₋₈ alkynyl,optionally substituted C₁₋₈ heteroalkyl, optionally substituted C₂₋₈heteroalkenyl, optionally substituted C₂₋₈ heteroalkynyl, optionallysubstituted C₃₋₁₀ carbocyclyl, optionally substituted 3-10 memberedheterocyclyl, optionally substituted C₆₋₁₀ aryl, or optionallysubstituted 5-10 membered heteroaryl;

each instance of R¹¹ is, independently, optionally substituted C₁₋₈alkyl, optionally substituted C₂₋₈ alkenyl, optionally substituted C₂₋₈alkynyl, optionally substituted C₁₋₈ heteroalkyl, optionally substitutedC₂₋₈ heteroalkenyl, optionally substituted C₂₋₈ heteroalkynyl,optionally substituted C₃₋₁₀ carbocyclyl, optionally substituted 3-10membered heterocyclyl, optionally substituted C₆₋₁₀ aryl, or optionallysubstituted 5-10 membered heteroaryl;

n is 0, 1, 2 or 3; and

m is 0, 1, 2, 3, 4 or 5.

In certain embodiments, R^(A) is Ring B, i.e., compounds encompassed byformula (II):

or a pharmaceutically acceptable salt or prodrug thereof, wherein Z¹,Z², L¹, X, Ring A, Ring B, R¹, R², n and m are as defined herein.

In certain embodiments, Ring A is a C₃₋₁₀ carbocyclyl or C₆₋₁₀ arylgroup. In some embodiments, Ring A is phenyl. In other embodiments, RingA is a 3-10 membered heterocyclyl group or a 5-10 membered heteroarylgroup. In some embodiments, Ring A is monocyclic, while in otherembodiments Ring A is bicyclic.

In certain embodiments, Ring B is a 3-10 membered heterocyclyl group ora 5-10 membered heteroaryl group. In some embodiments, Ring B ismonocyclic, while in other embodiments Ring B is bicyclic. For example,in certain embodiments, Ring B is a 5-6 membered monocyclic heteroarylgroup, while in other embodiments, Ring B is a 9-10 membered bicyclicheteroaryl group.

2. Compounds and Definitions

Definitions of specific functional groups and chemical terms aredescribed in more detail below. The chemical elements are identified inaccordance with the Periodic Table of the Elements, CAS version,Handbook of Chemistry and Physics, 75^(th) Ed., inside cover, andspecific functional groups are generally defined as described therein.Additionally, general principles of organic chemistry, as well asspecific functional moieties and reactivity, are described in OrganicChemistry, Thomas Sorrell, University Science Books, Sausalito, 1999;Smith and March March's Advanced Organic Chemistry, 5^(th) Edition, JohnWiley & Sons, Inc., New York, 2001; Larock, Comprehensive OrganicTransformations, VCH Publishers, Inc., New York, 1989; and Carruthers,Some Modern Methods of Organic Synthesis, 3^(rd) Edition, CambridgeUniversity Press, Cambridge, 1987.

Certain compounds of the present invention can comprise one or moreasymmetric centers, and thus can exist in various isomeric forms, e.g.,stereoisomers and/or diastereomers. Thus, provided compounds, andpharmaceutically acceptable compositions thereof, may be in the form ofan individual enantiomer, diastereomer or geometric isomer, or may be inthe form of a mixture of stereoisomers. In certain embodiments, thecompounds of the invention are enantiopure compounds. In certain otherembodiments, mixtures of stereoisomers or diastereomers are provided.

Furthermore, certain compounds, as described herein may have one or moredouble bonds that can exist as either the Z or E isomer, unlessotherwise indicated. The invention additionally encompasses thecompounds as individual isomers substantially free of other isomers and,alternatively, as mixtures of various isomers, e.g., racemic mixtures ofstereoisomers.

Where a particular enantiomer is preferred, it may, in some embodimentsbe provided substantially free of the corresponding enantiomer, and mayalso be referred to as “optically enriched.” “Optically-enriched,” asused herein, means that the compound is made up of a significantlygreater proportion of one enantiomer. In certain embodiments thecompound is made up of at least about 90% by weight of a preferredenantiomer. In other embodiments the compound is made up of at leastabout 95%, 98%, or 99% by weight of a preferred enantiomer. Preferredenantiomers may be isolated from racemic mixtures by any method known tothose skilled in the art, including chiral high pressure liquidchromatography (HPLC) and the formation and crystallization of chiralsalts or prepared by asymmetric syntheses. See, for example, Jacques, etal., Enantiomers, Racemates and Resolutions (Wiley Interscience, NewYork, 1981); Wilen, S. H., et al., Tetrahedron 33:2725 (1977); Eliel, E.L. Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); andWilen, S. H. Tables of Resolving Agents and Optical Resolutions p. 268(E. L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, Ind. 1972).

When a range of values is listed, it is intended to encompass each valueand sub-range within the range. For example “C₁₋₆ alkyl” is intended toencompass, C₁, C₂, C₃, C₄, C₅, C₆, C₁₋₆, C₁₋₅, C₁₋₄, C₁₋₃, C₁₋₂, C₂₋₆,C₂₋₅, C₂₋₄, C₂₋₃, C₃₋₆, C₃₋₅, C₃₋₄, C₄₋₆, C₄₋₅, C₅₋₆ alkyl.

As used herein a “direct bond” or “covalent bond” refers to a singlebond.

As used herein, the term “boronic acid” refers to any chemical compoundcomprising a —B(OH)₂ moiety. Arylboronic acid compounds readily formoligomeric anhydrides by dehydration of the boronic acid moiety (see,for example, Snyder et al., J. Am. Chem. Soc. (1958) 80: 3611). Thus,unless otherwise apparent from context, the term “boronic acid” isexpressly intended to encompass free boronic acids, oligomericanhydrides, including, but not limited to, dimers, trimers, andtetramers, and mixtures thereof.

The terms “boronic ester”, “borinic acid” and “borinic ester” are artunderstood terms referring to a —B(OR)₂ moiety, a —B(R)OH moiety and a—B(R)OR moiety, respectively, wherein R is a group other than hydrogen(e.g., for example, an optionally substituted C₁₋₈ alkyl, optionallysubstituted C₂₋₈ alkenyl, optionally substituted C₂₋₈ alkynyl,optionally substituted C₁₋₈ heteroalkyl, optionally substituted C₂₋₈heteroalkenyl, optionally substituted C₂₋₈ heteroalkynyl, optionallysubstituted C₃₋₁₀ carbocycyl, optionally substituted 3-10 memberedheterocycyl, optionally substituted C₆₋₁₀ aryl, or optionallysubstituted 5-10 membered heteroaryl group, or two R groups are joinedto form a 5- to 8-membered ring optionally containing 1 to 4 heteroatomsselected from optionally substituted nitrogen, oxygen or sulfur).

As used herein, alone or as part of another group, “halo” and “halogen”refer to fluorine (fluoro, —F), chlorine (chloro, —Cl), bromine (bromo,—Br), or iodine (iodo, —I).

As used herein, alone or as part of another group, “alkyl” refers to amonoradical of a straight-chain or branched saturated hydrocarbon grouphaving from 1 to 8 carbon atoms (“C₁₋₈ alkyl”). In some embodiments, analkyl group can have from 1 to 6 carbon atoms (“C₁₋₆ alkyl”). In someembodiments, an alkyl group can have from 1 to 4 carbon atoms (“C₁₋₄alkyl”). Examples of C₁₋₄ alkyl groups include methyl, ethyl, propyl,isopropyl, butyl, isobutyl, sec-butyl and tert-butyl. Examples of C₁₋₆alkyl groups include the aforementioned C₁₋₄ alkyl groups as well aspentyl, isopentyl, neopentyl, hexyl and the like. Additional examples ofalkyl groups include heptyl, octyl and the like. Unless otherwisespecified, each instance of an “optionally substituted” alkyl group isindependently unsubstituted or substituted with 1-5 groups as describedbelow.

As used herein, alone or as part of another group, “alkenyl” refers to amonoradical of a straight-chain or branched hydrocarbon group havingfrom 2 to 8 carbon atoms and one or more carbon-carbon double bonds(“C₂₋₈ alkenyl”). In some embodiments, an alkenyl group can have from 2to 6 carbon atoms (“C₂₋₆ alkenyl”). In some embodiments, an alkenylgroup can have from 2 to 4 carbon atoms (“C₂₋₄ alkenyl”). The one ormore carbon-carbon double bonds can be internal (such as in 2-butenyl)or terminal (such as in 1-butenyl). Examples of C₂₋₄ alkenyl groupsinclude ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl,butadienyl and the like. Examples of C₂₋₆ alkenyl groups include theaforementioned C₂₋₄ alkenyl groups as well as pentenyl, pentadienyl,hexenyl and the like. Additional examples of alkenyl include heptenyl,octenyl, octatrienyl and the like. Unless otherwise specified, eachinstance of an “optionally substituted” alkenyl group is independentlyunsubstituted or substituted with 1-5 groups as described below.

As used herein, alone or as part of another group, “alkynyl” refers to amonoradical of a straight-chain or branched hydrocarbon group havingfrom 2 to 8 carbon atoms and one or more carbon-carbon triple bonds(“C₂₋₈ alkynyl”). In some embodiments, an alkynyl group can have from 2to 6 carbon atoms (“C₂₋₆ alkynyl”). In some embodiments, an alkynylgroup can have from 2 to 4 carbon atoms (“C₂₋₄ alkynyl”). The one ormore carbon-carbon triple bonds can be internal (such as in 2-butynyl)or terminal (such as in 1-butynyl). Examples of C₂₋₄ alkynyl groupsinclude ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl and thelike. Examples of C₂₋₆ alkenyl groups include the aforementioned C₂₋₄alkynyl groups as well as pentynyl, hexynyl and the like. Additionalexamples of alkynyl include heptynyl, octynyl and the like. Unlessotherwise specified, each instance of an “optionally substituted”alkynyl group is independently unsubstituted or substituted with 1-5groups as described below.

As used herein, alone or as part of another group, “heteroalkyl” refersto an alkyl group, as defined herein, wherein one or more carbon atomsare replaced with one or more heteroatoms selected from optionallysubstituted nitrogen, oxygen and sulfur. For example, “heteroalkyl”refers to a monoradical of a straight-chain or branched hydrocarbongroup having from 1 to 8 carbon atoms and one or more heteroatoms (“C₁₋₈heteroalkynyl”). Unless otherwise specified, each instance of an“optionally substituted” heteroalkyl group is independentlyunsubstituted or substituted with 1-5 groups as described below.

As used herein, alone or as part of another group, “heteroalkenyl”refers to an alkenyl group, as defined herein, wherein one or morecarbon atoms are replaced with one or more heteroatoms selected fromoptionally substituted nitrogen, oxygen and sulfur. For example,“heteroalkenyl” refers to a monoradical of a straight-chain or branchedhydrocarbon group having from 2 to 8 carbon atoms, one or morecarbon-carbon double bonds, and one or more heteroatoms (“C₂₋₈heteroalkenyl”). Unless otherwise specified, each instance of an“optionally substituted” heteroalkenyl group is independentlyunsubstituted or substituted with 1-5 groups as described below.

As used herein, alone or as part of another group, “heteroalkynyl”refers to an alkynyl group, as defined herein, wherein one or morecarbon atoms are replaced with one or more heteroatoms selected fromoptionally substituted nitrogen, oxygen and sulfur. For example,“heteroalkynyl” refers to a monoradical of a straight-chain or branchedhydrocarbon group having from 2 to 8 carbon atoms, one or morecarbon-carbon triple bonds, and one or more heteroatoms (“C₂₋₈heteroalkynyl”). Unless otherwise specified, each instance of an“optionally substituted” heteroalkynyl group is independentlyunsubstituted or substituted with 1-5 groups as described below.

As used herein, alone or as part of another group, “alkylene” refers toa diradical of a straight-chain or branched saturated hydrocarbon grouphaving from 1 to 6 carbon atoms (“C₁₋₆ alkylene”). In some embodiments,an alkylene group can have from 1 to 4 carbon atoms (“C₁₋₄ alkylene”).In some embodiments, an alkylene group can have from 1 to 2 carbon atoms(“C₁₋₂ alkylene”). Examples of C₁₋₂ alkylene groups include methyleneand ethylene. Examples of C₁₋₄ alkylene groups include theaforementioned C₁₋₂ alkylene groups as well as trimethylene(1,3-propanediyl), propylene (1,2-propanediyl), tetramethylene(1,4-butanediyl), butylene (1,2-butanediyl), 1,3-butanediyl,2-methyl-1,3-propanediyl and the like. Examples of C₁₋₆ alkylene groupsinclude the aforementioned C₁₋₄ alkylene groups as well aspentamethylene (1,5-pentanediyl), pentylene (1,2-pentanediyl),hexamethylene (1,6-hexanediyl), hexylene (1,2-hexanediyl),2,3-dimethyl-1,4-butanediyl and the like. In some embodiments, analkylene group is an α,ω-diradical. Examples of α,ω-diradical alkylenegroups include methylene, ethylene, trimethylene, tetramethylene,pentamethylene and hexamethylene.

As used herein, alone or as part of another group, “alkenylene” refersto a diradical of a straight-chain or branched hydrocarbon group havingfrom 2 to 6 carbon atoms and one or more carbon-carbon double bonds(“C₂₋₆ alkenylene”). In some embodiments, an alkenylene group can havefrom 2 to 4 carbon atoms (“C₂₋₄ alkenylene”). In some embodiments, analkenylene group can have 2 carbon atoms, i.e., ethenediyl. The one ormore carbon-carbon double bonds can be internal (such as in1,4-but-2-enediyl) or terminal (such as in 1,4-but-1-enediyl). Examplesof C₂₋₄ alkenylene groups include ethenediyl, 1,2-propenediyl,1,3-propenediyl, 1,4-but-1-enediyl, 1,4-but-2-enediyl and the like.Examples of C₂₋₆ alkenylene groups include the aforementioned C₂₋₄alkenylene groups as well as 1,5-pent-1-enediyl, 1,4-pent-2-enediyl,1,6-hex-2-enediyl, 2,5-hex-3-enediyl, 2-methyl-1,4-pent-2-enediyl andthe like. In some embodiments, an alkenylene group is an α,ω-diradical.Examples of α,ω-diradical alkenylene groups include ethenediyl,1,3-propenediyl, 1,4-but-2-enediyl, 1,5-pent-1-enediyl,1,6-hex-3-enediyl and the like.

As used herein, alone or as part of another group, “alkynylene” refersto a diradical of a straight-chain or branched hydrocarbon group havingfrom 2 to 6 carbon atoms and one or more carbon-carbon triple bonds(“C₂₋₆ alkynylene”). In some embodiments, an alkynylene group can havefrom 2 to 4 carbon atoms (“C₂₋₄ alkynylene”). In some embodiments, analkynylene group can have 2 carbon atoms, i.e., ethynediyl. The one ormore carbon-carbon triple bonds can be internal (such as in1,4-but-2-ynediyl) or terminal (such as in 1,4-but-1-ynediyl). Examplesof C₂₋₄ alkynylene groups include ethynediyl, propynediyl,1,4-but-1-ynediyl, 1,4-but-2-ynediyl and the like. Examples of C₂₋₆alkynylene groups include the aforementioned C₂₋₄ alkynylene groups aswell as 1,5-pent-1-ynediyl, 1,4-pent-2-ynediyl, 1,6-hex-2-ynediyl,2,5-hex-3-ynediyl, 3-methyl-1,5-hex-1-ynediyl and the like. In someembodiments, an alkynylene group is an α,ω-diradical. Examples ofα,ω-diradical alkynylene groups include ethynediyl, propynediyl,1,4-but-2-ynediyl, 1,5-pent-1-ynediyl, 1,6-hex-3-ynediyl and the like.

As used herein, alone or as part of another group, “perhaloalkyl” refersto an alkyl group having from 1 to 3 carbon atoms, wherein all of thehydrogen atoms are each independently replaced with fluoro or chloro. Insome embodiments, all of the hydrogen atoms are each replaced withfluoro. In some embodiments, all of the hydrogen atoms are each replacedwith chloro. Examples of perhaloalkyl groups include —CF₃, —CF₂CF₃,—CF₂CF₂CF₃, —CCl₃, —CFCl₂, —CF₂Cl and the like.

As used herein, alone or as part of another group, “alkoxy” or“alkyloxy” refers to an —O-alkyl group having from 1 to 8 carbon atoms(“C₁₋₈ alkoxy”). In some embodiments, an alkoxy group can have from 1 to6 carbon atoms (“C₁₋₆ alkoxy”). In some embodiments, an alkoxy group canhave from 1 to 4 carbon atoms (“C₁₋₄ alkoxy”). Examples of C₁₋₄ alkoxygroups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxyand the like. Examples of C₁₋₆ alkoxy groups include the aforementionedC₁₋₄ alkoxy groups as well as pentyloxy, isopentyloxy, neopentyloxy,hexyloxy and the like. Additional examples of alkoxy groups includeheptyloxy, octyloxy and the like. Unless otherwise specified, eachinstance of an “optionally substituted” alkoxy group is independentlyunsubstituted or substituted with 1-5 groups as described below.

As used herein, alone or as part of another group, “perhaloalkoxy”refers to an alkoxy group having from 1 to 3 carbon atoms, wherein allof the hydrogen atoms are each independently replaced with fluoro orchloro. In some embodiments, all of the hydrogen atoms are each replacedwith fluoro. In some embodiments, all of the hydrogen atoms are eachreplaced with chloro. Examples of perhaloalkoxy groups include —OCF₃,—OCF₂CF₃, —OCF₂CF₂CF₃, —OCCl₃, —OCFCl₂, —OCF₂Cl and the like.

As used herein, alone or as part of another group, “alkylthio” refers toan —S-alkyl group having from 1 to 8 carbon atoms. In some embodiments,an alkylthio group can have from 1 to 6 carbon atoms. In someembodiments, an alkylthio group can have from 1 to 4 carbon atoms.Examples of C₁₋₄ alkylthio groups include methylthio, ethylthio,propylthio, isopropylthio, butylthio, isobutylthio and the like.Examples of C₁₋₆ alkylthio groups include the aforementioned C₁₋₄alkylthio groups as well as pentylthio, isopentylthio, hexylthio and thelike. Additional examples of alkylthio groups include heptylthio,octylthio and the like. Unless otherwise specified, each instance of an“optionally substituted” alkylthio group is independently unsubstitutedor substituted with 1-5 groups as described below.

As used herein, alone or as part of another group, “carbocyclyl” or“carbocycle” refers to a radical of a non-aromatic cyclic hydrocarbongroup having from 3 to 10 ring carbon atoms (“C₃₋₁₀ carbocyclyl”). Insome embodiments, a carbocyclyl group can have from 3 to 8 ring carbonatoms (“C₃₋₈ carbocyclyl”). In some embodiments, a carbocyclyl group canhave from 3 to 6 ring carbon atoms (”C₃₋₆ carbocyclyl”). Examples ofC₃₋₆ carbocyclyl groups include cyclopropyl, cyclobutyl, cyclopentyl,cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl and the like.Examples of C₃₋₈ carbocyclyl groups include the aforementioned C₃₋₆carbocyclyl groups as well as cycloheptyl, cycloheptadienyl,cycloheptatrienyl, cyclooctyl, bicyclo[2.2.1]heptanyl,bicyclo[2.2.2]octanyl and the like. Examples of C₃₋₁₀ carbocyclyl groupsinclude the aforementioned C₃₋₈ carbocyclyl groups as well asoctahydro-1H-indenyl, decahydronaphthalenyl, spiro[4.5]decanyl and thelike. As the foregoing examples illustrate, in some embodiments acarbocyclyl group can be monocyclic (“monocyclic carbocyclyl”) orbicyclic (e.g., containing a fused, bridged or spiro ring system), andcan be saturated or can contain one or more carbon-carbon double ortriple bonds. “Carbocyclyl” also refers to a phenyl group (as definedbelow) fused to a monocyclic carbocyclyl group. Examples of suchcarbocyclyl groups include 1,2,3,4-tetrahydronaphthalene (e.g.,1,2,3,4-tetrahydronaphthalen-1-yl, 1,2,3,4-tetrahydronaphthalen-5-yl,and the like), 2,3-dihydro-1H-indene (e.g., 2,3-dihydro-1H-inden-1-yl,2,3-dihydro-1H-inden-4-yl, and the like), indene (e.g., 1H-inden-1-yl,1H-inden-7-yl, and the like), 5,6,7,8-tetrahydroquinoline (e.g.,5,6,7,8-tetrahydroquinolin-5-yl, 5,6,7,8-tetrahydroquinolin-2-yl, andthe like), 4,5,6,7-tetrahydro-1H-indole (e.g.,4,5,6,7-tetrahydro-1H-indol-4-yl, 4,5,6,7-tetrahydro-1H-indol-3-yl, andthe like), 4,5,6,7-tetrahydrobenzofuran (e.g.,4,5,6,7-tetrahydrobenzofuran-7-yl, 4,5,6,7-tetrahydrobenzofuran-2-yl,and the like) and the like. Unless otherwise specified, each instance ofan “optionally substituted” carbocyclyl or carbocycle group isindependently unsubstituted or substituted with 1-5 groups as describedbelow.

In some embodiments, “carbocyclyl” or “carbocycle” can refer to amonocyclic, saturated carbocyclyl group (“cycloalkyl”) having from 3 to8 ring carbon atoms (“C₃₋₈ cycloalkyl”). In some embodiments, acycloalkyl group can have from 3 to 6 ring carbon atoms (“C₃₋₆cycloalkyl”). In some embodiments, a cycloalkyl group can have from 5 to6 ring carbon atoms (“C₅₋₆ cycloalkyl”). Examples of C₅₋₆ cycloalkylgroups include cyclopentyl and cyclohexyl. Examples of C₃₋₆ cycloalkylgroups include the aforementioned C₅₋₆ cycloalkyl groups as well ascyclopropyl and cyclobutyl. Examples of C₃₋₈ cycloalkyl groups includethe aforementioned C₃₋₆ cycloalkyl groups as well as cycloheptyl andcyclooctyl. Unless otherwise specified, each instance of an “optionallysubstituted” cycloalkyl group is independently unsubstituted orsubstituted with 1-5 groups as described below.

As used herein, alone or as part of another group, “heterocyclyl” or“heterocycle” refers to a radical of a 3- to 10-membered non-aromaticring system having ring carbon atoms and 1 to 4 ring heteroatoms, eachheteroatom independently selected from optionally substituted nitrogen,oxygen and sulfur. In some embodiments, a heterocyclyl group can havefrom 3 to 7 ring atoms selected from carbon atoms and 1 to 3heteroatoms, each heteroatom independently selected from optionallysubstituted nitrogen, oxygen and sulfur. In some embodiments, aheterocyclyl group can have from 5 to 7 ring atoms selected from carbonatoms and 1 or 2 heteroatoms, each heteroatom independently selectedfrom nitrogen, oxygen and sulfur. In some embodiments, a heterocyclylgroup can have from 5 to 6 ring atoms selected from carbon atoms and 1to 3 heteroatoms, each heteroatom independently selected from optionallysubstituted nitrogen, oxygen and sulfur.

In heterocyclyl groups that contain one or more optionally substitutednitrogen atoms, the point of attachment can be a carbon or theoptionally substituted nitrogen atom, as valency permits. Examples ofheterocyclyl groups with 1-2 ring heteroatoms include oxiranyl,aziridinyl, oxetanyl, azetidinyl, pyrrolidinyl, dihydropyrrolyl,tetrahydrofuranyl, dihydrofuranyl, dioxolanyl, tetrahydrothiophenyl,dihydrothiophenyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl,isoxazolidinyl, thiazolidinyl, piperidinyl, tetrahydropyridinyl,dihydropyridinyl, piperazinyl, tetrahydropyranyl, dioxanyl, morpholinyl,azepanyl, diazepanyl, diazepinyl, oxepanyl, dioxepanyl, oxazepanyl,oxazepinyl and the like. Examples of heterocyclyl groups with 1-3heteroatoms include the aforementioned heterocyclyl groups as well astriazolidinyl, oxadiazolidinyl, triazinanyl and the like. Heterocycylgroups can be monocyclic (as in the aforementioned examples), bicyclic,or tricyclic. Bicyclic heterocyclyl groups can include one or moreheteroatoms in one or both rings. Examples of such heterocyclyl groupsinclude tetrahydroindolyl, decahydroquinolinyl, decahydroisoquinolinyl,octahydrochromenyl, octahydroisochromenyl, decahydronaphthyridinyl,decahydro-1,8-naphthyridinyl, octahydropyrrolo[3,2-b]pyrrole and thelike.

“Heterocyclyl” or “heterocycle” also refers to a radical of a 5- to10-membered fused ring system having ring carbon atoms and 1 to 4 ringheteroatoms, each heteroatom independently selected from nitrogen,oxygen and sulfur, wherein one ring is aromatic and the other isnon-aromatic. In some embodiments, at least one heteroatom is present ineither the aromatic or non-aromatic ring, while in other embodiments, atleast one heteroatom is present in both rings. In heterocyclyl groupsthat contain one or more optionally substituted nitrogen atoms, thepoint of attachment can be a carbon or nitrogen atom, as valencypermits. Examples of such heterocyclyl groups include indolinyl (e.g.,indolin-1-yl, indolin-4-yl, and the like), isoindolinyl (e.g.,isoindolin-1-yl, isoindolin-4-yl, and the like),4,5,6,7-tetrahydro-1H-indolyl (e.g., tetrahydro-1H-indol-2-yl,4,5,6,7-tetrahydro-1H-indol-4-yl, and the like), dihydrobenzofuranyl(e.g., dihydrobenzofuran-3-yl, dihydrobenzofuran-5-yl, and the like),4,5,6,7-tetrahydrobenzofuranyl (e.g., 4,5,6,7-tetrahydrobenzofuran-2-yl,4,5,6,7-tetrahydrobenzofuran-5-yl, and the like), dihydrobenzothienyl(e.g., dihydrobenzothien-2-yl, dihydrobenzothien-4-yl, and the like),4,5,6,7-tetrahydrobenzothiophenyl (e.g.,4,5,6,7-tetrahydrobenzothiophen-2-yl,4,5,6,7-tetrahydrobenzothiophen-7-yl, and the like),1,2,3,4-tetrahydroquinolinyl (e.g., 1,2,3,4-tetrahydroquinolin-1-yl,1,2,3,4-tetrahydroquinolin-7-yl, and the like), chromanyl (e.g.,chroman-2-yl, chroman-5-yl, and the like), chromenyl (chromen-4-yl,chromen-8-yl, and the like), thiochromanyl (e.g., thiochroman-3-yl,isochroman-7-yl, and the like), 1H-benzo[e][1,4]diazepinyl (e.g.,1H-benzo[e][1,4]diazepin-2-yl, 1H-benzo[e][1,4]diazepin-6-yl, and thelike), 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl (e.g.,2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl,2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl, and the like),4,5,6,7-tetrahydro-1H-pyrrolo[2,3-b]pyridinyl (e.g.,4,5,6,7-tetrahydro-1H-pyrrolo-[2,3-b]pyridin-2-yl,4,5,6,7-tetrahydro-1H-pyrrolo[2,3-b]pyridin-4-yl, and the like),1,4,5,7-tetrahydropyrano[3,4-b]pyrrolyl (e.g.,1,4,5,7-tetrahydropyrano[3,4-b]pyrrol-2-yl,1,4,5,7-tetrahydropyrano[3,4-b]pyrrol-4-yl, and the like),2,3-dihydrofuro[2,3-b]pyridinyl (e.g.,2,3-dihydrofuro[2,3-b]pyridin-3-yl, 2,3-dihydrofuro[2,3-b]pyridin-5-yl,and the like), 4,5,6,7-tetrahydrofuro[3,2-c]pyridinyl (e.g.,4,5,6,7-tetrahydrofuro[3,2-c]pyridin-2-yl,4,5,6,7-tetrahydrofuro[3,2-c]pyridin-5-yl, and the like),4,5,6,7-tetrahydrothieno[3,2-b]pyridinyl (e.g.,4,5,6,7-tetrahydrothieno[3,2-b]pyridin-2-yl,4,5,6,7-tetrahydrothieno[3,2-b]pyridin-7-yl, and the like),5,6-dihydro-4H-furo[3,2-b]pyrrolyl (e.g.,5,6-dihydro-4H-furo[3,2-b]pyrrol-6-yl,5,6-dihydro-4H-furo[3,2-b]pyrrol-2-yl, and the like),6,7-dihydro-5H-furo[3,2-b]pyranyl (e.g.,6,7-dihydro-5H-furo[3,2-b]pyran-2-yl,6,7-dihydro-5H-furo[3,2-b]pyran-6-yl, and the like),5,7-dihydro-4H-thieno[2,3-c]pyranyl (e.g.,5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl,5,7-dihydro-4H-thieno[2,3-c]pyran-4-yl, and the like),1,2,3,4-tetrahydro-1,6-naphthyridinyl (e.g.,1,2,3,4-tetrahydro-1,6-naphthyridin-3-yl,1,2,3,4-tetrahydro-1,6-naphthyridin-8-yl, and the like), and the like.

Unless otherwise specified, each instance of an “optionally substituted”heterocyclyl group is independently unsubstituted or substituted with1-5 groups as described below.

As used herein, alone or as part of another group, “aryl” refers to aradical of an aromatic monocyclic or bicyclic ring system having 6 or 10ring carbon atoms. Examples of such aryl groups include phenyl,1-naphthyl and 2-naphthyl. Unless otherwise specified, each instance ofan “optionally substituted” aryl group is independently unsubstituted orsubstituted with 1-5 groups as described below.

The term “aralkyl” refers to an alkyl group substituted by an arylgroup, wherein the alkyl and aryl portions independently are optionallysubstituted as described below.

As used herein, alone or as part of another group, “heteroaryl” refersto a radical of a 5- to 10-membered aromatic ring system having ringcarbon atoms and 1 to 4 ring heteroatoms, each heteroatom independentlyselected from optionally substituted nitrogen, oxygen and sulfur.Examples of such heteroaryl groups include pyrrolyl, furanyl (furyl),thiophenyl (thienyl), pyrazolyl, imidazolyl, oxazolyl, isoxazolyl,thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl(pyridyl), pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl,benzofuranyl, benzothiophenyl (benzothienyl), indazolyl, benzimidazolyl,benzoxazolyl, benzisoxazolyl, benzothiazolyl, quinolinyl, isoquinolinyl,cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, naphthyridinyl andthe like. As the foregoing examples illustrate, in some embodiments aheteroaryl group can be monocyclic (“monocyclic heteroaryl”), and insome embodiments a heteroaryl group can be bicyclic (“bicyclicheteroaryl”). For bicyclic heteroaryl groups wherein one ring does notcontain a heteroatom (e.g., indolyl, quinolinyl, and the like) the pointof attachment may be on either ring, i.e., either the ring bearing aheteroatom (e.g., 2-indolyl) or the ring that does not contain aheteroatom (e.g., 5-indolyl). Unless otherwise specified, each instanceof an “optionally substituted” heteroaryl group is independentlyunsubstituted or substituted with 1-5 groups as described below.

The term “heteroaralkyl” refers to an alkyl group substituted by aheteroaryl group, wherein the alkyl and heteroaryl portionsindependently are optionally substituted as described below.

As used herein, the term “partially unsaturated” refers to a ring moietythat includes at least one double or triple bond. The term “partiallyunsaturated” is intended to encompass rings having multiple sites ofunsaturation, but is not intended to include aryl or heteroarylmoieties, as herein defined.

As described herein, compounds of the invention may contain “optionallysubstituted” moieties. In general, the term “substituted”, whetherpreceded by the term “optionally” or not, means that one or morehydrogens of the designated moiety are replaced with a suitablesubstituent. Unless otherwise indicated, an “optionally substituted”group may have a suitable substituent at each substitutable position ofthe group, and when more than one position in any given structure may besubstituted with more than one substituent selected from a specifiedgroup, the substituent may be either the same or different at everyposition. Combinations of substituents envisioned by this invention arepreferably those that result in the formation of stable or chemicallyfeasible compounds. The term “stable”, as used herein, refers tocompounds that are not substantially altered when subjected toconditions to allow for their production, detection, and, in certainembodiments, their recovery, purification, and use for one or more ofthe purposes disclosed herein.

Suitable monovalent substituents on a carbon atom of an “optionallysubstituted” group are independently halogen; —(CH₂)₀₋₄R^(∘);—(CH₂)₀₋₄OR^(∘); —O—(CH₂)₀₋₄C(O)OR^(∘); —(CH₂)₀₋₄CH(OR^(∘))₂;—(CH₂)₀₋₄SR^(∘); —(CH₂)₀₋₄Ph, which may be substituted with one or moreR^(∘); —(CH₂)₀₋₄O(CH₂)₀₋₁Ph which may be substituted with R^(∘);—CH═CHPh, which may be substituted with one or more R^(∘); —NO₂; —CN;—N₃; —(CH₂)₀₋₄N(R^(∘))₂; —(CH₂)₀₋₄N(R^(∘))C(O)R^(∘); —N(R^(∘))C(S)R^(∘);—(CH₂)₀₋₄N(R^(∘))C(O)NR^(∘) ₂; —N(R^(∘))C(S)NR^(∘) ₂;—(CH₂)₀₋₄N(R^(∘))C(O)OR^(∘); —N(R^(∘))N(R^(∘))C(O)R^(∘);—N(R^(∘))N(R^(∘))C(O)NR^(∘) ₂; —N(R^(∘))N(R^(∘))C(O)OR^(∘);—(CH₂)₀₋₄C(O)R^(∘); —C(S)R^(∘); —(CH₂)₀₋₄C(O)OR^(∘);—(CH₂)₀₋₄C(O)SR^(∘); —(CH₂)₀₋₄C(O)OSiR^(∘) ₃; —(CH₂)₀₋₄OC(O)R^(∘);—OC(O)(CH₂)₀₋₄SR, SC(S)SR^(∘); —(CH₂)₀₋₄SC(O)R^(∘); —(CH₂)₀₋₄C(O)NR^(∘)₂; —C(S)NR^(∘) ₂; —C(S)SR^(∘); —SC(S)SR^(∘), —(CH₂)₀₋₄OC(O)NR^(∘) ₂;—C(O)N(OR^(∘))R^(∘); —C(O)C(O)R^(∘); —C(O)CH₂C(O)R^(∘);—C(NOR^(∘))R^(∘); —(CH₂)₀₋₄SSR^(∘); —(CH₂)₀₋₄S(O)₂R^(∘);—(CH₂)₀₋₄S(O)₂OR^(∘); —(CH₂)₀₋₄OS(O)₂R^(∘); —S(O)₂NR^(∘) ₂;—(CH₂)₀₋₄S(O)R^(∘); —N(R^(∘))S(O)₂NR^(∘) ₂; —N(R^(∘))S(O)₂R^(∘);—N(OR^(∘))R^(∘); —C(NH)NR^(∘) ₂; —P(O)₂R^(∘); —P(O)R^(∘) ₂; —OP(O)R^(∘)₂; —OP(O)(OR^(∘))₂; SiR^(∘) ₃; —(C₁₋₄ alkylene)O—N(R^(∘))₂; or —(C₁₋₄alkylene)C(O)O—N(R^(∘))₂, wherein each R^(∘) may be substituted asdefined below and is independently hydrogen, C₁₋₈ alkyl, C₂₋₈ alkenyl,C₂₋₈ alkynyl, C₁₋₈ heteroalkyl, C₂₋₈ heteroalkenyl, C₂₋₈ heteroalkynyl,—CH₂Ph, —O(CH₂)₀₋₁Ph, or a 5- or 6-membered saturated, partiallyunsaturated, or aromatic ring having 0-4 heteroatoms independentlyselected from nitrogen, oxygen, or sulfur; or, notwithstanding thedefinition above, two independent occurrences of R^(∘), taken togetherwith the atom(s) to which they are bound, form a 3- to 12-memberedsaturated, partially unsaturated, or aromatic mono- or bicyclic ringhaving 0-4 heteroatoms independently selected from nitrogen, oxygen, orsulfur, which may be substituted as defined below.

Suitable monovalent substituents on R^(∘) (or the ring formed by twoindependent occurrences of R^(∘) together with the atoms to which theyare bound), are independently halogen, —(CH₂)₀₋₂R^(•), —(CH₂)₀₋₂OH,—(CH₂)₀₋₂OR^(•), —(CH₂)₀₋₂CH(OR^(•))₂, —CN, —N₃, —(CH₂)₀₋₂C(O)R^(•),—(CH₂)₀₋₂C(O)OH, —(CH₂)₀₋₂C(O)OR^(•), —(CH₂)₀₋₂SR^(•), —(CH₂)₀₋₂SH,—(CH₂)₀₋₂NH₂, —(CH₂)₀₋₂NHR^(•), —(CH₂)₀₋₂NR^(•) ₂, —NO₂, —SiR^(•) ₃,—OSiR^(•) ₃, —C(O)SR^(•), —(C₁₋₄ alkylene)C(O)OR^(•), or —SSR^(•)wherein each R^(•) is unsubstituted or substituted with one or morehalogens, and is independently selected from C₁₋₄ alkyl, C₂₋₄ alkenyl,C₂₋₄ alkynyl, —CH₂Ph, —O(CH₂)₀₋₁Ph, or a 5- or 6-membered saturated,partially unsaturated, or aromatic ring having 0-4 heteroatomsindependently selected from nitrogen, oxygen, or sulfur. Suitabledivalent substituents on a saturated carbon atom of R^(∘) include ═O and═S.

Suitable divalent substituents on a saturated carbon atom of an“optionally substituted” group include the following: ═O, ═S, ═NNR*₂,═NNHC(O)R*, ═NNHC(O)OR*, ═NNHS(O)₂R*, ═NR*, ═NOR*, —O(C(R*₂))₂₋₃O—, or—S(C(R*₂))₂₋₃S—, wherein each independent occurrence of R* is selectedfrom hydrogen; C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, each of which maybe substituted as defined below; or an unsubstituted 5- or 6-memberedsaturated, partially unsaturated, or aromatic ring having 0-4heteroatoms independently selected from nitrogen, oxygen, or sulfur.Suitable divalent substituents that are bound to vicinal substitutablecarbons of an “optionally substituted” group include: —O(CR*₂)₂₋₃O—,wherein each independent occurrence of R* is selected from hydrogen;C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, each of which may be substitutedas defined below; or an unsubstituted 5- or 6-membered saturated,partially unsaturated, or aromatic ring having 0-4 heteroatomsindependently selected from nitrogen, oxygen, or sulfur.

Suitable substituents on a C₁₋₆ alkyl, C₂₋₆ alkenyl, or C₂₋₆ alkynyl R*group include halogen, —R^(•), -(haloR^(•)), —OH, —OR^(•), —CN, —C(O)OH,—C(O)OR^(•), —NH₂, —NHR^(•), —NR^(•) ₂, or —NO₂, wherein each R^(•) isunsubstituted or substituted with one or more halogens, and isindependently C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, —CH₂Ph,—O(CH₂)₀₋₁Ph, or a 5- or 6-membered saturated, partially unsaturated, oraromatic ring having 0-4 heteroatoms independently selected fromnitrogen, oxygen, or sulfur.

Suitable substituents on a substitutable nitrogen of an “optionallysubstituted” group include —R^(†), —NR^(†) ₂, —C(O)R^(†), —C(O)OR^(†),—C(O)C(O)R^(†), —C(O)CH₂C(O)R^(†), —S(O)₂R^(†), —S(O)₂NR^(†) ₂,—C(S)NR^(†) ₂, —C(NH)NR^(†) ₂, or —N(R^(†))S(O)₂R^(†); wherein eachR^(†) is independently hydrogen; C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,each of which may be substituted as defined below; unsubstituted —OPh;or an unsubstituted 5- or 6-membered saturated, partially unsaturated,or aromatic ring having 0-4 heteroatoms independently selected fromnitrogen, oxygen, or sulfur; or, notwithstanding the definition above,two independent occurrences of R^(†), taken together with the atom(s) towhich they are bound form an unsubstituted 3- to 12-membered saturated,partially unsaturated, or aromatic mono- or bicyclic ring having 0-4heteroatoms independently selected from nitrogen, oxygen, or sulfur.

Suitable substituents on a C₁₋₆ alkyl, C₂₋₆ alkenyl, or C₂₋₆ alkynylR^(†) group are independently halogen, —R^(•), —OH, —OR^(•), —CN,—C(O)OH, —C(O)OR^(•), —NH₂, —NHR^(•), —NR^(•) ₂, or —NO₂, wherein eachR^(•) is unsubstituted or substituted with one or more halogens, and isindependently C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, —CH₂Ph,—O(CH₂)₀₋₁Ph, or a 5- or 6-membered saturated, partially unsaturated, oraromatic ring having 0-4 heteroatoms independently selected fromnitrogen, oxygen, or sulfur.

As used herein, the term “pharmaceutically acceptable salt” refers tothose salts which are, within the scope of sound medical judgment,suitable for use in contact with the tissues of humans and lower animalswithout undue toxicity, irritation, allergic response and the like, andarc commensurate with a reasonable benefit/risk ratio. Pharmaceuticallyacceptable salts are well known in the art. For example, S. M. Berge etal., describe pharmaceutically acceptable salts in detail in J.Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein byreference. Pharmaceutically acceptable salts of the compounds of thisinvention include those derived from suitable inorganic and organicacids and bases. Examples of pharmaceutically acceptable, nontoxic acidaddition salts are salts of an amino group formed with inorganic acidssuch as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuricacid and perchloric acid or with organic acids such as acetic acid,oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid ormalonic acid or by using other methods used in the art such as ionexchange. Other pharmaceutically acceptable salts include adipate,alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate,borate, butyrate, camphorate, camphorsulfonate, citrate,cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate,formate, fumarate, glucoheptonate, glycerophosphate, gluconate,hemisulfate, heptanoate, hexanoate, hydroiodide,2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, laurylsulfate, malate, maleate, malonate, methanesulfonate,2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate,pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate,pivalate, propionate, stearate, succinate, sulfate, tartrate,thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and thelike. Salts derived from appropriate bases include alkali metal,alkaline earth metal, ammonium and N⁺(C₁₋₄alkyl)₄ salts. Representativealkali or alkaline earth metal salts include sodium, lithium, potassium,calcium, magnesium, and the like. Further pharmaceutically acceptablesalts include, when appropriate, nontoxic ammonium, quaternary ammonium,and amine cations formed using counterions such as halide, hydroxide,carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and arylsulfonate.

As used herein, the term “prodrug” refers to a derivative of a parentcompound that requires transformation within the body in order torelease the parent compound. In certain cases, a prodrug has improvedphysical and/or delivery properties over the parent compound. Prodrugsare typically designed to enhance pharmaceutically and/orpharmacokinetically based properties associated with the parentcompound. The advantage of a prodrug can lie in its physical properties,such as enhanced water solubility for parenteral administration atphysiological pH compared to the parent compound, or it enhancesabsorption from the digestive tract, or it may enhance drug stabilityfor long-term storage. The compounds of the invention readily undergodehydration to form oligomeric anhydrides by dehydration of the boronicacid moiety to form dimers, trimers, and tetramers, and mixturesthereof. These oligomeric species hydrolyze under physiologicalconditions to reform the boronic acid. As such, the oligomericanhydrides are contemplated as a “prodrug” of the compounds describedherein, and may be used in the treatment of disorder and/or conditions awherein the inhibition of FAAH provides a therapeutic effect.

Exemplary prodrugs of the compounds described herein include, but arenot limited to, compounds wherein Z¹ and Z² taken together form a 5- to8-membered ring having at least one heteroatom atom selected fromoptionally substituted nitrogen, oxygen and sulfur directly attached toboron (B), wherein the ring is comprised of carbon atoms and optionallyone or more additional heteroatoms independently selected fromoptionally substituted nitrogen, oxygen and sulfur.

Other examples of prodrugs of the compounds described herein aretrifluoroborate prodrugs which hydrolyze to the boronic acid (i.e., —BF₃hydrolyzing to —B(OH)₂) at acidic pH. Salt forms of the boronic acid(e.g., Na⁺, Li⁺, Mg²⁺, Ca²⁺, and the like) are also considered prodrugs.Amino acids can be used to form prodrugs, such as, for example, serineand cysteine protected boronic acids. 1,2 and 1,3 hydroxy sugars can beused to form prodrugs, such as, for example, glycerol, erythritol,threitol, ribitol, arabinitol, xylitol, allitol, altritol, galactitol,sorbitol, mannitol, and iditol protected boronic acids. Other sugarswhich are useful in the formation of prodrugs include, but are notlimited to, maltitol, lactitol, and isomalt; other monosaccharides whichinclude hexoses (e.g., allose, altrose, glucose, mannose, gulose, idose,galactose, talose) and pentoses (e.g., ribose, arabinaose, xylose,lyxose); pentaerythritols and structural derivatives thereof, such asmethylated, ethylated, acetate, ethoxylate, and propoxylate derivatives;and phenolic polyols such as 1,2,4 benzenetriol, 5-methylbenzene1,2,3-triol, 2,3,4-trihydroxybenzaldehyde, and3,4,5-trihydroxybenzamide. Prodrugs also include NMIDA-derivatives.

As used herein, the term “tautomer” includes two or moreinterconvertable compounds resulting from at least one formal migrationof a hydrogen atom and at least one change in valency (e.g., a singlebond to a double bond, a triple bond to a single bond, or vice versa).The exact ratio of the tautomers depends on several factors, includingtemperature, solvent, and pH. Tautomerizations (i.e., the reactionproviding a tautomeric pair) may catalyzed by acid or base. Exemplarytautomerizations include keto-to-enol; amide-to-imide; lactam-to-lactim;enamine-to-imine; and enamine-to-(a different) enamine tautomerizations.

As used herein, the term “isomers” includes any and all geometricisomers and stereoisomers. For example, “isomers” include cis- andtrans-isomers, E- and Z-isomers, R- and S-enantiomers, diastereomers,(D)-isomers, (L)-isomers, racemic mixtures thereof, and other mixturesthereof, as falling within the scope of the invention. For instance, anisomer/enantiomer may, in some embodiments, be provided substantiallyfree of the corresponding enantiomer, and may also be referred to as“optically enriched.” “Optically-enriched,” as used herein, means thatthe compound is made up of a significantly greater proportion of oneenantiomer. In certain embodiments the compound of the present inventionis made up of at least about 90% by weight of a preferred enantiomer. Inother embodiments the compound is made up of at least about 95%, 98%, or99% by weight of a preferred enantiomer. Preferred enantiomers may beisolated from racemic mixtures by any method known to those skilled inthe art, including chiral high pressure liquid chromatography (HPLC) andthe formation and crystallization of chiral salts or prepared byasymmetric syntheses. See, for example, Jacques, et al., Enantiomers,Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen,S. H., et al., Tetrahedron 33:2725 (1977); Eliel, E. L. Stereochemistryof Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, S. H. Tables ofResolving Agents and Optical Resolutions p. 268 (E. L. Eliel, Ed., Univ.of Notre Dame Press, Notre Dame, Ind. 1972).

3. Description of Exemplary Compounds (i) Z¹ and Z²

As defined generally above, in certain embodiments, Z¹ is —OH or —OR³and Z² is —OH, —OR⁴, optionally substituted C₁₋₈ alkyl, optionallysubstituted C₂₋₈ alkenyl, optionally substituted C₂₋₈ alkynyl,optionally substituted C₁₋₈ heteroalkyl, optionally substituted C₂₋₈heteroalkenyl, optionally substituted C₂₋₈ heteroalkynyl, optionallysubstituted C₃₋₁₀ carbocyclyl, optionally substituted 3-10 memberedheterocyclyl, optionally substituted C₆₋₁₀ aryl, or optionallysubstituted 5-10 membered heteroaryl group.

In certain embodiments, Z¹ is —OH and Z² is —OH.

In certain embodiments, Z¹ is —OH and Z² is —OR⁴.

In certain embodiments, Z¹ is —OR³ and Z² is —OR⁴.

In certain embodiments, Z¹ is —OH or —OR³, and Z² is optionallysubstituted C₁₋₈ alkyl, optionally substituted C₂₋₈ alkenyl, optionallysubstituted C₂₋₈ alkynyl or an optionally substituted C₃₋₁₀ carbocyclyl.

In other embodiments, Z¹ is —OH or —OR³, and Z² is optionallysubstituted C₁₋₈ heteroalkyl, optionally substituted C₂₋₈ heteroalkenyl,optionally substituted C₂₋₈ heteroalkynyl, or an optionally substituted3-10 membered heterocyclyl.

In yet other embodiments, Z¹ is —OH or —OR³, and Z² is an optionallysubstituted C₆₋₁₀ aryl.

In yet other embodiments, Z¹ is —OH or —OR³, and Z² is an optionallysubstituted 5-10 membered heteroaryl.

Alternatively, in certain embodiments, Z¹ and Z² taken together with theboron atom to which they are bound, form a 5- to 8-membered ring havingat least one O, S, N or NR⁵ atom directly attached to the boron atom,

wherein R⁵ is hydrogen, —SO₂R¹¹, —SOR¹¹, —C(O)R¹¹, —CO₂R¹¹,—C(O)N(R¹¹)₂, optionally substituted C₁₋₈ alkyl, optionally substitutedC₂₋₈ alkenyl, optionally substituted C₂₋₈ alkynyl, optionallysubstituted C₁₋₈ heteroalkyl, optionally substituted C₂₋₈ heteroalkenyl,optionally substituted C₂₋₈ heteroalkynyl, optionally substituted C₃₋₁₀carbocyclyl, optionally substituted 3-10 membered heterocyclyl,optionally substituted C₆₋₁₀ aryl, or optionally substituted 5-10membered heteroaryl, and

each instance of R¹¹ is, independently, optionally substituted C₁₋₈alkyl, optionally substituted C₂₋₈ alkenyl, optionally substituted C₂₋₈alkynyl, optionally substituted C₁₋₈ heteroalkyl, optionally substitutedC₂₋₈ heteroalkenyl, optionally substituted C₂₋₈ heteroalkynyl,optionally substituted C₃₋₁₀ carbocyclyl, optionally substituted 3-10membered heterocyclyl, optionally substituted C₆₋₁₀ aryl, or optionallysubstituted 5-10 membered heteroaryl.

In certain embodiments, Z¹ and Z² taken together with the boron atom towhich they are bound, form a 5- to 8-membered ring having at least oneO, S, N or NR⁵ atom directly attached to the boron atom,

wherein the 5- to 8-membered ring is optionally substituted with one ormore hydrogen, —SO₂R¹¹, —SOR¹¹, —C(O)R¹¹, —CO₂R¹¹, —C(O)N(R¹¹)₂,—C(O)NH(R¹¹), optionally substituted C₁₋₈ alkyl, optionally substitutedC₂₋₈ alkenyl, optionally substituted C₂₋₈ alkynyl, optionallysubstituted C₁₋₈ heteroalkyl, optionally substituted C₂₋₈ heteroalkenyl,optionally substituted C₂₋₈ heteroalkynyl, optionally substituted C₃₋₁₀carbocyclyl, optionally substituted 3-10 membered heterocyclyl,optionally substituted C₆₋₁₀ aryl, or optionally substituted 5-10membered heteroaryl groups, or two groups present on the ring are joinedto form a 5- to 8-membered monocylic or bicyclic ring optionallycontaining one or more heteroatoms selected from O, S, N or NR⁵,

wherein each instance of R¹⁸ is independently, optionally substitutedC₁₋₈ alkyl, optionally substituted C₂₋₈ alkenyl, optionally substitutedC₂₋₈ alkynyl, optionally substituted C₁₋₈ heteroalkyl, optionallysubstituted C₂₋₈ heteroalkenyl, optionally substituted C₂₋₈heteroalkynyl, optionally substituted C₃₋₁₀ carbocyclyl, optionallysubstituted 3-10 membered heterocyclyl, optionally substituted C₆₋₁₀aryl, or optionally substituted 5-10 membered heteroaryl.

In certain embodiments, the 5- to 8-membered ring is optionallysubstituted with one or more —C(═O)R¹⁸, —C(═O)OR¹⁸, —C(═O)NH(R¹⁸),—C(═O)N(R¹⁸)₂ and optionally substituted C₁₋₈ alkyl groups.

For example, in certain embodiments, Z¹ and Z², taken together with theboron atom to which they are bound, form a 5-membered ring having atleast one O, S, N or NR⁵ atom directly attached to the boron atom.Exemplary 5-membered rings include, but are not limited to:

wherein each R⁵ is as defined above and herein.

In other embodiments, Z¹ and Z², taken together with the boron atom towhich they are bound, form a 6-membered ring having at least one O, S, Nor NR⁵ atom directly attached to the boron atom. Exemplary 6-memberedrings include, but are not limited to:

In yet other embodiments, Z¹ and Z² form an 8-membered ring having atleast one O, S, N or NR⁵ atom directly attached to the boron atom.Exemplary 8-membered ring structures include, but are not limited to:

wherein each R⁵ is as defined above and herein.

Furthermore, as generally defined above, in certain embodiments, Z¹ is—OH or —OR³, and Z² and Ring A taken together form an optionallysubstituted 5- to 7-membered ring.

For example, in certain embodiments, Z¹ is —OH or —OR³, and Z² and RingA taken together form an optionally substituted 6-membered ring.Exemplary ring structures include, but are not limited to:

wherein Ring A is as defined above and herein.

(ii) L¹

As defined generally above, in certain embodiments, L¹ is a covalentbond, an optionally substituted straight or branched C₁₋₆ alkylene or anoptionally substituted straight or branched C₂₋₆ alkenylene moiety.

In certain embodiments L¹ is a covalent bond.

In some embodiments, L¹ is an optionally substituted C₁₋₆ alkylenemoiety. In some embodiments, L¹ is an optionally substituted C₁₋₃alkylene moiety. In other embodiments, L¹ is an optionally substitutedC₁₋₂ alkylene moiety. In certain embodiments, L¹ is a —CH₂— group. Inother embodiments, L¹ is a —CH₂CH₂— group. In yet other embodiments, L¹is a —CH═CH— group.

(iii) Ring A

As defined generally above, Ring A is an optionally substituted C₃₋₁₀carbocyclyl, optionally substituted 3-10 membered heterocyclyl,optionally substituted C₆₋₁₀ aryl, or optionally substituted 5-10membered heteroaryl. Ring A is monocyclic or bicyclic. In certainembodiments, Ring A is aromatic. In certain embodiments, Ring A issaturated or partially unsaturated.

In certain embodiments, Ring A is an optionally substituted C₆ or C₈monocyclic aryl group. Such monocyclic ring systems include, but are notlimited to:

wherein each of X, R^(A), R¹ and n is as defined above and herein.

In certain embodiments, Ring A is an optionally substituted phenyl ringsystem of formula:

wherein each of X, R^(A), R¹ and n is as defined above and herein.

In certain embodiments, Ring A is phenyl and has at least one fluorinesubstituent (i.e., n is at least one and R¹ is F). In certainembodiments, Ring A has at least two fluorine substituents (i.e., n isat least 2 and each R¹ is F). In certain embodiments, Ring A has atleast three fluorine substituents (i.e., n is at least 3 and each R¹ isF). In certain embodiments, at least one R¹ group is fluoro in the orthoposition relative to the boron atom. However, in certain embodiments,compounds containing fluorine substituents on Ring A are specificallyexcluded (i.e., when R¹ is F). In certain embodiments, compoundscontaining fluorine substituents ortho to the boron atom on Ring A arespecifically excluded (i.e., when R¹ is F at the ortho position of RingA with respect to the boron atom).

In certain embodiments, Ring A is an optionally substituted phenyl ringsystem of any one of formulae:

wherein each of X, R^(A), R¹ and n is as defined above and herein.

In other embodiments, Ring A is an optionally substituted phenyl ringsystem having an —XR^(A) group para to the boron atom, i.e., a phenylring of any one of formulae:

wherein each of X, R^(A), and R¹ is as defined above and herein.

In yet other embodiments, Ring A is an optionally substituted phenylring system having an —XR^(A) group meta to the boron atom, i.e., aphenyl ring of any one of formulae:

wherein each of X, R^(A), and R¹ is as defined above and herein.

In yet other embodiments, Ring A is an optionally substituted phenylring system having an —XR^(A) group ortho to the boron atom, i.e., aphenyl ring of any one of formulae:

wherein each of X, R^(A), and R¹ is as defined above and herein.

In certain embodiments, Ring A is phenyl, X is a covalent bond and R^(A)is hydrogen, i.e., Ring A is an optionally substituted phenyl ringsystem of formula:

wherein each of R¹ and n is as defined above and herein. Examples ofsuch ring systems include:

wherein each R¹ is as defined above and herein.

In other embodiments, Ring A is an optionally substituted saturated orpartially unsaturated C₃₋₁₀ or C₃₋₈ monocyclic ring system. Suchmonocyclic ring systems include, but are not limited to:

wherein each of X, R^(A), R¹ and n is as defined above and herein.

In certain embodiments, Ring A is an optionally substituted 5-8 memberedor 5-6 membered monocyclic heteroaryl group. Such aromatic monocyclicring systems include, but are not limited to, 5-membered rings of any offollowing formulae:

and 6-membered rings of the formulae:

wherein each of X, R^(A), R¹ and n is as defined above and herein,

R¹⁴ is hydrogen, —SO₂R¹¹, —SOR¹¹, —C(O)R¹¹, —CO₂R¹¹, —C(O)N(R¹¹)₂,—C(O)NH(R¹¹), —C(O)NH₂, optionally substituted C₁₋₈ alkyl, optionallysubstituted C₂₋₈ alkenyl, optionally substituted C₂₋₈ alkynyl,optionally substituted C₁₋₈ heteroalkyl, optionally substituted C₂₋₈heteroalkenyl, optionally substituted C₂₋₈ heteroalkynyl, optionallysubstituted C₃₋₁₀ carbocyclyl, optionally substituted 3-10 memberedheterocyclyl, optionally substituted C₆₋₁₀ aryl, or optionallysubstituted 5-10 membered heteroaryl, and

each instance of R¹¹ is, independently, optionally substituted C₁₋₈alkyl, optionally substituted C₂₋₈ alkenyl, optionally substituted C₂₋₈alkynyl, optionally substituted C₁₋₈ heteroalkyl, optionally substitutedC₂₋₈ heteroalkenyl, optionally substituted C₂₋₈ heteroalkynyl,optionally substituted C₃₋₁₀ carbocyclyl, optionally substituted 3-10membered heterocyclyl, optionally substituted C₆₋₁₀ aryl, or optionallysubstituted 5-10 membered heteroaryl.

In certain embodiments, Ring A is an optionally substituted furanylgroup. In certain embodiments, Ring A is a furanyl group of the formula:

wherein each of X, R^(A), R¹ and n is as defined above and herein.

In certain embodiments, Ring A is an optionally substituted thiophenylgroup. In certain embodiments, Ring A is a thiophenyl group of theformula:

wherein each of X, R^(A), R¹ and n is as defined above and herein.

In certain embodiments, Ring A is an optionally substituted pyridinylgroup. In certain embodiments, Ring A is pyridinyl group of the formula:

wherein each of X, R^(A), R¹ and n is as defined above and herein.

In other embodiments, Ring A is an optionally substituted saturated orpartially unsaturated 3-8 membered or 5-8-membered monocyclicheterocyclyl group. Examples of such saturated or partially unsaturatedmonocyclic ring systems include, but are not limited to:

wherein each of X, R^(A), R¹, R¹⁴ and n is as defined above and herein.

In certain embodiments, Ring A is an optionally substituted bicyclicaryl group. Such bicyclic ring systems include, but are not limited to:

wherein each of X, R^(A), R¹ and n is as defined above and herein. Forexample, in certain embodiments, Ring A is a bicyclic group of any offormulae:

wherein each of X, R^(A), R¹ and n is as defined above and herein.

In other embodiments, Ring A is an optionally substituted bicyclic C₈₋₁₀carbocyclyl group. In some embodiments, both rings of the bicyclic C₈₋₁₀carbocyclyl group are saturated or partially saturated. In otherembodiments, one ring of the bicyclic C₈₋₁₀ carbocyclyl group issaturated or partially saturated and the other ring is aromatic. Suchbicyclic C₈₋₁₀ carbocyclyl ring systems include, but are not limited to:

wherein each of X, R^(A), R¹ and n is as defined above and herein.

In certain embodiments, Ring A is an optionally substituted 6-10membered bicyclic heteroaryl group. In certain embodiments, Ring A is anoptionally substituted 9-10 membered bicyclic heteroaryl group. Incertain embodiments, Ring A is an optionally substituted 9 memberedbicyclic heteroaryl group. In certain embodiments, the optionallysubstituted 9-membered bicyclic heteroaryl is a 6,5-fused heteroarylring. In certain embodiments, the optionally substituted 10-memberedbicyclic heteroaryl is a 6,6-fused heteroaryl ring.

For example, in certain embodiments, Ring A is a 6,5-fused heteroarylring of any of formulae:

wherein each of X, R^(A), R¹, R¹⁴ and n is as defined above and herein.

In certain embodiments, Ring A is a 6,6-fused heteroaryl ring of any offormulae:

wherein each of X, R^(A), R¹ and n is as defined above and herein.

In other embodiments, Ring A is an optionally substituted bicyclic 6-10membered heterocyclyl group. In some embodiments, both rings of thebicyclic 6-10 membered heterocyclyl group are saturated or partiallysaturated. In other embodiments, one ring of the bicyclic 6-10 memberedheterocyclyl group is saturated or partially saturated and the otherring is aromatic. Such bicyclic heterocyclyl ring systems include, butare not limited to:

wherein each of X, R^(A), R¹, R¹⁴ and n is as defined above and herein.

It will be appreciated that in any of the above drawings of bicyclicRing A having one or more floating substituents (e.g., —R¹ and/or—X—R^(A)) that the floating substituent may be present on anysubstitutable carbon atom on either ring of the fused ring system.

(iv) X

As is also defined generally above, X is a covalent bond, —O—, —N═N—,—C═N—, —NR⁶—, —C(NR⁶)—, —S—, —C(O)—, —S(O)—, —S(O)₂—, optionallysubstituted C₁₋₆ alkylene, or optionally substituted C₂₋₆ alkenylene,wherein one, two or three methylene units of the C ₁₋₆ alkylene or C₂₋₆alkenylene are optionally and independently replaced with one or more—O—, —N═N—, —C═N—, —NR⁶—, —C(NR)—, —S—, —C(O)—, —S(O)—, or —S(O)₂—.

In certain embodiments, X is a covalent bond.

In certain embodiments, X is —O—.

In certain embodiments, X is —NR⁶—.

In certain embodiments, X is —S—.

In certain embodiments, X is an optionally substituted C₁₋₆ alkylene. Inother embodiments, X is an optionally substituted C₁₋₄ alkylene. In yetother embodiments, X is an optionally substituted C₁₋₂ alkylene. Incertain embodiments, X is —(CH₂)₄—. In certain embodiments, X is—(CH₂)₃—. In certain embodiments, X is —(CH₂)₂—. In certain embodiments,X is —CH₂—.

In certain embodiments, X is an optionally substituted C₂₋₆ alkenylene.In other embodiments, X is an optionally substituted C₂₋₄ alkenylene. Inyet other embodiments, X is an optionally substituted C₂ alkenylene. Incertain embodiments, X is —CH═CH—.

In certain embodiments, X is an optionally substituted C₁₋₆ alkylene,wherein one methylene unit is replaced with —O—. In certain embodiments,X is —CH₂O— or —OCH₂—.

In certain embodiments, X is an optionally substituted C₁₋₆ alkylene,wherein one methylene unit is replaced with —NR⁶—. In certainembodiments, X is —CH₂NR⁶— or —NR⁶CH₂—.

In certain embodiments, X is a covalent bond, C(O), —O—, —CH₂O—, —OCH₂—,—NR⁶—, or —CH₂NR⁶—, or —NR⁶CH₂—.

In certain embodiments, X is a covalent bond, —O—, or optionallysubstituted C₁₋₆ alkylene.

(v) R^(A)

As is defined generally above, R^(A) is hydrogen, halogen, —OR⁷, —CF₃,—CN, —NO₂, —SO₂R⁷, —SOR⁷, —C(O)R⁷, —CO₂R⁷, —C(O)N(R⁷)₂, —CHO, —N₃,—N₂R⁷, —N(R⁷)₂, or Ring B having formula:

wherein Ring B is optionally substituted C₃₋₁₀ carbocyclyl, optionallysubstituted 3-10 membered heterocyclyl, optionally substituted C₆₋₁₀aryl, or optionally substituted 5-10 membered heteroaryl, and R², R⁷ andm are as defined herein.

In certain embodiments, R^(A) is hydrogen.

In certain embodiments, R^(A) is Ring B, as defined above and herein.

(vi) Ring B

As described herein, Ring B is optionally substituted C₃₋₁₀ carbocyclyl,optionally substituted 3-10 membered heterocyclyl, optionallysubstituted C₆₋₁₀ aryl, or optionally substituted 5-10 memberedheteroaryl. Ring B is monocyclic or bicyclic. In certain embodiments,Ring B is aromatic.

In some embodiments, Ring B is an optionally substituted C₆ or C₈monocyclic aryl group. Such monocyclic aryl ring systems include, butare not limited to:

wherein each of R² and m is as defined above and herein.

In certain embodiments, Ring B is an optionally substituted phenyl ringof formula:

wherein each of R² and m is as defined above and herein.

In certain embodiments, Ring B is an optionally substituted phenyl ringof any one of formulae:

wherein R² is as defined above and herein.

In certain embodiments, both of Ring B and Ring A are phenyl.

In other embodiments, Ring B is an optionally substituted saturated orpartially unsaturated C₃₋₁₀ or C₅₋₈ monocyclic carbocyclyl group. Suchmonocyclic ring systems include, but are not limited to:

wherein each of R² and m is as defined above and herein.

In certain embodiments, Ring B is an optionally substituted 5-8 memberedor 5-6 membered monocyclic heteroaryl group.

In certain embodiments, Ring B is an optionally substituted 5-memberedheteroaryl group. Such monocyclic heteroaryl systems include, but arenot limited to, any of formulae:

wherein each of R² and m is as defined above and herein,

R¹⁶ is hydrogen, —SO₂R¹¹, —SOR¹¹, —C(O)R¹¹, —CO₂R¹¹, —C(O)NH₂,—C(O)NH(R¹¹), —C(O)N(R¹¹)₂, optionally substituted C₁₋₈ alkyl,optionally substituted C₂₋₈ alkenyl, optionally substituted C₂₋₈alkynyl, optionally substituted C₁₋₈ heteroalkyl, optionally substitutedC₂₋₈ heteroalkenyl, optionally substituted C₂₋₈ heteroalkynyl,optionally substituted C₃₋₁₀ carbocyclyl, optionally substituted 3-10membered heterocyclyl, optionally substituted C₆₋₁₀ aryl, or optionallysubstituted 5-10 membered heteroaryl, and

each instance of R¹¹ is, independently, optionally substituted C₁₋₈alkyl, optionally substituted C₂₋₈ alkenyl, optionally substituted C₂₋₈alkynyl, optionally substituted C₁₋₈ heteroalkyl, optionally substitutedC₂₋₈ heteroalkenyl, optionally substituted C₂₋₈ heteroalkynyl,optionally substituted C₃₋₁₀ carbocyclyl, optionally substituted 3-10membered heterocyclyl, optionally substituted C₆₋₁₀ aryl, or optionallysubstituted 5-10 membered heteroaryl.

In certain embodiments, Ring B is an optionally substituted 6-memberedmonocyclic heteroaryl group. Such monocyclic heteroaryl systems include,but are not limited to, 6-membered rings of any of formulae:

wherein each of R² and m is as defined above and herein.

In other embodiments, Ring B is an optionally substituted saturated orpartially unsaturated monocyclic 3 to 10 membered heterocyclyl group.Such saturated or partially unsaturated monocyclic heterocyclyl systemsinclude, but are not limited to:

wherein each of R², R¹⁶ and m is as defined above and herein.

In certain embodiments, Ring B is an optionally substituted C₁₀ bicyclicaryl group (i.e., naphthyl) having the formula:

wherein each of R² and m is as defined above and herein.

In other embodiments, Ring B is a bicyclic C₈₋₁₀ carbocyclyl group. Insome embodiments, both rings of the bicyclic C₈₋₁₀ carbocyclyl group aresaturated or partially saturated. In other embodiments, one ring of thebicyclic C₈₋₁₀ carbocyclyl group is saturated or partially saturated andthe other ring is aromatic. Such bicyclic ring systems include, but arenot limited to:

wherein each of R² and m is as defined above and above and describedherein.

In certain embodiments, Ring B is an optionally substituted 6-10membered bicyclic heteroaryl group. In certain embodiments, Ring B is anoptionally substituted 9-10 membered bicyclic heteroaryl group. Incertain embodiments, an optionally substituted 9-membered bicyclicheteroaryl group is a 6,5-fused bicyclic heteroaryl group. In certainembodiments, an optionally substituted 10-membered bicyclic heteroarylgroup is a 6,6-fused bicyclic heteroaryl group.

Exemplary heteroaryl systems include, but are not limited to, 6,5-fusedring systems of any of formulae:

and 6,6-fused ring systems of any of formulae:

wherein each of R², R¹⁶ and m is as defined above and herein.

In certain embodiments, Ring B is an optionally substituted saturated orpartially saturated 9-10 membered bicyclic heterocyclyl group. Suchbicyclic heterocyclyl systems include, but are not limited to:

wherein each of R², R¹⁶ and m is as defined above and herein.

It will be appreciated that in any of the above drawings of bicyclicRing B having one or more floating substituents (e.g., —R²) that thefloating substituent may be present on any substitutable carbon atom oneither ring of the fused bicyclic ring system.

(vii) R¹ and n

As defined generally above, each instance of R¹ is, independently,halogen, —OR⁸, —CF₃, —CN, —NO₂, —SO₂R⁸, —SOR⁸, —C(O)R⁸, —CO₂R⁸,—C(O)N(R⁸)₂, —N₃, —N₂R⁸, —N(R⁸)₂, —B(OH₂), optionally substituted C₁₋₈alkyl, optionally substituted C₂₋₈ alkenyl, optionally substituted C₂₋₈alkynyl, optionally substituted C₁₋₈ heteroalkyl, optionally substitutedC₂₋₈ heteroalkenyl, optionally substituted C₂₋₈ heteroalkynyl,optionally substituted C₃₋₁₀ carbocyclyl, optionally substituted 3-10membered heterocyclyl, optionally substituted C₆₋₁₀ aryl, or anoptionally substituted 5-10 membered heteroaryl group; and wherein R⁸ isas described herein.

In certain embodiments, each instance of R¹ is, independently, halogen,—OR⁸, —CF₃, —CN, —NO₂, —SO₂R⁸, —SOR⁸, —C(O)R⁸, —CO₂R⁸, —C(O)N(R⁸)₂, —N₃,—N₂R⁸, or —N(R⁸)₂, optionally substituted C₁₋₈ alkyl, optionallysubstituted C₂₋₈ alkenyl, or optionally substituted C₂₋₈ alkynyl.

In certain embodiments, each instance of R¹ is, independently, halogen,—OR⁸ or optionally substituted C₁₋₈ alkyl. In some embodiments, R¹ ishalogen. In other embodiments, R¹ is —F or —Cl. In certain embodiments,R¹ is —Cl. In other embodiments, R¹ is —F.

In certain embodiments, at least one R¹ is ortho to the boron atom. Inother embodiments, at least one R¹ is meta to the boron atom. In yetother embodiments, at least one R¹ is para to the boron atom.

In certain embodiments, at least one R¹ is alpha to the boron atom. Inother embodiments, at least one R¹ is beta to the boron atom. In yetother embodiments, at least one R¹ is gamma to the boron atom.

In certain embodiments, n is 0, 1, 2 or 3. In some embodiments, n is 0,1 or 2. In other embodiments, n is 1 or 2. In yet other embodiments, nis 3. In yet other embodiments, n is 2. In still yet other embodiments,n is 1. In still yet other embodiments, n is 0.

It is understood that when n is 0 then Ring A is not substituted with anR¹ group, but instead is substituted with hydrogen. It is alsounderstood that when n is 0, X is a covalent bond and R^(A) is hydrogen,then Ring A is unsubstituted.

(viii) R² and m

As defined generally above, each instance of R² is, independently,halogen, —OR⁹, —CF₃, —CN, —NO₂, —SO₂R⁹, —SOR⁹, —C(O)R⁹, —CO₂R⁹,—C(O)N(R⁹)₂, —N₃, —N₂R⁹, —N(R⁹)₂, optionally substituted C₁₋₈ alkyl,optionally substituted C₂₋₈ alkenyl, optionally substituted C₂₋₈alkynyl, optionally substituted C₁₋₈ heteroalkyl, optionally substitutedC₂₋₈ heteroalkenyl, optionally substituted C₂₋₈ heteroalkynyl,optionally substituted C₃₋₁₀ carbocyclyl, optionally substituted 3-10membered heterocyclyl, optionally substituted C₆₋₁₀ aryl, or optionallysubstituted 5-10 membered heteroaryl group; and wherein R⁹ is asdescribed herein.

In certain embodiments, each instance of R² is, independently, halogen,—OR⁹, —CF₃, —CN, —NO₂, —SO₂R⁹, —SOR⁹, —C(O)R⁹, —CO₂R⁹, —C(O)N(R⁹)₂, —N₃,—N₂R⁹, —N(R⁹)₂, optionally substituted C₁₋₈ alkyl, optionallysubstituted C₂₋₈ alkenyl, or optionally substituted C₂₋₈ alkynyl.

In certain embodiments, each instance of R² is, independently, halogenor —OR⁹. In some embodiments, R² is halogen. In other embodiments, R² is—F or —Cl. In certain embodiments, R² is —Cl. In yet other embodiments,R² is —F.

In certain embodiments, at least one R² is ortho to X. In otherembodiments, at least one R² is meta to X. In yet other embodiments, atleast one R² is para to X.

In certain embodiments, at least one R² is alpha to X. In otherembodiments, at least one R² is beta to X. In yet other embodiments, atleast one R² is gamma to X.

In certain embodiments, m is 0, 1, 2, 3, 4 or 5. In some embodiments, mis 0, 1, 2 or 3. In some embodiments, m is 0, 1 or 2. In otherembodiments, m is 1 or 2. In yet other embodiments, m is 3. In stillother embodiments, m is 2. In still yet other embodiments, m is 1. Instill other embodiments, m is 0.

It is understood that when m is 0, then Ring B is not substituted withan R² group, but instead is substituted with hydrogen.

(ix) Compounds of Formula (II) Wherein Ring A is Bicyclic

In certain embodiments, the present invention provides compounds offormula (I):

or a pharmaceutically acceptable salt or prodrug thereof, wherein Z¹,Z², L¹, X, R¹, R^(A), and n are as defined above and herein, and whereinRing A is an optionally substituted C₁₀ bicyclic aryl or an optionallysubstituted 9-10 membered bicyclic heteroaryl.

In certain embodiments, Ring A is an optionally substituted C₁₀ bicyclicaryl group. In certain embodiments, Ring A is an optionally substitutednaphthyl group.

In certain embodiments, Ring A is an optionally substituted 9-10membered bicyclic heteroaryl group.

In certain embodiments, Ring A is an optionally substituted 10-memberedbicyclic heteroaryl group. In certain embodiments, Ring A is a 6,6-fusedbicyclic heteroaryl. In certain embodiments, Ring A is a 6,6-fusedbicyclic heteroaryl containing 1 to 2 N atoms. In certain embodiments,Ring A is a 6,6-fused bicyclic heteroaryl containing 1 N atom. Incertain embodiments, Ring A is a 6,6-fused bicyclic heteroarylcontaining 2 N atoms.

In certain embodiments, Ring A is an optionally substituted isoquinolinegroup. In certain embodiments, Ring A is an optionally substitutedquinolinyl group. In certain embodiments, Ring A is an optionallysubstituted quinoxalinyl group.

In certain embodiments, the present invention provides 6,6-fusedbicyclic compounds of formula (III):

or a pharmaceutically acceptable salt or prodrug thereof,wherein:

(i) Z¹ is —OH or —OR³ and Z² is —OH, —OR⁴, an optionally substitutedC₁₋₈ alkyl, optionally substituted C₂₋₈ alkenyl, optionally substitutedC₂₋₈ alkynyl, optionally substituted C₁₋₈ heteroalkyl, optionallysubstituted C₂₋₈ heteroalkenyl, optionally substituted C₂₋₈heteroalkynyl, optionally substituted C₃₋₁₀ carbocyclyl, optionallysubstituted 3-10 membered heterocyclyl, optionally substituted C₆₋₁₀aryl, or optionally substituted 5-10 membered heteroaryl;

(ii) Z¹ and Z² taken together form a 5- to 8-membered ring having atleast one O, S, N or NR⁵ directly bonded to the boron atom; or

(iii) Z¹ is —OH or —OR³, and Z² and Ring A taken together form anoptionally substituted 5- to 7-membered ring;

W¹ and W² are independently selected from CR¹², C and N;

X is a covalent bond, —O—, —N═N—, —C═N—, —NR⁶—, —C(NR⁶)—, —S—, —C(O)—,—S(O)—, —S(O)₂—, or optionally substituted C₁₋₆ alkylene, wherein one,two or three methylene units of the C₁₋₆ alkylene are optionally andindependently replaced with one or more groups selected from —O—, —N═N—,—C═N—, —NR⁶—, —C(NR⁶)—, —S—, —C(O)—, —S(O)—, and —S(O)₂—;

R^(A) is hydrogen, halogen, —OR⁷, —CF₃, —CN, —NO₂, —SO₂R⁷, —SOR⁷,—C(O)R⁷, —CO₂R⁷, —C(O)N(R⁷)₂, —N₃, —N₂R⁷, —N(R⁷)₂, or Ring B havingformula:

wherein Ring B is optionally substituted C₃₋₁₀ carbocyclyl, optionallysubstituted 3-10 membered heterocyclyl, optionally substituted C₆₋₁₀aryl, or optionally substituted 5-10 membered heteroaryl;

each instance of R¹ is, independently, halogen, —OR⁸, —CF₃, —CN, —NO₂,—SO₂R⁸, —SOR⁸, —C(O)R⁸, —CO₂R⁸, —C(O)N(R⁸)₂, —N₃, —N₂R⁸, —N(R⁸)₂,—B(OH₂), optionally substituted C₁₋₈ alkyl, optionally substituted C₂₋₈alkenyl, optionally substituted C₂₋₈ alkynyl, optionally substitutedC₁₋₈ heteroalkyl, optionally substituted C₂₋₈ heteroalkenyl, optionallysubstituted C₂₋₈ heteroalkynyl, optionally substituted C₃₋₁₀carbocyclyl, optionally substituted 3-10 membered heterocyclyl,optionally substituted C₆₋₁₀ aryl, or optionally substituted 5-10membered heteroaryl;

each instance of R² is, independently, halogen, —OR⁹, —CF₃, —CN, —NO₂,—SO₂R⁹, —SOR⁹, —C(O)R⁹, —CO₂R⁹, —C(O)N(R⁹)₂, —N₃, —N₂R⁹, —N(R⁹)₂,optionally substituted C₁₋₈ alkyl, optionally substituted C₂₋₈ alkenyl,optionally substituted C₂₋₈ alkynyl, optionally substituted C₁₋₈heteroalkyl, optionally substituted C₂₋₈ heteroalkenyl, optionallysubstituted C₂₋₈ heteroalkynyl, optionally substituted C₃₋₁₀carbocyclyl, optionally substituted 3-10 membered heterocyclyl,optionally substituted C₆₋₁₀ aryl, or optionally substituted 5-10membered heteroaryl;

each instance of R³ and R⁴ is, independently, optionally substitutedC₁₋₈ alkyl, optionally substituted C₂₋₈ alkenyl, optionally substitutedC₂₋₈ alkynyl, optionally substituted C₁₋₈ heteroalkyl, optionallysubstituted C₂₋₈ heteroalkenyl, optionally substituted C₂₋₈heteroalkynyl, optionally substituted C₃₋₁₀ carbocyclyl, optionallysubstituted 3-10 membered heterocyclyl, optionally substituted C₆₋₁₀aryl, or optionally substituted 5-10 membered heteroaryl;

each instance of R⁵, R⁶, R⁷, R⁸, R⁹, and R¹⁰ is, independently,hydrogen, —C(O)R¹¹, —SO₂R¹¹, —SOR¹¹, —C(O)R¹¹, —CO₂R¹¹, —C(O)N(R¹¹)₂,—C(O)NH(R¹¹), —C(O)NH₂, optionally substituted C₁₋₈ alkyl, optionallysubstituted C₂₋₈ alkenyl, optionally substituted C₂₋₈ alkynyl,optionally substituted C₁₋₈ heteroalkyl, optionally substituted C₂₋₈heteroalkenyl, optionally substituted C₂₋₈ heteroalkynyl, optionallysubstituted C₃₋₁₀ carbocyclyl, optionally substituted 3-10 memberedheterocyclyl, optionally substituted C₆₋₁₀ aryl, or optionallysubstituted 5-10 membered heteroaryl;

each instance of R¹¹ is, independently, optionally substituted C₁₋₈alkyl, optionally substituted C₂₋₈ alkenyl, optionally substituted C₂₋₈alkynyl, optionally substituted C₁₋₈ heteroalkyl, optionally substitutedC₂₋₈ heteroalkenyl, optionally substituted C₂₋₈ heteroalkynyl,optionally substituted C₃₋₁₀ carbocyclyl, optionally substituted 3-10membered heterocyclyl, optionally substituted C₆₋₁₀ aryl, or optionallysubstituted 5-10 membered heteroaryl;

each instance of R¹² is, independently, hydrogen, halogen, —CF₃,optionally substituted C₁₋₈ alkyl, optionally substituted C₂₋₈ alkenyl,or optionally substituted C₂₋₈ alkynyl;

n is, independently, 0, 1, 2 or 3 and m is 0, 1, 2, 3, 4 or 5.

In certain embodiments, the present invention provides 6,6-fusedbicyclic compounds of the formula (III-a), (III-b), (III-c), (III-d) or(III-e):

or a pharmaceutically acceptable salt or prodrug thereof, wherein W¹,W², Z¹, Z², X, R¹, R^(A), and n are as defined above and herein.

In certain embodiments, n is 0. In certain embodiments, n is 1 or 2. Incertain embodiments, n is 1.

In certain embodiments, R¹ is optionally substituted C₁₋₈ alkyl. Incertain embodiments, R¹ is —CH₃.

In certain embodiments, X is a covalent bond, —(C═O)—, —O—, —CH₂O—,—OCH₂—, —NH—, —N(R⁹)—, —N(R⁹)CH₂—, —CH₂N(R⁹)— or an optionallysubstituted C₁₋₆ alkylene. In certain embodiments, X is a covalent bond,—(C═O)—, —O—, —CH₂O—, —OCH₂—, —NH—, —N(R⁹)—, —N(R⁹)CH₂—, —CH₂N(R⁹)—,—CH₂—, —(CH₂)₂—, —(CH₂)₃—, —(CH₂)₄—, or —(CH₂)₅—.

In certain embodiments, R^(A) is hydrogen.

In certain embodiments, R^(A) is Ring B. In certain embodiments, Ring Bis an optionally substituted aryl, optionally substituted pyridinyl,optionally substituted pyrazinyl, optionally substituted pyrimidinyl,optionally substituted 1,2,3,4-tetrahydroquinolinyl, optionallysubstituted cyclopentyl or optionally substituted cyclohexyl.

In certain embodiments, m is 0. In certain embodiments, m is 1 or 2. Incertain embodiments, m is 1.

In certain embodiments, R² is halogen, —OR⁹, —CN, —NO₂, or —N(R⁹)₂. Incertain embodiments, R² is Cl, CN, NO₂, OH, OCH₃, OC₄H₉, or N(CH₃)₂.

In certain embodiments, at least one of W¹ and W² is N.

In certain embodiments, W¹ is N and W² is C or CR¹². In certainembodiments, W² is N and W¹ is C or CR¹². In some embodiments, W¹ is Nand W² is CH. In some embodiments, W² is N and W¹ is CH. In certainembodiments, wherein W¹ is N and W² is C, CH or CR¹², or wherein W² is Nand W¹ is C, CH or CR¹², the following compounds are specificallyexcluded:

(i) compounds wherein n is 0, X is a covalent bond and R^(A) ishydrogen;

(ii) compounds wherein n is 1, R¹ is fluoro, X is —CH₂—, and R^(A) ishydrogen; and/or

(iii) compounds wherein n is 1, R¹ is chloro, X is a covalent bond, andR^(A) is hydrogen.

In certain embodiments, both W¹ and W² are N. In certain embodiments,wherein both W¹ and W² are N, the following compounds are specificallyexcluded:

(i) compounds wherein n is 0, X is a covalent bond and R^(A) ishydrogen.

In certain embodiments, both W¹ and W² are, independently, C or CR¹². Incertain embodiments, both W¹ and W² are CH. In certain embodiments,wherein both W¹ and W² are C, CH or CR¹², the following compounds arespecifically excluded:

-   -   (i) compounds wherein n is 0, X is a covalent bond and R^(A) is        hydrogen, —OH, —OCH₃, —OCH₂CH₃ or —OCH₂C₆H₅;    -   (ii) compounds wherein n is 1, R¹ is —CHO or —CH₂N(R⁹)C₆H₅, X is        a covalent bond, and R^(A) is hydrogen;    -   (iii) compounds wherein n is 0, X is a covalent bond, and R^(A)        is an optionally substituted phenyl or napthyl ring (Ring B);        and/or    -   (iv) compounds wherein n is 0 and X is —C═N—NH—(C═S)— or        —C═N—NH—(C═O)—.

In certain embodiments, the following compounds are specificallyexcluded:

or a pharmaceutically acceptable salt or prodrug thereof.

In certain embodiments, W¹ is C or CH and W² is N, providing 6,6-fusedbicyclic compounds of the formula (III-e):

or a pharmaceutically acceptable salt or prodrug thereof, wherein Z¹,Z², L¹, X, R¹, R^(A), and n are as defined above and herein. Examples ofsuch compounds include compounds of any of formulae (III-e1), (III-e2),(III-e3), (III-e4) and (III-e5):

or a pharmaceutically acceptable salt or prodrug thereof, wherein Z¹,Z², X, R¹, R^(A), and n are as defined above and herein.

In certain embodiments, both W¹ and W² are N, providing 6,6-fusedbicyclic compounds of the formula (III-f):

or a pharmaceutically acceptable salt or prodrug thereof, wherein Z¹,Z², L¹, X, R¹, R^(A), and n are as defined above and herein. Examples ofsuch compounds include compounds of any of formulae (III-f1), (III-f2),(III-f3) or (III-f4):

or a pharmaceutically acceptable salt or prodrug thereof, wherein Z¹,Z², X, R¹, R^(A), and n are as defined above and herein.

In certain embodiments, both W¹ and W² are C or CH, providing 6,6-fusedbicyclic compounds of formula (III-g):

or a pharmaceutically acceptable salt or prodrug thereof, wherein Z¹,Z², L¹, X, R¹, R^(A), and n are as defined above and herein. Examples ofsuch compounds include compounds of any of formulae (III-g1), (III-g2),(III-g3), (III-g4), (III-g5), (III-g6) or (III-g7):

or a pharmaceutically acceptable salt or prodrug thereof, wherein Z¹,Z², X, R¹, R^(A), and n are as defined above and herein.

Exemplary 6,6-fused bicyclic compounds encompassed by formulae (I),(III), and subgenera thereof, are provided below in Tables 1-3.

TABLE 1

TABLE 2

TABLE 3

In certain embodiments, Ring A is an optionally substituted 9-memberedbicyclic heteroaryl group. In certain embodiments, Ring A is a 6,5-fusedbicyclic heteroaryl group. In certain embodiments, Ring A is a 6,5-fusedbicyclic heteroaryl group containing 2-3 heteroatoms selected from O, S,N and NR¹⁴, wherein:

R¹⁴ is, independently, hydrogen, —SO₂R¹¹, —SOR¹¹, —C(O)R¹¹, —CO₂R¹¹,—C(O)N(R¹¹)₂, —C(O)NH(R¹¹), —C(O)NH₂, optionally substituted C₁₋₈ alkyl,optionally substituted C₂₋₈ alkenyl, optionally substituted C₂₋₈alkynyl, optionally substituted C₁₋₈ heteroalkyl, optionally substitutedC₂₋₈ heteroalkenyl, optionally substituted C₂₋₈ heteroalkynyl,optionally substituted C₃₋₁₀ carbocyclyl, optionally substituted 3-10membered heterocyclyl, optionally substituted C₆₋₁₀ aryl, or optionallysubstituted 5-10 membered heteroaryl; and

each instance of R¹¹ is, independently, optionally substituted C₁₋₈alkyl, optionally substituted C₂₋₈ alkenyl, optionally substituted C₂₋₈alkynyl, optionally substituted C₁₋₈ heteroalkyl, optionally substitutedC₂₋₈ heteroalkenyl, optionally substituted C₂₋₈ heteroalkynyl,optionally substituted C₃₋₁₀ carbocyclyl, optionally substituted 3-10membered heterocyclyl, optionally substituted C₆₋₁₀ aryl, or optionallysubstituted 5-10 membered heteroaryl.

In certain embodiments, Ring A is a 6,5-fused bicyclic heteroaryl groupcontaining 2 heteroatoms selected from O, S, N and NR¹⁴. In certainembodiments, Ring A is a 6,5-fused bicyclic heteroaryl group containing3 heteroatoms selected from O, S, N and NR¹⁴.

In certain embodiments, Ring A is an optionally substitutedbenzoxazolyl, optionally substituted benzthiazolyl, optionallysubstituted benzimidazolyl, an optionally substituted indazolyl or anoptionally substituted imidazopyridinyl group.

In certain embodiments, the present invention provides compounds offormula (IV):

or pharmaceutically acceptable salt or prodrug thereof,wherein:

(i) Z¹ is —OH or —OR³ and Z² is —OH, —OR⁴, an optionally substitutedC₁₋₈ alkyl, optionally substituted C₂₋₈ alkenyl, optionally substitutedC₂₋₈ alkynyl, optionally substituted C₁₋₈ heteroalkyl, optionallysubstituted C₂₋₈ heteroalkenyl, optionally substituted C₂₋₈heteroalkynyl, optionally substituted C₃₋₁₀ carbocyclyl, optionallysubstituted 3-10 membered heterocyclyl, optionally substituted C₆₋₁₀aryl, or optionally substituted 5-10 membered heteroaryl;

(ii) Z¹ and Z² taken together form a 5- to 8-membered ring having atleast one O, S, N or NR⁵ atom directly bonded to the boron atom; or

(iii) Z¹ is —OH or —OR³, and Z² and Ring A taken together form anoptionally substituted 5- to 7-membered ring;

each of Y³, Y⁴ and Y⁵ is independently selected from C, CR¹³, N, NR¹⁴, Oand S, with the proviso that at least one of Y³, Y⁴ or Y⁵ is aheteroatom selected from N, NR¹⁴, O or S;

Y⁶ is C or N;

X is a covalent bond, —O—, —N═N—, —C═N—, —NR⁶—, —C(NR⁶)—, —S—, —C(O)—,—S(O)—, —S(O)₂—, or optionally substituted C₁₋₆ alkylene, wherein one,two or three methylene units of the C₁₋₆ alkylene are optionally andindependently replaced with one or more groups selected from —O—, —N═N—,—C═N—, —NR⁶—, —C(NR⁶)—, —S—, —C(O)—, —S(O)—, and —S(O)₂—;

R^(A) is hydrogen, halogen, —OR⁷, —CF₃, —CN, —NO₂, —SO₂R⁷, —SOR⁷,—C(O)R⁷, —CO₂R⁷, —C(O)N(R⁷)₂, —N₃, —N₂R⁷, —N(R⁷)₂, or Ring B havingformula:

wherein Ring B is optionally substituted C₃₋₁₀ carbocyclyl, optionallysubstituted 3-10 membered heterocyclyl, optionally substituted C₆₋₁₀aryl, or optionally substituted 5-10 membered heteroaryl;

each instance of R¹ is, independently, halogen, —OR⁸, —CF₃, —CN, —NO₂,—SO₂R⁸, —SOR⁸, —C(O)R⁸, —CO₂R⁸, —C(O)N(R⁸)₂, —N₃, —N₂R⁸, —N(R⁸)₂,—B(OH₂), optionally substituted C₁₋₈ alkyl, optionally substituted C₂₋₈alkenyl, optionally substituted C₂₋₈ alkynyl, optionally substitutedC₁₋₈ heteroalkyl, optionally substituted C₂₋₈ heteroalkenyl, optionallysubstituted C₂₋₈ heteroalkynyl, optionally substituted C₃₋₁₀carbocyclyl, optionally substituted 3-10 membered heterocyclyl,optionally substituted C₆₋₁₀ aryl, or optionally substituted 5-10membered heteroaryl;

each instance of R² is, independently, halogen, —OR⁹, —CF₃, —CN, —NO₂,—SO₂R⁹, —SOR⁹, —C(O)R⁹, —CO₂R⁹, —C(O)N(R⁹)₂, —N₃, —N₂R⁹, —N(R⁹)₂,optionally substituted C₁₋₈ alkyl, optionally substituted C₂₋₈ alkenyl,optionally substituted C₂₋₈ alkynyl, optionally substituted C₁₋₈heteroalkyl, optionally substituted C₂₋₈ heteroalkenyl, optionallysubstituted C₂₋₈ heteroalkynyl, optionally substituted C₃₋₁₀carbocyclyl, optionally substituted 3-10 membered heterocyclyl,optionally substituted C₆₋₁₀ aryl, or optionally substituted 5-10membered heteroaryl;

each instance of R³ and R⁴ is, independently, optionally substitutedC₁₋₈ alkyl, optionally substituted C₂₋₈ alkenyl, optionally substitutedC₂₋₈ alkynyl, optionally substituted C₁₋₈ heteroalkyl, optionallysubstituted C₂₋₈ heteroalkenyl, optionally substituted C₂₋₈heteroalkynyl, optionally substituted C₃₋₁₀ carbocyclyl, optionallysubstituted 3-10 membered heterocyclyl, optionally substituted C₆₋₁₀aryl, or optionally substituted 5-10 membered heteroaryl;

each instance of R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, and R¹⁴ is, independently,hydrogen, —SO₂R¹¹, —SOR¹¹, —C(O)R¹¹, —CO₂R¹¹, —C(O)N(R¹¹)₂,—C(O)NH(R¹¹), —C(O)NH₂, optionally substituted C₁₋₈ alkyl, optionallysubstituted C₂₋₈ alkenyl, optionally substituted C₂₋₈ alkynyl,optionally substituted C₁₋₈ heteroalkyl, optionally substituted C₂₋₈heteroalkenyl, optionally substituted C₂₋₈ heteroalkynyl, optionallysubstituted C₃₋₁₀ carbocyclyl, optionally substituted 3-10 memberedheterocyclyl, optionally substituted C₆₋₁₀ aryl, or optionallysubstituted 5-10 membered heteroaryl;

each instance of R¹¹ is, independently, optionally substituted C₁₋₈alkyl, optionally substituted C₂₋₈ alkenyl, optionally substituted C₂₋₈alkynyl, optionally substituted C₁₋₈ heteroalkyl, optionally substitutedC₂₋₈ heteroalkenyl, optionally substituted C₂₋₈ heteroalkynyl,optionally substituted C₃₋₁₀ carbocyclyl, optionally substituted 3-10membered heterocyclyl, optionally substituted C₆₋₁₀ aryl, or optionallysubstituted 5-10 membered heteroaryl;

each instance of R¹³ is, independently, hydrogen, halogen, —CF₃,optionally substituted C₁₋₈ alkyl, optionally substituted C₂₋₈ alkenyl,or optionally substituted C₂₋₈ alkynyl;

n is 0, 1, 2 or 3; and

m is 0, 1, 2, 3, 4 or 5.

In certain embodiments, the present invention provides compounds of anyof formulae (IV-a), (IV-b), (IV-c), (IV-d) or (IV-e):

or pharmaceutically acceptable salts or prodrugs thereof, wherein Y³,Y⁴, Y⁵, Y⁶, Z¹, Z², R¹, X, n and R^(A) are as defined above and herein.

In certain embodiments, n is 0. In certain embodiments, n is 1 or 2. Incertain embodiments, n is 1.

In certain embodiments, R¹ is halogen. In certain embodiments, R¹ is —F.In certain embodiments, R¹ is —Br.

In certain embodiments, X is a covalent bond or an optionallysubstituted C₁₋₆ alkylene. In certain embodiments, X is a covalent bond.In certain embodiments, X is —CH₂—, —(CH₂)₂—, —(CH₂)₃—, —(CH₂)₄—,—(CH₂)₅— or —(CH₂)₅(C═O)—.

In certain embodiments, R^(A) is hydrogen. In certain embodiments, R^(A)is —CF₃.

In certain embodiments, R^(A) is Ring B. In certain embodiments, Ring Bis an optionally substituted phenyl, optionally substitutedpyrrolidinone or an optionally substituted piperidinyl.

In certain embodiments, m is 0. In certain embodiments, m is 1 or 2. Incertain embodiments, m is 1.

In certain embodiments, R² is optionally substituted C₁₋₈ alkyl,optionally substituted C₆₋₁₀ aryl, —SO₂R⁹, —SOR⁹, —C(O)R⁹, or —CO₂R⁹. Incertain embodiments, R² is —C₃H₇, —CH₂CH(CH₃)₂, —CO₂tBu,—C(O)(CH₂)₂C₆H₅, —C₆H₅, —CH₂C₅, or —SO₂C₆H₅.

In certain embodiments, two of Y³, Y⁴ and Y⁵ are, independently,heteroatoms selected from N, NR¹⁴, O or S, and Y⁶ is C.

In certain embodiments, one of Y³, Y⁴, Y⁵ is a heteroatom selected fromN, NR¹⁴, O or S, and Y⁶ is C or N.

In certain embodiments, one of Y³, Y⁴, Y⁵ is a heteroatom selected fromN, NR¹⁴, O or S, and Y⁶ is N.

In certain embodiments, Y³ is O or S. In certain embodiments, Y³ is O.In certain embodiments, Y³ is S.

In certain embodiments, Y⁶ is C.

In certain embodiments, Y³ is O or S, Y⁴ is C, Y⁵ is N and Y⁶ is C. Incertain embodiments, wherein Y³ is O or S; Y⁴ is C; Y⁵ is N and Y⁶ is C,the following compounds are specifically excluded:

(i) compounds wherein n is 0, X is a covalent bond, and R^(A) ishydrogen; and/or

(ii) compounds wherein n is 0, X is —CH₂—, and R^(A) is hydrogen.

In certain embodiments, Y³ is O or S, Y⁴ and Y⁵ are, independently, C orCR¹³ and Y⁶ is C. In certain embodiments, wherein Y³ is O or S, Y⁴ andY⁵ are, independently, C or CR¹³ and Y⁶ is C, the following compoundsare specifically excluded:

-   -   (i) compounds wherein n is 0, X is a covalent bond or —CH₂—, and        R^(A) is hydrogen or chloro;    -   (ii) compounds wherein n is 0, X is —CH₂O— or —OCH₂— and R^(A)        is —C₆H₅; and/or    -   (iii) compounds wherein n or is 0, X is —(C═O)—, and R^(A) is        —C₆H₅.

In certain embodiments, Y³ and Y⁴ are, independently, N or NR¹⁴, Y⁵ is Cor CR¹³ and Y⁶ is C. In certain embodiments, wherein Y³ and Y⁴ are,independently, N or NR¹⁴, Y⁵ is C or CR¹³ and Y⁶ is C, the followingcompounds are specifically excluded:

(i) compounds wherein n is 0, X is a covalent bond, and R^(A) ishydrogen.

In certain embodiments, Y³ and Y⁵ are, independently, N or NR¹⁴, Y⁴ is Cor CR¹³, and Y⁶ is C. In certain embodiments, wherein Y³ and Y⁵ are,independently, N or NR¹⁴, Y⁴ is C or CR¹³, and Y⁶ is C, the followingcompounds are specifically excluded:

(i) compounds wherein n is 0, X is a covalent bond, and R^(A) ishydrogen.

In certain embodiments, Y³ and Y⁶ are, independently, N and Y⁴ and Y⁵are, independently, C or CR¹³. In certain embodiments, wherein Y³ and Y⁶are, independently, N and Y⁴ and Y⁵ are, independently, C or CR¹³, thefollowing compounds are specifically excluded:

(i) compounds wherein n is 0, X is a covalent bond, and R^(A) ishydrogen.

In certain embodiments, Y³ is N or NR¹⁴, and Y⁴, Y⁵ and Y⁶ are,independently, C or CR¹³. In certain embodiments, wherein Y³ is N orNR¹⁴, and Y⁴, Y⁵ and Y⁶ are, independently, C or CR¹³, the followingcompounds are specifically excluded:

-   -   (i) compounds wherein n is 0, X is a covalent bond, and R^(A) is        hydrogen;    -   (ii) compounds wherein n is 0, X is —OCH₂— or —CH₂O—, and R^(A)        is —C₆H₅; and/or    -   (iii) compounds wherein n is 0, 1 or 2, R¹ is —OH or —OCH₃, X is        —(C═O)— and R^(A) is —OR⁷.

In certain embodiments, the following compounds are specificallyexcluded:

or pharmaceutically acceptable salts or prodrugs thereof.

In certain embodiments, the present invention provides compounds of theformula (IV-f):

or pharmaceutically acceptable salts or prodrugs thereof, wherein Y³,Z¹, Z², R¹, X, n and R^(A) are as defined above and herein. Examples ofsuch compounds include compounds of the formulae (IV-f1) and (IV-f2):

or a pharmaceutically acceptable salt or prodrug thereof, wherein Y³,Z¹, Z², R¹, X, n and R^(A) are as defined above and herein.

In certain embodiments, the present invention provides compounds of theformula (IV-g):

or a pharmaceutically acceptable salt or prodrug thereof, wherein Y³,Z¹, Z², R¹, X, n and R^(A) are as defined above and herein. Examples ofsuch compounds include compounds of either of formulae (IV-g1) and(IV-g2):

or a pharmaceutically acceptable salt or prodrug thereof, wherein Y³,Z¹, Z², R¹, X, n and R^(A) are as defined above and herein.

In certain embodiments, the present invention provides compounds offormula (IV-h):

or a pharmaceutically acceptable salt or prodrug thereof, wherein Z¹,Z², R¹, X, n and R^(A) are as defined above and herein. Examples of suchcompounds include compounds of the formulae (IV-h1) and (IV-h2):

In certain embodiments, the present invention provides compounds ofeither of formulae (IV-i) or (IV-k):

or a pharmaceutically acceptable salt or prodrug thereof, wherein Z¹,Z², R¹, X, n and R^(A) are as defined above and herein. Examples of suchcompounds include compounds of any of formulae (IV-i1), (IV-i2), (IV-k1)and (IV-k2):

or a pharmaceutically acceptable salt or prodrug thereof, wherein Z¹,Z², R¹, X, n and R^(A) are as defined above and herein.

In certain embodiments, the present invention provides compounds of theformulae (IV-m) or (IV-n):

or a pharmaceutically acceptable salt or prodrug thereof, wherein R¹⁴,Z¹, Z², R¹, X, n and R^(A) are as defined above and herein.

Exemplary 6,5-fused bicyclic compounds encompassed by formulae (I),(IV), and subgenera thereof, are provided below in Tables 4-8.

TABLE 4

TABLE 5

TABLE 6

TABLE 7

TABLE 8 317

(x) Compounds of Formula II, Wherein Ring B is Het-B

In certain embodiments, the present invention provides compounds offormula (II):

or a pharmaceutically acceptable salt or prodrug thereof, wherein Z¹,Z², L¹, X, Ring A, Ring B, R¹, R², n and m are as defined above andherein.

In certain embodiments, Ring B is optionally substituted 3-10 memberedheterocyclyl or optionally substituted 5-10 membered heteroaryl (i.e.,referred to as “Het-B”). Such ring systems are depicted and described indetail above and herein.

For example, in certain embodiments, the present invention providescompounds of formula (V):

or a pharmaceutically acceptable salt or prodrug thereof;wherein:

(i) Z¹ is —OH or —OR³ and Z² is —OH, —OR⁴, an optionally substitutedC₁₋₈ alkyl, optionally substituted C₂₋₈ alkenyl, optionally substitutedC₂₋₈ alkynyl, optionally substituted C₁₋₈ heteroalkyl, optionallysubstituted C₂₋₈ heteroalkenyl, optionally substituted C₂₋₈heteroalkynyl, optionally substituted C₃₋₁₀ carbocyclyl, optionallysubstituted 3-10 membered heterocyclyl, optionally substituted C₆₋₁₀aryl, or optionally substituted 5-10 membered heteroaryl;

(ii) Z¹ and Z² taken together form a 5- to 8-membered ring having atleast one O, S, N or NR⁵ atom directly bonded to the boron atom; or

(iii) Z¹ is —OH or —OR³, and Z² and Ring A taken together form anoptionally substituted 5- to 7-membered ring;

W³ is C, CR¹⁵, or N;

X is a covalent bond, —O—, —N═N—, —C═N—, —NR⁶—, —C(NR⁶)—, —S—, —C(O)—,—S(O)—, —S(O)₂—, or optionally substituted C₁₋₆ alkylene, wherein one,two or three methylene units of the C₁₋₆ alkylene are optionally andindependently replaced with one or more groups selected from —O—, —N═N—,—C═N—, —NR⁶—, —C(NR⁶)—, —S—, —C(O)—, —S(O)—, and —S(O)₂—;

Het-B is an optionally substituted 3-10 membered heterocyclyl or anoptionally substituted 5-10 membered heteroaryl ring;

each instance of R¹ is, independently, halogen, —OR⁸, —CF₃, —CN, —NO₂,—SO₂R⁸, —SOR⁸, —C(O)R⁸, —CO₂R⁸, —C(O)N(R⁸)₂, —N₃, —N₂R⁸, —N(R⁸)₂,—B(OH₂), optionally substituted C₁₋₈ alkyl, optionally substituted C₂₋₈alkenyl, optionally substituted C₂₋₈ alkynyl, optionally substitutedC₁₋₈ heteroalkyl, optionally substituted C₂₋₈ heteroalkenyl, optionallysubstituted C₂₋₈ heteroalkynyl, optionally substituted C₃₋₁₀carbocyclyl, optionally substituted 3-10 membered heterocyclyl,optionally substituted C₆₋₁₀ aryl, or optionally substituted 5-10membered heteroaryl;

each instance of R² is, independently, halogen, —OR⁹, —CF₃, —CN, —NO₂,—SO₂R⁹, —SOR⁹, —C(O)R⁹, —CO₂R⁹, —C(O)N(R⁹)₂, —N₃, —N₂R⁹, —N(R⁹)₂,optionally substituted C₁₋₈ alkyl, optionally substituted C₂₋₈ alkenyl,optionally substituted C₂₋₈ alkynyl, optionally substituted C₁₋₈heteroalkyl, optionally substituted C₂₋₈ heteroalkenyl, optionallysubstituted C₂₋₈ heteroalkynyl, optionally substituted C₃₋₁₀carbocyclyl, optionally substituted 3-10 membered heterocyclyl,optionally substituted C₆₋₁₀ aryl, or optionally substituted 5-10membered heteroaryl;

each instance of R³ and R⁴ is, independently, optionally substitutedC₁₋₈ alkyl, optionally substituted C₂₋₈ alkenyl, optionally substitutedC₂₋₈ alkynyl, optionally substituted C₁₋₈ heteroalkyl, optionallysubstituted C₂₋₈ heteroalkenyl, optionally substituted C₂₋₈heteroalkynyl, optionally substituted C₃₋₁₀ carbocyclyl, optionallysubstituted 3-10 membered heterocyclyl, optionally substituted C₆₋₁₀aryl, or optionally substituted 5-10 membered heteroaryl;

each instance of R⁵, R⁶, R⁷, R⁸, R⁹, and R¹⁰ is, independently,hydrogen, —SO₂R¹¹, —SOR¹¹, —C(O)R¹¹, —CO₂R¹¹, —C(O)N(R¹¹)₂,—C(O)NH(R¹¹), —C(O)NH₂, optionally substituted C₁₋₈ alkyl, optionallysubstituted C₂₋₈ alkenyl, optionally substituted C₂₋₈ alkynyl,optionally substituted C₁₋₈ heteroalkyl, optionally substituted C₂₋₈heteroalkenyl, optionally substituted C₂₋₈ heteroalkynyl, optionallysubstituted C₃₋₁₀ carbocyclyl, optionally substituted 3-10 memberedheterocyclyl, optionally substituted C₆₋₁₀ aryl, or optionallysubstituted 5-10 membered heteroaryl;

each instance of R¹¹ is, independently, hydrogen, optionally substitutedC₁₋₈ alkyl, optionally substituted C₂₋₈ alkenyl, optionally substitutedC₂₋₈ alkynyl, optionally substituted C₁₋₈ heteroalkyl, optionallysubstituted C₂₋₈ heteroalkenyl, optionally substituted C₂₋₈heteroalkynyl, optionally substituted C₃₋₁₀ carbocyclyl, optionallysubstituted 3-10 membered heterocyclyl, optionally substituted C₆₋₁₀aryl, or optionally substituted 5-10 membered heteroaryl;

R¹⁵ is hydrogen, halogen, —CF₃, optionally substituted C₁₋₈ alkyl,optionally substituted C₂₋₈ alkenyl, or optionally substituted C₂₋₈alkynyl;

n is 0, 1, 2 or 3; and

m is 0, 1, 2, 3, 4, or 5.

In certain embodiments, each n is 0. In certain embodiments, each n isindependently 1 or 2. In certain embodiments, each n is 1.

In certain embodiments, R¹ is halogen, —OR⁸, —CF₃, optionallysubstituted C₁₋₈ alkyl or optionally substituted 5-membered heteroaryl.In certain embodiments, R¹ is —Cl, —F, —OCH₃, —OCH₂CH₂C₆H₅, —O(CH₂)₃CH₃,—CH₂C(CH₃)₂, or an optionally substituted oxadiazolyl.

In certain embodiments, X is a covalent bond or an optionallysubstituted C₁₋₆ alkylene. In certain embodiments, X is a covalent bond.In certain embodiments, X is —CH₂— or —CH═CH—.

In certain embodiments, each m is 0. In certain embodiments, each m isindependently 1 or 2. In certain embodiments, each m is 1.

In certain embodiments, R² is selected from —OR⁹, —N(R⁹)₂, optionallysubstituted C₁₋₈ alkyl, optionally substituted C₂₋₈ alkenyl, optionallysubstituted C₁₋₈ heteroalkyl, optionally substituted C₆₋₁₀ aryl, oroptionally substituted 5-10 membered heteroaryl. In certain embodiments,R² is selected from optionally substituted C₁₋₈ alkyl, optionallysubstituted C₆₋₁₀ aryl, or optionally substituted 5-10 memberedheteroaryl.

In certain embodiments, R² is selected from —CH₃, —CH₂CH₃, —CH₂C(CH₃)₂,—(CH₂)₂CH₃, —C(CH₃)₃, —(CH₂)₃CH₃, —CH₂C(CH₃)₂, —(CH₂)₄CH₃, —(CH₂)₅CH₃,—(CH₂)₃C(CH₃)₂, —(CH₂)₆CH₃, —(CH₂)₄CH₃, —CH₂CH₂CF₃, —CH(CH₃)(CH₂)₃CH₃,—CH═CH(CH₂)₂CH₃, —(CH₂)₂CH(CH₃)CH₂CH₃, —CH₂CH₂CH₂CF₃, —CH₂CH₂CF₂CF₃,—C(OH)(CH₃)₂, —CH₂CH₂CH₂(C═O)-(oxadiazole), optionally substitutedpyridinyl, -C₆H₅, optionally substituted phenyl, optionally substitutedbenzyl, —CH₂CH₂Ph, optionally substituted furanyl, optionallysubstituted imidazolyl, optionally substituted thiazolyl, —OCH₃,—OCH₂CH₃, —CH₂OCH₃, —CH₂OCH₂CH₃, —CH₂CH₂CH₂OCH₃, —CH₂NHBoc,—CH₂CH₂NHBoc, —CH₂CH₂NHAc, —CH₂CH₂NH(C═O)OCH₃, —N(CH₃)₂,—CH₂CH₂N(—C═OCH₂CH₂CH₂—), —CH₂CH₂(C═O)N(—CH₂CH₂CH₂CH₂CH₂—), —CH₂C₅H₉,—CH₂C₆H₁₁, —CH₂CH₂C₅H₉, —CH₂CH₂C₆H₁₁, —CH₂(furanyl), —CH₂(thiophenyl),and —CH₂(indanyl). In certain embodiments, R² is selected from—(CH₂)₄CH₃, —CH₂CH₂CF₂CF₃, optionally substituted pyridinyl andoptionally substituted phenyl. In certain embodiments, R² is selectedfrom —(CH₂)₄CH₃, —CH₂CH₂CF₂CF₃, -pyridinyl or —C₆H₅.

In certain embodiments, W³ is C or CR¹⁵. In certain embodiments, W³ is Cor CH. In certain embodiments, W³ is CH. In certain embodiments, W³ isN.

In certain embodiments, the present invention provides compounds offormula (V-a):

or a pharmaceutically acceptable salt or prodrug thereof, wherein W³,Z¹, Z², X, Het-B, R¹, R², m and n are as defined above and herein.Examples of such compounds, wherein Ring A is substituted ortho, meta,or para to the boron atom with the group X-HetB, are provided incompounds of any of formulae (V-b), (V-c) or (V-d):

or a pharmaceutically acceptable salt or prodrug thereof, wherein W³,Z¹, Z², X, Het-B, R¹, R², m and n are as defined above and herein.

Exemplary Het-B rings include, but are not limited to,

wherein Y¹, Y², Y⁷, Y⁸, W⁴, W⁵, W⁶, W⁷ and p are as defined below, andR² and m are as defined above and herein.

For example, in certain embodiments, the present invention providescompounds of formula (V-e):

or a pharmaceutically acceptable salt or prodrug thereof, wherein W³,Z¹, Z², X, Het-B, R¹, R², m and n are as defined above and herein, andY¹ is O, S or NR¹⁶.

In certain embodiments, Y¹ is O or S. In certain embodiments, Y¹ is O.In certain embodiments, Y¹ is S. For example, in certain embodiments,the present invention provides compounds of any of formulae (V-e1),(V-e2), (V-e3), (V-e4), (V-e5), (V-e6), or (V-e7):

or a pharmaceutically acceptable salt or prodrug thereof, wherein W³,Z¹, Z², X, Het-B, R¹, R², m and n are as defined above and herein.

In certain embodiments, the present invention provides compounds offormula (V-f):

or a pharmaceutically acceptable salt or prodrug thereof, wherein W³,Z¹, Z², X, R¹, R², m and n are as defined above and herein. For example,in certain embodiments, the present invention provides compounds of anyof formulae (V-f1), (V-f2), (V-f3) or (V-f4):

or a pharmaceutically acceptable salt or prodrug thereof, wherein W³,Z¹, Z², X, Het-B, R¹, R², m and n are as defined above and herein.

In certain embodiments, the present invention provides compounds offormula (V-g):

or a pharmaceutically acceptable salt or prodrug thereof, wherein W³,Z¹, Z², X, R¹, R², and m and n are as defined above and herein. Forexample, in certain embodiments, the present invention providescompounds of either of formulae (V-g1) and (V-g2):

or a pharmaceutically acceptable salt or prodrug thereof, wherein W³,R¹⁶, Z¹, Z², X, R¹, R², m and n are as defined above and herein.

In certain embodiments, the present invention provides compounds offormula (V-h):

or a pharmaceutically acceptable salt or prodrug thereof, wherein W³,Z¹, Z², X, R¹, R², m and n are as defined above and herein, and Y² is O,S or NR¹⁶.

In certain embodiments, the present invention provides compounds offormulae (V-h1) or (V-h2):

or a pharmaceutically acceptable salt or prodrug thereof, wherein Y²,W³, Z¹, Z², X, R¹, R², m and n are as defined above and herein.

In certain embodiments, Y² is O or S. In certain embodiments, Y² is O.In certain embodiments, Y² is S. For example, in certain embodiments,the present invention provides compounds of any of formulae (V-h3),(V-h4), (V-h5), (V-h6), (V-h7), (V-h8), (V-h9) or (V-h10):

or a pharmaceutically acceptable salt or prodrug thereof, wherein W³,R¹⁶, Z¹, Z², X, R¹, R², m and n are as defined above and herein.

In certain embodiments, the present invention provides compounds offormula (V-i):

or pharmaceutically acceptable salts or prodrugs thereof, wherein W³,Z¹, Z², R¹, R², m and n are as defined above and herein,

Y⁷ and Y⁸ are independently selected from N, NR¹⁶, O and S, and

W⁴ is C, CR¹⁷ or N, wherein R¹⁷ is hydrogen, halogen, —CF₃, optionallysubstituted C₁₋₈ alkyl, optionally substituted C₂₋₈ alkenyl, oroptionally substituted C₂₋₈ alkynyl.

In certain embodiments, Y⁷ is O or S and Y⁸ is N. In certainembodiments, Y⁷ is O and Y⁸ is N. In certain embodiments, Y⁷ is S and Y⁸is N.

In certain embodiments, W⁴ is N.

In certain embodiments, W⁴ is C or CR¹⁷. In certain embodiments, W⁴ is Cor CH.

In certain embodiments, the present invention provides compounds offormulae (V-i1):

or pharmaceutically acceptable salts or prodrugs thereof, wherein W³,Z¹, Z², X, R¹, R², m, n, W⁴, Y⁷ and Y⁸, are as defined above and herein.

In certain embodiments, the present invention provides compounds of theformula (V-j):

or a pharmaceutically acceptable salt or prodrug thereof, wherein W³,Z¹, Z², X, R¹, R², m and n are as defined above and herein, W⁵ is N orN¹⁶, and the dashed line represents a single or double bond. In certainembodiments, the dashed line is a single bond. In certain embodiments,the dashed line is a double bond. For example, in certain embodiments,the present invention provides compounds of formulae (V-j1), (V-j2),(V-j3), (V-j4), (V-j5) or (V-j6):

or a pharmaceutically acceptable salt or prodrug thereof, wherein W³,Z¹, Z², X, R¹, R², R¹⁶, m and n are as defined above and herein.

In certain embodiments, the present invention provides compounds offormula (V-k):

or a pharmaceutically acceptable salt or prodrug thereof, wherein W³,Z¹, Z², R¹, R², m and n are as defined above and herein, and p is 1 or2. For example, in certain embodiments, the present invention providescompounds of either of formulae (V-k1) or (V-k2):

or a pharmaceutically acceptable salt or prodrug thereof, wherein W³,Z¹, Z², R¹, R², m and n are as defined above and herein.

In certain embodiments, the present invention provides compounds offormula (V-m):

or pharmaceutically acceptable salts or prodrugs thereof, wherein W³,Z¹, Z², X, R¹, R², R¹⁶, m, and n, arc as defined above and herein, andW⁶ and W⁷ arc selected from N or CH, with the proviso that one or bothof W⁶ and W⁷ is N. For example, in certain embodiments, the presentinvention provides compounds of either of formulae (V-m1), (V-m2) or(V-m3):

or pharmaceutically acceptable salts or prodrugs thereof, wherein W³,W⁶, Z¹, Z², X, R¹, R², R¹⁶, m, and n, are as defined above and herein.

Additional Embodiments Wherein Het-B is an Optionally Substituted 3-10Membered Heterocyclyl Ring

As generally defined above, in certain embodiments, Het-B is anoptionally substituted 3-10 membered heterocyclyl ring.

In certain embodiments, Het-B is an optionally substituted 3-10 memberedheterocyclyl ring, wherein said heterocyclyl ring has 1 to 3 heteroatomsselected from N, NR¹⁶, O and S, and R¹⁶ is, independently, hydrogen,—SO₂R¹¹, —SOR¹¹, —C(O)R¹¹, —CO₂R¹¹, —C(O)N(R¹¹)₂, —C(O)NH(R¹¹),—C(O)NH₂, optionally substituted C₁₋₈ alkyl, optionally substituted C₂₋₈alkenyl, optionally substituted C₂₋₈ alkynyl, optionally substitutedC₁₋₈ heteroalkyl, optionally substituted C₂₋₈ heteroalkenyl, optionallysubstituted C₂₋₈ heteroalkynyl, optionally substituted C₃₋₁₀carbocyclyl, optionally substituted 3-10 membered heterocyclyl,optionally substituted C₆₋₁₀ aryl, or optionally substituted 5-10membered heteroaryl.

In certain embodiments, Het-B is an optionally substituted 5-6 memberedmonocyclic heterocyclyl ring.

In certain embodiments, Het-B is an optionally substituted 5-memberedmonocyclic heterocyclyl ring. In certain embodiments, Het-B is anoptionally substituted 5-membered monocyclic heterocyclyl ringcontaining 1 to 3 heteroatoms selected from N, NR¹⁶, O and S. In certainembodiments, Het-B is an optionally substituted 5-membered monocyclicheterocyclyl ring containing 1 heteroatom selected from N, NR¹⁶, O andS. In certain embodiments, Het-B is an optionally substituted 5-memberedmonocyclic heterocyclyl ring containing 2 heteroatoms selected from N,NR¹⁶, O and S. In certain embodiments, Het-B is an optionallysubstituted 5-membered monocyclic heterocyclyl ring containing 3heteroatoms selected from N, NR¹⁶, O and S. In certain embodiments,Het-B is an optionally substituted 5-membered monocyclic heterocyclylring selected from the group consisting of optionally substituted1,3-dioxolanyl, optionally substituted 4,5-dihydroisoxazolyl, optionallysubstituted isoxazolidinyl, optionally substituted oxazolidinyl,optionally substituted tetrahydrofuranyl, optionally substitutedpyrrolidinyl and optionally substituted pyrrolyl-2,5-dione.

In certain embodiments, wherein Het-B is an optionally substitutedpyrrolidinyl (i.e., containing 1 heteroatom selected from N or NR¹⁶),the following compounds are specifically excluded:

-   -   (i) compounds wherein W³ is CH, n is 0, m is 0 and X is a        covalent bond or —CH₂OCH₂—;    -   (ii) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (iii) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A        taken together form a 5-membered ring containing 1 O atom.

In certain embodiments, Het-B is an optionally substituted 6-memberedmonocyclic heterocyclyl ring containing 1 to 3 heteroatoms selected fromN, NR¹⁶, O and S. In certain embodiments, Het-B is an optionallysubstituted 6-membered monocyclic heterocyclyl ring containing 1heteroatom selected from N, NR¹⁶, O and S. In certain embodiments, Het-Bis an optionally substituted 6-membered monocyclic heterocyclyl ringcontaining 2 heteroatoms selected from N, NR¹⁶, O and S. In certainembodiments, Het-B is an optionally substituted 6-membered monocyclicheterocyclyl ring containing 3 heteroatoms selected from N, NR¹⁶, O andS. In certain embodiments, Het-B is an optionally substituted 6-memberedmonocyclic heterocyclyl ring selected from the group consisting ofoptionally substituted 1,3-dioxanyl, optionally substituted piperidinyl,optionally substituted piperazinyl, optionally substituted morpholinyl,and optionally substituted tetrahydropyranyl.

In certain embodiments, wherein Het-B is an optionally substitutedpiperidinyl (i.e., containing 1 heteroatom selected from N or NR¹⁶), thefollowing compounds are specifically excluded:

-   -   (i) compounds wherein W³ is CH, n is 0, m is 0 and X is —(C═O)—        or a covalent bond;    -   (ii) compounds wherin W³ is CH, n is 1, R¹ is fluoro, and X is        —OCH₂CH₂— or —CH₂CH₂O—;    -   (iii) compounds wherein W³ is CH, n is 0 and X is —(C═O)—;    -   (iv) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (v) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A taken        together form a 5-membered ring containing 1 O atom.

In certain embodiments, wherein Het-B is an optionally substitutedpiperazinyl (i.e., containing 2 heteroatoms selected from N or NR¹⁶),the following compounds are specifically excluded:

-   -   (i) compounds wherein W³ is CH, n is 1, and X is a covalent        bond, —OCH₂(C═O)— or —(C═O)CH₂O—;    -   (ii) compounds wherein W³ is N, n is 1, R¹ is —CH₃ and X is a        covalent bond;    -   (iii) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (iv) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A        taken together form a 5-membered ring containing 1 O atom.

In certain embodiments, wherein Het-B is an optionally substitutedmorpholynyl (i.e., containing 1 heteroatom selected from O and 1heteroatom selected from N or NR¹⁶), the following compounds arespecifically excluded:

-   -   (i) compounds wherein W³ is CH, n is 0 or 1, m is 0 and X is        —(C═O)— or a covalent bond;    -   (ii) compounds wherein W³ is N, n is 1, R¹ is —CH₃ and X is a        covalent bond;    -   (iii) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (iv) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A        taken together form a 5-membered ring containing 1 O atom.

In certain embodiments, wherein Het-B is an optionally substitutedtetrahydropyranyl (i.e., containing 2 O heteroatoms), the followingcompounds are specifically excluded:

-   -   (i) compounds wherein W³ is CH, n is 0, m is 0 and X is —O— or        —CH₂OCH₂—;    -   (ii) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (iii) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A        taken together form a 5-membered ring containing 1 O atom.

In certain embodiments, Het-B is an optionally substituted 9-10 memberedbicyclic heterocyclyl ring.

In certain embodiments, Het-B is an optionally substituted 9-memberedbicyclic heterocyclyl ring containing 1 to 3 heteroatoms selected fromN, NR¹⁶, O and S. In certain embodiments, Het-B is an optionallysubstituted 9-membered bicyclic heterocyclyl ring containing 1heteroatom selected from N, NR¹⁶, O and S. In certain embodiments, Het-Bis an optionally substituted 9-membered bicyclic heterocyclyl ringcontaining 2 heteroatoms selected from N, NR¹⁶, O and S. In certainembodiments, Het-B is an optionally substituted 9-membered bicyclicheterocyclyl ring containing 3 heteroatoms selected from N, NR¹⁶, O andS. In certain embodiments, Het-B is an optionally substituted 9-memberedbicyclic heterocyclyl ring selected from the group consisting ofoptionally substituted indolinyl, optionally substitutedisoindolinyl-1,3-dione, and optionally substitutedbenzo[d][1,3]dioxolyl.

In certain embodiments, wherein Het-B is an optionally substitutedindolinyl (i.e., containing 1 heteroatom selected from N or NR¹⁶), thefollowing compounds are specifically excluded:

-   -   (i) compounds wherein W³ is CH, n is 0, m is 0, and X is —CH₂—;    -   (ii) compounds wherein W³ is CH, n is 1, R¹ is fluoro, m is 0,        and X is —CH₂—;    -   (iii) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (iv) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A        taken together form a 5-membered ring containing 1 O atom.

In certain embodiments, wherein Het-B is an optionally substitutedisoindolinyl-1,3-dione (i.e., containing 1 heteroatom selected from N orNR¹⁶), the following compounds are specifically excluded:

-   -   (i) compounds wherein W³ is CH, n is 0, m is 0 and X is —CH₂—;    -   (ii) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (iii) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A        taken together form a 5-membered ring containing 1 O atom.

In certain embodiments, wherein Het-B is an optionally substitutedbenzo[d][1,3]dioxolyl (i.e., containing 2 O heteroatoms), the followingcompounds are specifically excluded:

-   -   (i) compounds wherein W³ is CH, n is 0, m is 0 and X is —O—;    -   (ii) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (iii) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A        taken together form a 5-membered ring containing 1 O atom.

In certain embodiments, Het-B is an optionally substituted 10-memberedbicyclic heterocyclyl ring containing 1 to 3 heteroatoms selected fromN, NR¹⁶, O and S. In certain embodiments, Het-B is an optionallysubstituted 10-membered bicyclic heterocyclyl ring containing 1heteroatom selected from N, NR¹⁶, O and S. In certain embodiments, Het-Bis an optionally substituted 10-membered bicyclic heterocyclyl ringcontaining 2 heteroatoms selected from N, NR¹⁶, O and S. In certainembodiments, Het-B is an optionally substituted 10-membered bicyclicheterocyclyl ring containing 3 heteroatoms selected from N, NR¹⁶, O andS. In certain embodiments, Het-B is an optionally substituted 9-memberedbicyclic heterocyclyl ring selected from the group consisting ofoptionally substituted 1,2,3,4-tetrahydroquinolinyl.

In certain embodiments, wherein Het-B is an optionally substituted1,2,3,4-tetrahydroquinolinyl (i.e., containing 1 heteroatom selectedfrom N or NR¹⁶), the following compounds are specifically excluded:

-   -   (iv) compounds wherein W³ is CH, n is 0, m is 0 and X is —CH₂—;    -   (v) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (vi) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A        taken together form a 5-membered ring containing 1 O atom.

Additional Embodiments Wherein Het-B is an Optionally Substituted 5-10Membered Heteroaryl Ring

As generally defined above, in certain embodiments, Het-B is anoptionally substituted 5-10 membered heteroaryl ring.

In certain embodiments, Het-B is an optionally substituted 5-10 memberedheteroaryl ring, wherein said heteroaryl ring has 1 to 3 heteroatomsselected from N, NR¹⁶, O and S, and R¹⁶ is, independently, hydrogen,—SO₃R¹¹, —SOR¹¹, —C(O)R¹¹, —CO₂R¹¹, —C(O)N(R¹¹)₂, —C(O)NH(R¹¹),—C(O)NH₂, optionally substituted C₁₋₈ alkyl, optionally substituted C₂₋₈alkenyl, optionally substituted C₂₋₈ alkynyl, optionally substitutedC₁₋₈ heteroalkyl, optionally substituted C₂₋₈ heteroalkenyl, optionallysubstituted C₂₋₈ heteroalkynyl, optionally substituted C₃₋₁₀carbocyclyl, optionally substituted 3-10 membered heterocyclyl,optionally substituted C₆₋₁₀ aryl, or optionally substituted 5-10membered heteroaryl.

In certain embodiments, Het-B is an optionally substituted 5-6 memberedmonocyclic heteroaryl ring.

In certain embodiments, Het-B is an optionally substituted 5-memberedmonocyclic heteroaryl ring containing 1 to 3 heteroatoms selected fromN, NR¹⁶, O and S. In certain embodiments, Het-B is an optionallysubstituted 5-membered monocyclic heteroaryl ring containing 1heteroatom selected from N, NR¹⁶, O and S. In certain embodiments, Het-Bis an optionally substituted 5-membered monocyclic heteroaryl ringcontaining 2 heteroatoms selected from N, NR¹⁶, O and S. In certainembodiments, Het-B is an optionally substituted 5-membered monocyclicheteroaryl ring containing 3 heteroatoms selected from N, NR¹⁶, O and S.In certain embodiments, Het-B is an optionally substituted 5-memberedmonocyclic heteroaryl ring selected from the group consisting ofoptionally substituted triazolyl, optionally substituted oxadiazolyl,optionally substituted thiadiazolyl, optionally substituted imidazolyl,optionally substituted pyrazolyl, optionally substituted thiazolyl,optionally substituted isothiazolyl, optionally substituted oxazolyl,optionally substituted isoxazolyl, optionally substituted thiophenyl,optionally substituted furanyl and optionally substituted pyrrolyl.

In certain embodiments, wherein Het-B is an optionally substitutedoxadiazolyl group (i.e., containing one O and two N atoms), thefollowing compounds are specifically excluded:

-   -   (i) compounds wherein W³ is CH, X is a covalent bond, n is 0 and        m is 0;    -   (ii) compounds wherein W³ is CH, X is a covalent bond, n is 0, m        is 1 and R² is an unsubstituted furanyl group;    -   (iii) compounds wherein W³ is CH, X is a covalent bond, n is 0,        m is 1 and R² is —CH₃;    -   (iv) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (v) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A taken        together form a 5-membered ring containing 1 O atom.

In certain embodiments, wherein Het-B is an optionally substitutedthiadiazolyl group (i.e., containing one S and two N atoms), thefollowing compounds are specifically excluded:

(i) compounds wherein W³ is CH, X is a covalent bond, n is 0 and m is 0;

-   -   (ii) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (iii) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A        taken together form a 5-membered ring containing 1 O atom.    -   In certain embodiments, wherein Het-B is an optionally        substituted triazolyl group (i.e., containing three heteroatoms        selected from N and NR¹⁶), the following compounds are        specifically excluded:

(i) compounds wherein W³ is CH, X is a covalent bond, n is 0 and m is 0;

-   -   (ii) compounds wherein W³ is CH, X is —OCH₂— or —CH₂O—, n is 1,        R¹ is fluoro, m is 1 and R² is a cyclohexyl group;    -   (iii) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (iv) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A        taken together form a 5-membered ring containing 1 O atom.

In certain embodiments, wherein Het-B is an optionally substitutedoxazolyl group (i.e., containing one N atom and one O atom), thefollowing compounds are specifically excluded:

-   -   (i) compounds wherein W³ is CH, X is a covalent bond, n is 0 and        m is 0;    -   (ii) compounds wherein W³ is CH, n is 1, R¹ is fluoro, X is        —OCH₂— or —CH₂O—, and m is 0;    -   (iii) compounds wherein W³ is CH, X is a covalent bond, n is 0,        m is 2 and each R² is independently —CH₃, an optionally        substituted C₁₋₈ alkyl or C₁₋₈ heteroalkyl group;    -   (iv) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (v) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A taken        together form a 5-membered ring containing 1 O atom.

In certain embodiments, wherein Het-B is an optionally substitutedthiazolyl group (i.e., containing one S atom and one N atom), thefollowing compounds are specifically excluded:

-   -   (i) compounds wherein W is CH, n is 0, X is a covalent bond, m        is 1 and R² is —CH₃;    -   (ii) compounds wherein W is CH, n is 1, R¹ is fluoro, X is        —OCH₂— or —CH₂O— and m is 0;    -   (iii) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (iv) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A        taken together form a 5-membered ring containing 1 O atom.

In certain embodiments, wherein Het-B is an optionally substitutedpyrazolyl group (i.e., containing two heteroatoms selected from N orNR¹⁶), the following compounds are specifically excluded:

-   -   (i) compounds wherein W³ is CH, n is 1, R¹ is fluoro, X is        —OCH₂— or —CH₂O—, and m is 0;    -   (ii) compounds wherein W³ is CH, n is 0, X is —OCH₂CH₂— or        —CH₂CH₂O— and m is 0;    -   (iii) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (iv) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A        taken together form a 5-membered ring containing 1 O atom.

In certain embodiments, wherein Het-B is an optionally substitutedimidazolyl group (i.e., containing two heteroatoms selected from N orNR¹⁶), the following compounds are specifically excluded:

-   -   (i) compounds wherein W³ is CH, n is 1, R¹ is fluoro, X is        —OCH₂— or —CH₂O—, and m is 0;    -   (ii) compounds wherein W³ is CH, n is 0, X is —OCH₂CH₂— or        —CH₂CH₂O— and m is 0;    -   (iii) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (iv) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A        taken together form a 5-membered ring containing 1 O atom.

In certain embodiments, wherein Het-B is an optionally substitutedthiophenyl group (i.e., containing one S atom), the following compoundsare specifically excluded:

-   -   (i) compounds wherein W³ is CH, n is 0, m is 0 and X is a        covalent bond;    -   (ii) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (iii) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A        taken together form a 5-membered ring containing 1 O atom.

In certain embodiments, wherein Het-B is an optionally substitutedfuranyl group (i.e., containing one O atom), the following compounds arespecifically excluded:

-   -   (i) compounds wherein W³ is CH, n is 0, X is —(C═O)NHCH₂— or        —CH₂NH(C═O)— and m is 0;    -   (ii) compounds wherein W³ is CH, n is 0, m is 0 and X is a        covalent bond;    -   (iii) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (iv) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A        taken together form a 5-membered ring containing 1 O atom.

In certain embodiments, wherein Het-B is an optionally substitutedpyrrolyl group (i.e., containing one heteroatom selected from N orNR¹⁶), the following compounds are specifically excluded:

-   -   (i) compounds wherein W³ is CH, n is 0 and X is a covalent bond;    -   (ii) compounds wherein W³ is CH, n is 0 and X is —SO₂—;    -   (iii) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (iv) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A        taken together form a 5-membered ring containing 1 O atom.

In certain embodiments, Het-B is an optionally substituted 6-memberedmonocyclic heteroaryl ring containing 1 to 3 heteroatoms selected fromN, NR¹⁶, O and S. In certain embodiments, Het-B is an optionallysubstituted 6-membered monocyclic heteroaryl ring containing 1heteroatom selected from N, NR¹⁶, O and S. In certain embodiments, Het-Bis an optionally substituted 6-membered monocyclic heteroaryl ringcontaining 2 heteroatoms selected from N, NR¹⁶, O and S. In certainembodiments, Het-B is an optionally substituted 6-membered monocyclicheteroaryl ring containing 3 heteroatoms selected from N, NR¹⁶, O and S.In certain embodiments, Het-B is an optionally substituted pyridinylgroup (e.g., 2-pyridinyl, 3-pyridinyl, 4-pyridinyl).

However, in certain embodiments, Het-B is not an optionally substituted6-membered monocyclic heteroaryl ring. In certain embodiments, Het-B isnot an optionally substituted pyridinyl. Alternatively, in certainembodiments, wherein Het-B is an optionally substituted pyridinyl group,the following compounds are specifically excluded:

-   -   (i) 3-pyridinyl compounds wherein W³ is CH, n is 1, R¹ is a        fluoro group ortho to the boron atom, X is a covalent bond, —O—,        —CH₂O—, —OCH₂—, —OCH₂CH₂— or — CH₂CH₂O—, and m is 0;    -   (ii) 3-pyridinyl compounds wherein W³ is CH, n is 0, X is a        covalent bond and m is 0;    -   (iii) 2-pyridinyl compounds wherein W³ is CH, n is 1, R¹ is        fluoro ortho to the boron atom, X is —OCH₂CH₂CH₂O—, —CH₂O—,        —OCH₂—, —OCH₂CH₂— or —CH₂CH₂O—, and m is 0;    -   (iv) 2-pyridinyl compounds wherein W³ is CH, n is 0, X is        —(C═O)NH— or —NH(C═O)— and m is 0;    -   (v) 4-pyridinyl compounds wherein W³ is CH, n is 1, R¹ is fluoro        ortho to the boron atom, X is —CH₂O— or —OCH₂—, and m is 0;    -   (vi) 4-pyridinyl compounds wherein W³ is CH, n is 0, X is a        covalent bond and m is 0;    -   (vii) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (viii) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A        taken together form a 5-membered ring containing 1 O atom.

In certain embodiments, Het-B is an optionally substituted 9-10 memberedbicyclic heteroaryl ring.

In certain embodiments, Het-B is an optionally substituted 9-memberedbicyclic heteroaryl ring containing 1 to 3 heteroatoms selected from N,NR¹⁶, O and S (e.g., a 6-5 fused heteroaryl ring). In certainembodiments, Het-B is an optionally substituted 9-membered bicyclicheteroaryl ring containing 1 heteroatom selected from N, NR¹⁶, O and S.In certain embodiments, Het-B is an optionally substituted 9-memberedbicyclic heteroaryl ring containing 2 heteroatoms selected from N, NR¹⁶,O and S. In certain embodiments, Het-B is an optionally substituted9-membered bicyclic heteroaryl ring containing 3 heteroatoms selectedfrom N, NR¹⁶, O and S. In certain embodiments, Het-B is an optionallysubstituted 9-membered bicyclic heteroaryl ring selected from the groupconsisting of optionally substituted benzthiazolyl, optionallysubstituted benzoxazolyl, optionally substituted benzisoxazolyl,optionally substituted benzimidazolyl, optionally substituted indazolyl,optionally substituted benzofuranyl, optionally substitutedbenzothiophcnyl and optionally substituted indolyl.

In certain embodiments, wherein Het-B is an optionally substitutedbenzoxazolyl group (i.e., containing one N atom and one O atom), thefollowing compounds are specifically excluded:

-   -   (i) compounds wherein W³ is CH, X is a covalent bond, n is 0 and        m is 0;    -   (ii) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (iii) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A        taken together form a 5-membered ring containing 1 O atom.

In certain embodiments, wherein Het-B is an optionally substitutedbenzisoxazolyl group (i.e., containing one N atom and one O atom), thefollowing compounds are specifically excluded:

-   -   (i) compounds wherein W³ is CH, X is a covalent bond, n is 0 and        m is 0;    -   (ii) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (iii) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A        taken together form a 5-membered ring containing 1 O atom.

In certain embodiments, wherein Het-B is an optionally substitutedbenzthiazolyl group (i.e., containing one N atom and one S atom), thefollowing compounds are specifically excluded:

-   -   (i) compounds wherein W³ is CH, X is a covalent bond, n is 0 and        m is 0;    -   (ii) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (iii) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A        taken together form a 5-membered ring containing 1 O atom.

In certain embodiments, wherein Het-B is an optionally substitutedbenzimidazolyl group (i.e., containing two heteroatoms selected from Nor NR¹⁶), the following compounds are specifically excluded:

-   -   (i) compounds wherein W³ is CH, X is a covalent bond, n is 0 and        m is 0;    -   (ii) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (iii) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A        taken together form a 5-membered ring containing 1 O atom.

In certain embodiments, wherein Het-B is an optionally substitutedindazolyl group (i.e., containing two heteroatoms selected from N orNR¹⁶), the following compounds arc specifically excluded:

-   -   (i) compounds wherein W³ is CH, X is a covalent bond, n is 0 and        m is 0;    -   (ii) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (iii) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A        taken together form a 5-membered ring containing 1 O atom.

In certain embodiments, wherein Het-B is an optionally substitutedindolyl group (i.e., containing one heteroatom selected from N or NR¹⁶),the following compounds are specifically excluded:

-   -   (i) compounds wherein W³ is CH, X is —CH₂—, n is 0 and m is 0;    -   (ii) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (iii) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A        taken together form a 5-membered ring containing 1 O atom.

In certain embodiments, Het-B is an optionally substituted 10-memberedbicyclic heteroaryl ring containing 1 to 3 heteroatoms selected from N,NR¹⁶, O and S (e.g., a 6,6-fused heteroaryl ring). In certainembodiments, Het-B is an optionally substituted 10-membered bicyclicheteroaryl ring containing 1 heteroatom selected from N, NR¹⁶, O and S.In certain embodiments, Het-B is an optionally substituted 10-memberedbicyclic heteroaryl ring containing 2 heteroatoms selected from N, NR¹⁶,O and S. In certain embodiments, Het-B is an optionally substituted10-membered bicyclic heteroaryl ring containing 3 heteroatoms selectedfrom N, NR¹⁶, O and S. In certain embodiments, Het-B is an optionallysubstituted 10-membered bicyclic heteroaryl ring selected from the groupconsisting of optionally substituted quinolinyl, optionally substitutedisoquinolinyl or optionally substituted quinoxalinyl.

In certain embodiments, wherein Het-B is an optionally substitutedquinolinyl group (i.e., containing one heteroatom selected from N), thefollowing compounds are specifically excluded:

-   -   (iv) compounds wherein W³ is CH, X is a covalent bond, n is 0, m        is 1 and R² is —CO₂H;    -   (v) compounds wherein W³ is CH, n is 1 and R¹ is CH₂OH; and/or    -   (vi) compounds wherein Z¹ is —OH or —OR³, and Z² and Ring A        taken together form a 5-membered ring containing 1 O atom.

In certain embodiments, the following compounds arc specificallyexcluded:

and pharmaceutically acceptable salts or prodrugs thereof.

Exemplary compounds encompassed by formulae (II), (V), and subgenerathereof, are provided below in Tables 9-20.

TABLE 9 126

127

129

128

134

130

137

138

TABLE 10 141

142

143

144

131

TABLE 11 11

13

18

17

19

22

28

31

63

296

281

286

282

283

260

261

262

263

264

265

268

269

271

272

284

285

9

12

10

20

23

86

25

26

57

21

29

30

64

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

59

51

51

53

54

65

66

67

68

69

70

71

239

73

74

75

76

77

78

79

80

81

82

83

84

85

TABLE 12 48

62

49

50

266

TABLE 13 272

273

24

TABLE 14 7

TABLE 15 226

227

222

232

92

231

TABLE 16 154

159

161

162

163

164

165

167

168

166

160

156

148

TABLE 17 276

225

3

8

89

1

2

90

TABLE 18 173

174

175

179

180

181

182

182

TABLE 19 224

223

259

87

TABLE 20 233

236

279

280

318

329

Additionally, in certain embodiments, the present invention providescompounds of formula (VI):

or a pharmaceutically acceptable salt or prodrug thereof,

wherein:

(i) Z¹ is —OH or —OR³ and Z² is —OH, —OR⁴, an optionally substitutedC₁₋₈ alkyl, optionally substituted C₂₋₈ alkenyl, optionally substitutedC₂₋₈ alkynyl, optionally substituted C₁₋₈ heteroalkyl, optionallysubstituted C₂₋₈ heteroalkenyl, optionally substituted C₂₋₈heteroalkynyl, optionally substituted C₃₋₁₀ carbocyclyl, optionallysubstituted 3-10 membered heterocyclyl, optionally substituted C₆₋₁₀aryl, or optionally substituted 5-10 membered heteroaryl;

(ii) Z¹ and Z² taken together form a 5- to 8-membered ring having atleast one O, S, N or NR⁵ atom directly bonded to the boron atom; or

-   -   (iii) Z¹ is —OH or —OR³, and Z² and Ring A taken together form        an optionally substituted 5- to 7-membered ring;

Y⁹ is an S or O;

X is a covalent bond, —O—, —N═N—, —C═N—, —NR⁶—, —C(NR⁶)—, —S—, —C(O)—,—S(O)—, —S(O)₂—, or optionally substituted C₁₋₆ alkylene, wherein one,two or three methylene units of the C₁₋₆ alkylene are optionally andindependently replaced with one or more groups selected from —O—, —N═N—,—C═N—, —NR⁶—, —C(NR⁶)—, —S—, —C(O)—, —S(O)—, and —S(O)₂—;

Het-B is an optionally substituted 3-10 membered heterocyclyl or anoptionally substituted 5-10 membered heteroaryl ring;

each instance of R¹ is, independently, halogen, —OR⁸, —CF₃, —CN, —NO₂,—SO₂R⁸, —SOR⁸, —C(O)R⁸, —CO₂R⁸, —C(O)N(R⁸)₂, —N₃, —N₂R⁸, —N(R⁸)₂,—B(OH₂), optionally substituted C₁₋₈ alkyl, optionally substituted C₂₋₈alkenyl, optionally substituted C₂ ₈ alkynyl, optionally substitutedC₁₋₈ heteroalkyl, optionally substituted C₂₋₈ heteroalkenyl, optionallysubstituted C₂₋₈ heteroalkynyl, optionally substituted C₃₋₁₀carbocyclyl, optionally substituted 3-10 membered heterocyclyl,optionally substituted C₆₋₁₀ aryl, or optionally substituted 5-10membered heteroaryl;

each instance of R² is, independently, halogen, —OR⁹, —CF₃, —CN, —NO₂,—SO₂R⁹, —SOR⁹, —C(O)R⁹, —CO₂R⁹, —C(O)N(R⁹)₂, —N₃, —N₂R⁹, —N(R⁹)₂,optionally substituted C₁₋₈ alkyl, optionally substituted C₂₋₈ alkenyl,optionally substituted C₂₋₈ alkynyl, optionally substituted C₁₋₈heteroalkyl, optionally substituted C₂₋₈ heteroalkenyl, optionallysubstituted C₂₋₈ heteroalkynyl, optionally substituted C₃₋₁₀carbocyclyl, optionally substituted 3-10 membered heterocyclyl,optionally substituted C₆₋₁₀ aryl, or optionally substituted 5-10membered heteroaryl;

each instance of R³ and R⁴ is, independently, optionally substitutedC₁₋₈ alkyl, optionally substituted C₂₋₈ alkenyl, optionally substitutedC₂₋₈ alkynyl, optionally substituted C₁₋₈ heteroalkyl, optionallysubstituted C₂₋₈ heteroalkenyl, optionally substituted C₂₋₈heteroalkynyl, optionally substituted C₃₋₁₀ carbocyclyl, optionallysubstituted 3-10 membered heterocyclyl, optionally substituted C₆₋₁₀aryl, or optionally substituted 5-10 membered heteroaryl;

each instance of R⁵, R⁶, R⁷, R⁸, R⁹, and R¹⁰ is, independently,hydrogen, —SO₂R¹¹, —SOR¹¹, —C(O)R¹¹, —CO₂R¹¹, —C(O)N(R¹¹)₂,—C(O)NH(R¹¹), —C(O)NH₂, optionally substituted C₁₋₈ alkyl, optionallysubstituted C₂₋₈ alkenyl, optionally substituted C₂₋₈ alkynyl,optionally substituted C₁₋₈ heteroalkyl, optionally substituted C₂₋₈heteroalkenyl, optionally substituted C₂₋₈ heteroalkynyl, optionallysubstituted C₃₋₁₀ carbocyclyl, optionally substituted 3-10 memberedheterocyclyl, optionally substituted C₆₋₁₀ aryl, or optionallysubstituted 5-10 membered heteroaryl;

each instance of R¹¹ is, independently, optionally substituted C₁₈alkyl, optionally substituted C₂₋₈ alkenyl, optionally substituted C₂₋₈alkynyl, optionally substituted C₁₋₈ heteroalkyl, optionally substitutedC₂₋₈ heteroalkenyl, optionally substituted C₂₋₈ heteroalkynyl,optionally substituted C₃₋₁₀ carbocyclyl, optionally substituted 3-10membered heterocyclyl, optionally substituted C₆₋₁₀ aryl, or optionallysubstituted 5-10 membered heteroaryl;

n is 0, 1, 2 or 3 and m is 0, 1, 2, 3, 4, or 5.

In certain embodiments, the present invention provides compounds of anyof formulae (VI-a), (VI-b), (VI-c), (VI-d) or (VI-e):

or a pharmaceutically acceptable salt or prodrug thereof, wherein Y⁹,Z¹, Z², Het-B, X, R¹, R², m and n are as defined above and herein.

Exemplary Het-B rings include, but are not limited to,

wherein Y¹, Y², Y⁷, Y⁸, W⁵, W⁶, W⁷, p, R² and m are as defined above andherein.

In certain embodiments, Het-B of formula (VI), and subgenera thereof, isselected from

In certain embodiments, Het-B of formula (VI), and subgenera thereof, isselected from

For example, in certain embodiments, the present invention providescompounds of formula (VI-e):

or a pharmaceutically acceptable salt or prodrug thereof, wherein Y⁹,Z¹, Z², X, R¹, R², m and n are as defined above and herein. For example,in certain embodiments, the present invention provides compounds of anyof formulae (VI-e1), (VI-e2), (VI-e3), (VI-e4) or (VI-e5):

or a pharmaceutically acceptable salt or prodrug thereof, wherein Y⁹,Z¹, Z², X, R¹, R², m and n are as defined above and herein.

In certain embodiments, n is 0.

In certain embodiments, X is a covalent bond.

In certain embodiments, m is 1. In certain embodiments, R² is selectedfrom optionally substituted C₁₋₈ alkyl or optionally substituted C₆₋₁₀aryl. In certain embodiments, R² is selected from —CH₃, —CH₂CH₃,—(CH₂)₂CH₃, —(CH₂)₃CH₃, —(CH₂)₄CH₃, optionally substituted phenyl,optionally substituted benzyl, and —(CH₂)₂C₆H₅.

In certain embodiments, Y⁹ is a S atom. In certain embodiments, Y⁹ is anO atom.

In certain embodiments, Het-B is an optionally substituted 3-10 memberedheterocyclyl ring having 2 to 3 heteroatoms selected from N, NR¹⁶, O andS. In certain embodiments, Het-B is an optionally substituted 5-10membered heteroaryl ring having 2 to 3 heteroatoms selected from N,NR¹⁶, O and S. In certain embodiments, Het-B is an optionallysubstituted 5-membered heteroaryl ring having 2 to 3 heteroatomsselected from N, NR¹⁶, O and S.

In certain embodiments, Het-B is an optionally substituted 5-memberedmonocyclic heteroaryl ring selected from the group consisting of anoptionally substituted triazolyl, optionally substituted oxadiazolyl,optionally substituted thiadiazolyl, optionally substituted imidazolyl,optionally substituted pyrazolyl, optionally substituted thiazolyl,optionally substituted isothiazolyl, optionally substituted oxazolyl andoptionally substituted isoxazolyl.

In certain embodiments, compounds of formula (VI) or subgenera thereof,wherein Y⁹ is S, X is a covalent bond, n is 0, m is 0 and Het-B is C₆H₅or unsubstituted thiophenyl, are specifically excluded.

In certain embodiments, the following compounds are specificallyexcluded:

or a pharmaceutically acceptable salt or prodrug thereof.

Exemplary compounds encompassed by formulae (II), (VI), and subgenerathereof, are provided below in Table 21.

TABLE 21 72

72

61

60

55

58

27

56

240

4. Pharmaceutically Acceptable Compositions and Formulations

In certain embodiments, the present invention provides apharmaceutically acceptable composition comprising a compound of any offormulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, ora pharmaceutically acceptable salt or prodrug thereof, and apharmaceutically acceptable excipient, medium, or carrier.

In some embodiments, the present invention provides a pharmaceuticallyacceptable composition comprising a compound of any of formulae (I),(II), (III), (IV), (V), or (VI), or subgenera thereof, or apharmaceutically acceptable salt or prodrug thereof, as provided in anyof Tables 1 through 20, and a pharmaceutically acceptable excipient,medium, or carrier.

In some embodiments, the present invention provides a pharmaceuticallyacceptable composition comprising a compound of any of formulae (I),(II), (III), (IV), (V), or (VI), or subgenera thereof, or apharmaceutically acceptable salt or prodrug thereof, as provided in theExamples, and a pharmaceutically acceptable excipient, medium, orcarrier.

In other embodiments, the present invention provides a pharmaceuticallyacceptable composition comprising a compound of any of formulae (I),(II), (III), (IV), (V), or (VI), or subgenera thereof, or apharmaceutically acceptable salt or prodrug thereof, as provided in theExamples having a K, of less than or equal to 0.01 microM or having a K,of between 0.01 microM and 0.1 microM (i.e., compounds with activitiesdesignated “A” and “B”), and a pharmaceutically acceptable excipient,medium, or carrier.

In yet other embodiments, the present invention provides apharmaceutically acceptable composition comprising a compound of any offormulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, ora pharmaceutically acceptable salt or prodrug thereof, as provided inthe Examples having a K_(i) of less than or equal to 0.01 microM (i.e.,compounds with activities designated “A”) and a pharmaceuticallyacceptable excipient, medium, or carrier.

In still yet other embodiments, the present invention provides apharmaceutically acceptable composition comprising a compound of any offormulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, ora pharmaceutically acceptable salt or prodrug thereof, and apharmaceutically acceptable excipient, medium, or carrier, wherein saidcompound is selected from the any compound depicted in the Examples.

As described above, pharmaceutically acceptable compositions of thepresent invention additionally comprise a pharmaceutically acceptableexcipient, which, as used herein, includes any and all solvents,diluents, or other liquid vehicle, dispersion or suspension aids,surface active agents, isotonic agents, thickening or emulsifyingagents, preservatives, solid binders, lubricants and the like, as suitedto the particular dosage form desired. Remington's PharmaceuticalSciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton,Pa., 1980) discloses various carriers used in formulatingpharmaceutically acceptable compositions and known techniques for thepreparation thereof. Except insofar as any conventional carrier mediumis incompatible with the compounds of the invention, such as byproducing any undesirable biological effect or otherwise interacting ina deleterious manner with any other component(s) of the pharmaceuticallyacceptable composition, its use is contemplated to be within the scopeof this invention.

Some examples of materials which can serve as pharmaceuticallyacceptable carriers include, but are not limited to, ion exchangers,alumina, aluminum stearate, lecithin, serum proteins, such as humanscrum albumin, buffer substances such as phosphates, glycinc, sorbicacid, or potassium sorbate, partial glyceride mixtures of saturatedvegetable fatty acids, water, salts or electrolytes, such as protaminesulfate, disodium hydrogen phosphate, potassium hydrogen phosphate,sodium chloride, zinc salts, colloidal silica, magnesium trisilicate,polyvinyl pyrrolidone, polyacrylates, waxes,polyethylene-polyoxypropylene-block polymers, wool fat, sugars such aslactose, glucose and sucrose; starches such as corn starch and potatostarch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethyl cellulose and cellulose acetate; powdered tragacanth;malt; gelatin; talc; excipients such as cocoa butter and suppositorywaxes; oils such as peanut oil, cottonseed oil; safflower oil; sesameoil; olive oil; corn oil and soybean oil; glycols; such a propyleneglycol or polyethylene glycol; esters such as ethyl oleate and ethyllaurate; agar; buffering agents such as magnesium hydroxide and aluminumhydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer'ssolution; ethyl alcohol, and phosphate buffer solutions, as well asother non-toxic compatible lubricants such as sodium lauryl sulfate andmagnesium stearate, as well as coloring agents, releasing agents,coating agents, sweetening, flavoring and perfuming agents,preservatives and antioxidants can also be present in the composition,according to the judgment of the formulator.

Provided formulations of pharmaceutically acceptable compositionsdescribed herein may be prepared by any method known or hereafterdeveloped in the art of pharmacology. In general, such preparatorymethods include the step of bringing the active ingredient intoassociation with a carrier and/or one or more other accessoryingredients, and then, if necessary and/or desirable, shaping and/orpackaging the product into a desired single- or multi-dose unit.

A pharmaceutically acceptable composition of the invention may beprepared, packaged, and/or sold in bulk, as a single unit dose, and/oras a plurality of single unit doses. As used herein, a “unit dose” isdiscrete amount of the pharmaceutically acceptable compositioncomprising a predetermined amount of the active ingredient. The amountof the active ingredient is generally equal to the dosage of the activeingredient which would be administered to a subject and/or a convenientfraction of such a dosage such as, for example, one-half or one-third ofsuch a dosage.

Relative amounts of the active ingredient, the pharmaceuticallyacceptable carrier, and/or any additional ingredients in apharmaceutically acceptable composition of the invention will vary,depending upon the identity, size, and/or condition of the subjecttreated and further depending upon the route by which the composition isto be administered. By way of example, the composition may comprisebetween 0.1% and 100% (w/w) active ingredient.

In some embodiments, the pharmaceutically acceptable excipient is atleast 95%, 96%, 97%, 98%, 99%, or 100% pure. In some embodiments, theexcipient is approved for use in humans and for veterinary use. In someembodiments, the excipient is approved by United States Food and DrugAdministration. In some embodiments, the excipient is pharmaceuticalgrade. In some embodiments, the excipient meets the standards of theUnited States Pharmacopoeia (USP), the European Pharmacopoeia (EP), theBritish Pharmacopoeia, and/or the International Pharmacopoeia.

Pharmaceutically acceptable excipients used in the manufacture ofprovided pharmaceutically acceptable compositions include, but are notlimited to, inert diluents, dispersing and/or granulating agents,surface active agents and/or emulsifiers, disintegrating agents, bindingagents, preservatives, buffering agents, lubricating agents, and/oroils. Such excipients may optionally be included in the inventiveformulations. Excipients such as cocoa butter and suppository waxes,coloring agents, coating agents, sweetening, flavoring, and perfumingagents can be present in the composition, according to the judgment ofthe formulator.

Exemplary diluents include, but are not limited to, calcium carbonate,sodium carbonate, calcium phosphate, dicalcium phosphate, calciumsulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose,cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol,inositol, sodium chloride, dry starch, cornstarch, powdered sugar, etc.,and combinations thereof.

Exemplary granulating and/or dispersing agents include, but are notlimited to, potato starch, corn starch, tapioca starch, sodium starchglycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite,cellulose and wood products, natural sponge, cation-exchange resins,calcium carbonate, silicates, sodium carbonate, cross-linkedpoly(vinyl-pyrrolidone) (crospovidonc), sodium carboxymethyl starch(sodium starch glycolatc), carboxymethyl cellulose, cross-linked sodiumcarboxymethyl cellulose (croscarmellose), methylcellulose,pregelatinized starch (starch 1500), microcrystalline starch, waterinsoluble starch, calcium carboxymethyl cellulose, magnesium aluminumsilicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds,etc., and combinations thereof.

Exemplary surface active agents and/or emulsifiers include, but are notlimited to, natural emulsifiers (e.g. acacia, agar, alginic acid, sodiumalginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin,egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidalclays (e.g. bentonite [aluminum silicate] and Veegum [magnesium aluminumsilicate]), long chain amino acid derivatives, high molecular weightalcohols (e.g. stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetinmonostearate, ethylene glycol distearate, glyceryl monostearate, andpropylene glycol monostearate, polyvinyl alcohol), carbomers (e.g.carboxy polymethylene, polyacrylic acid, acrylic acid polymer, andcarboxyvinyl polymer), carrageenan, cellulosic derivatives (e.g.carboxymethylcellulose sodium, powdered cellulose, hydroxymethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose,methylcellulose), sorbitan fatty acid esters (e.g. polyoxyethylenesorbitan monolaurate [Tween 20], polyoxyethylene sorbitan [Tween 60],polyoxyethylene sorbitan monooleate [Tween 80], sorbitan monopalmitate[Span 40], sorbitan monostearate [Span 60], sorbitan tristearate [Span65], glyceryl monooleate, sorbitan monooleate [Span 80]),polyoxyethylene esters (e.g. polyoxyethylene monostearate [Myrj 45],polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil,polyoxymethylene stearate, and Solutol), sucrose fatty acid esters,polyethylene glycol fatty acid esters (e.g. Cremophor), polyoxyethyleneethers, (e.g. polyoxyethylene lauryl ether [Brij 30]),poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamineoleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyllaurate, sodium lauryl sulfate, Pluronic F 68, Poloxamer 188,cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride,docusate sodium, etc. and/or combinations thereof.

Exemplary binding agents include, but are not limited to, starch (e.g.cornstarch and starch paste); gelatin; sugars (e.g. sucrose, glucose,dextrose, dextrin, molasses, lactose, lactitol, mannitol, etc.); naturaland synthetic gums (e.g. acacia, sodium alginate, extract of Irish moss,panwar gum, ghatti gum, mucilage of isapol husks,carboxymethylcellulose, methylcellulose, ethylcellulose,hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropylmethylcellulose, microcrystalline cellulose, cellulose acetate,poly(vinyl-pyrrolidone), magnesium aluminum silicate (Veegum), and larcharabogalactan); alginates; polyethylene oxide; polyethylene glycol;inorganic calcium salts; silicic acid; polymethacrylates; waxes; water;alcohol; etc.; and combinations thereof.

Exemplary preservatives may include antioxidants, chelating agents,antimicrobial preservatives, antifungal preservatives, alcoholpreservatives, acidic preservatives, and other preservatives.

Exemplary antioxidants include, but are not limited to, alphatocopherol, ascorbic acid, acorbyl palmitate, butylated hydroxyanisole,butylated hydroxytoluene, monothioglycerol, potassium metabisulfite,propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite,sodium metabisulfite, and sodium sulfite.

Exemplary chelating agents include ethylenediaminetetraacetic acid(EDTA), citric acid monohydrate, disodium edetate, dipotassium edetate,edetic acid, fumaric acid, malic acid, phosphoric acid, sodium edetate,tartaric acid, and trisodium edetate. Exemplary antimicrobialpreservatives include, but are not limited to, benzalkonium chloride,benzethonium chloride, benzyl alcohol, bronopol, cetrimide,cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol,chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea,phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate,propylene glycol, and thimerosal.

Exemplary antifungal preservatives include, but are not limited to,butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoicacid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodiumbenzoate, sodium propionate, and sorbic acid.

Exemplary alcohol preservatives include, but are not limited to,ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol,chlorobutanol, hydroxybenzoate, and phenylethyl alcohol.

Exemplary acidic preservatives include, but are not limited to, vitaminA, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid,dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.

Other preservatives include, but are not limited to, tocopherol,tocopherol acetate, deteroxime mesylate, cetrimide, butylatedhydroxyanisol (BHA), butylated hydroxytoluened (BHT), ethylenediamine,sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodiumbisulfite, sodium metabisulfite, potassium sulfite, potassiummetabisulfite, Glydant Plus, Phcnonip, methylparaben, German 115,Germaben II, Neolone, Kathon, and Euxyl. In certain embodiments, thepreservative is an anti-oxidant. In other embodiments, the preservativeis a chelating agent.

Exemplary buffering agents include, but are not limited to, citratebuffer solutions, acetate buffer solutions, phosphate buffer solutions,ammonium chloride, calcium carbonate, calcium chloride, calcium citrate,calcium glubionate, calcium gluceptate, calcium gluconate, D-gluconicacid, calcium glycerophosphate, calcium lactate, propanoic acid, calciumlevulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid,tribasic calcium phosphate, calcium hydroxide phosphate, potassiumacetate, potassium chloride, potassium gluconate, potassium mixtures,dibasic potassium phosphate, monobasic potassium phosphate, potassiumphosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride,sodium citrate, sodium lactate, dibasic sodium phosphate, monobasicsodium phosphate, sodium phosphate mixtures, tromethamine, magnesiumhydroxide, aluminum hydroxide, alginic acid, pyrogen-free water,isotonic saline, Ringer's solution, ethyl alcohol, etc., andcombinations thereof.

Exemplary lubricating agents include, but are not limited to, magnesiumstearate, calcium stearate, stearic acid, silica, talc, malt, glycerylbehanate, hydrogenated vegetable oils, polyethylene glycol, sodiumbenzoate, sodium acetate, sodium chloride, leucine, magnesium laurylsulfate, sodium lauryl sulfate, etc., and combinations thereof.

Exemplary oils include, but are not limited to, almond, apricot kernel,avocado, babassu, bergamot, black current seed, borage, cade, camomile,canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, codliver, coffee, corn, cotton seed, emu, eucalyptus, evening primrose,fish, flaxseed, geraniol, gourd, grape seed, hazel nut, hyssop,isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon,litsea cubeba, macademia nut, mallow, mango seed, meadowfoam seed, mink,nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel,peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary,safflower, sandalwood, sasquana, savoury, sea buckthorn, sesame, sheabutter, silicone, soybean, sunflower, tea tree, thistle, tsubaki,vetiver, walnut, and wheat germ oils. Exemplary oils include, but arenot limited to, butyl stearate, caprylic triglyceride, caprictriglyceride, cyclomethicone, diethyl sebacate, dimethicone 360,isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol,silicone oil, and combinations thereof.

Liquid dosage forms for oral and parenteral administration include, butare not limited to, pharmaceutically acceptable emulsions,microcmulsions, solutions, suspensions, syrups and elixirs. In additionto the active ingredients, the liquid dosage forms may comprise inertdiluents commonly used in the art such as, for example, water or othersolvents, solubilizing agents and emulsifiers such as ethyl alcohol,isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol,benzyl benzoate, propylene glycol, 1,3-butylene glycol,dimethylformamide, oils (in particular, cottonseed, groundnut, corn,germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfurylalcohol, polyethylene glycols and fatty acid esters of sorbitan, andmixtures thereof. Besides inert diluents, the oral compositions caninclude adjuvants such as wetting agents, emulsifying and suspendingagents, sweetening, flavoring, and perfuming agents. In certainembodiments for parenteral administration, the conjugates of theinvention are mixed with solubilizing agents such as Cremophor,alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins,polymers, and combinations thereof.

Injectable preparations, for example, sterile injectable aqueous oroleaginous suspensions may be formulated according to the known artusing suitable dispersing or wetting agents and suspending agents. Thesterile injectable preparation may be a sterile injectable solution,suspension or emulsion in a nontoxic parenterally acceptable diluent orsolvent, for example, as a solution in 1,3-butanediol. Among theacceptable vehicles and solvents that may be employed are water,Ringer's solution, U.S.P. and isotonic sodium chloride solution. Inaddition, sterile, fixed oils are conventionally employed as a solventor suspending medium. For this purpose any bland fixed oil can beemployed including synthetic mono- or diglycerides. In addition, fattyacids such as oleic acid are used in the preparation of injectables.

The injectable formulations can be sterilized, for example, byfiltration through a bacterial-retaining filter, or by incorporatingsterilizing agents in the form of sterile solid compositions which canbe dissolved or dispersed in sterile water or other sterile injectablemedium prior to use.

In order to prolong the effect of a drug, it is often desirable to slowthe absorption of the drug from subcutaneous or intramuscular injection.This may be accomplished by the use of a liquid suspension ofcrystalline or amorphous material with poor water solubility. The rateof absorption of the drug then depends upon its rate of dissolutionwhich, in turn, may depend upon crystal size and crystalline form.Alternatively, delayed absorption of a parenterally administered drugform is accomplished by dissolving or suspending the drug in an oilvehicle.

Compositions for rectal or vaginal administration arc typicallysuppositories which can be prepared by mixing the conjugates of thisinvention with suitable non-irritating excipients or carriers such ascocoa butter, polyethylene glycol or a suppository wax which are solidat ambient temperature but liquid at body temperature and therefore meltin the rectum or vaginal cavity and release the active ingredient.

Solid dosage forms for oral administration include capsules, tablets,pills, powders, and granules. In such solid dosage forms, the activeingredient is mixed with at least one inert, pharmaceutically acceptableexcipient or carrier such as sodium citrate or dicalcium phosphateand/or a) fillers or extenders such as starches, lactose, sucrose,glucose, mannitol, and silicic acid, b) binders such as, for example,carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone,sucrose, and acacia, c) humectants such as glycerol, d) disintegratingagents such as agar, calcium carbonate, potato or tapioca starch,alginic acid, certain silicates, and sodium carbonate, e) solutionretarding agents such as paraffin, f) absorption accelerators such asquaternary ammonium compounds, g) wetting agents such as, for example,cetyl alcohol and glycerol monostearate, h) absorbents such as kaolinand bentonite clay, and i) lubricants such as talc, calcium stearate,magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate,and mixtures thereof. In the case of capsules, tablets and pills, thedosage form may comprise buffering agents.

Solid compositions of a similar type may be employed as fillers in softand hard-filled gelatin capsules using such excipients as lactose ormilk sugar as well as high molecular weight polyethylene glycols and thelike. The solid dosage forms of tablets, dragees, capsules, pills, andgranules can be prepared with coatings and shells such as entericcoatings and other coatings well known in the pharmaceutical formulatingart. They may optionally comprise opacifying agents and can be of acomposition that they release the active ingredient(s) only, orpreferentially, in a certain part of the intestinal tract, optionally,in a delayed manner. Examples of embedding compositions which can beused include polymeric substances and waxes. Solid compositions of asimilar type may be employed as fillers in soft and hard-filled gelatincapsules using such excipients as lactose or milk sugar as well as highmolecular weight polethylene glycols and the like.

The active ingredients can be in micro-encapsulated form with one ormore excipients as noted above. The solid dosage forms of tablets,dragees, capsules, pills, and granules can be prepared with coatings andshells such as enteric coatings, release controlling coatings and othercoatings well known in the pharmaceutical formulating art. In such soliddosage forms the active ingredient may be admixed with at least oneinert diluent such as sucrose, lactose or starch. Such dosage forms maycomprise, as is normal practice, additional substances other than inertdiluents, e.g., tableting lubricants and other tableting aids such amagnesium stearate and microcrystalline cellulose. In the case ofcapsules, tablets and pills, the dosage forms may comprise bufferingagents. They may optionally comprise opacifying agents and can be of acomposition that they release the active ingredient(s) only, orpreferentially, in a certain part of the intestinal tract, optionally,in a delayed manner. Examples of embedding compositions which can beused include polymeric substances and waxes.

Dosage forms for topical and/or transdermal administration of a compoundof this invention may include ointments, pastes, creams, lotions, gels,powders, solutions, sprays, inhalants and/or patches. Generally, theactive ingredient is admixed under sterile conditions with apharmaceutically acceptable carrier and/or any needed preservativesand/or buffers as may be required. Additionally, the present inventioncontemplates the use of transdermal patches, which often have the addedadvantage of providing controlled delivery of an active ingredient tothe body. Such dosage forms may be prepared, for example, by dissolvingand/or dispensing the active ingredient in the proper medium.Alternatively or additionally, the rate may be controlled by eitherproviding a rate controlling membrane and/or by dispersing the activeingredient in a polymer matrix and/or gel.

Suitable devices for use in delivering intradermal pharmaceuticallyacceptable compositions described herein include short needle devicessuch as those described in U.S. Pat. Nos. 4,886,499; 5,190,521;5,328,483; 5,527,288; 4,270,537; 5,015,235; 5,141,496; and 5,417,662.Intradermal compositions may be administered by devices which limit theeffective penetration length of a needle into the skin, such as thosedescribed in PCT publication WO 99/34850 and functional equivalentsthereof Jet injection devices which deliver liquid vaccines to thedermis via a liquid jet injector and/or via a needle which pierces thestratum corneum and produces a jet which reaches the dermis aresuitable. Jet injection devices are described, for example, in U.S. Pat.Nos. 5,480,381; 5,599,302; 5,334,144; 5,993,412; 5,649,912; 5,569,189;5,704,911; 5,383,851; 5,893,397; 5,466,220; 5,339,163; 5,312,335;5,503,627; 5,064,413; 5,520,639; 4,596,556; 4,790,824; 4,941,880;4,940,460; and PCT publications WO 97/37705 and WO 97/13537. Ballisticpowder/particle delivery devices which use compressed gas to acceleratevaccine in powder form through the outer layers of the skin to thedermis are suitable. Alternatively or additionally, conventionalsyringes may be used in the classical mantoux method of intradermaladministration.

Formulations suitable for topical administration include, but are notlimited to, liquid and/or semi liquid preparations such as liniments,lotions, oil in water and/or water in oil emulsions such as creams,ointments and/or pastes, and/or solutions and/or suspensions.Topically-administrable formulations may, for example, comprise fromabout 1% to about 10% (w/w) active ingredient, although theconcentration of the active ingredient may be as high as the solubilitylimit of the active ingredient in the solvent. Formulations for topicaladministration may further comprise one or more of the additionalingredients described herein.

A pharmaceutically acceptable composition of the invention may beprepared, packaged, and/or sold in a formulation suitable for pulmonaryadministration via the buccal cavity. Such a formulation may comprisedry particles which comprise the active ingredient and which have adiameter in the range from about 0.5 to about 7 nanometers or from about1 to about 6 nanometers. Such compositions are conveniently in the formof dry powders for administration using a device comprising a dry powderreservoir to which a stream of propellant may be directed to dispersethe powder and/or using a self propelling solvent/powder dispensingcontainer such as a device comprising the active ingredient dissolvedand/or suspended in a low-boiling propellant in a sealed container. Suchpowders comprise particles wherein at least 98% of the particles byweight have a diameter greater than 0.5 nanometers and at least 95% ofthe particles by number have a diameter less than 7 nanometers.Alternatively, at least 95% of the particles by weight have a diametergreater than 1 nanometer and at least 90% of the particles by numberhave a diameter less than 6 nanometers. Dry powder compositions mayinclude a solid fine powder diluent such as sugar and are convenientlyprovided in a unit dose form.

Low boiling propellants generally include liquid propellants having aboiling point of below 65° F. at atmospheric pressure. Generally thepropellant may constitute 50 to 99.9% (w/w) of the composition, and theactive ingredient may constitute 0.1 to 20% (w/w) of the composition.The propellant may further comprise additional ingredients such as aliquid non-ionic and/or solid anionic surfactant and/or a solid diluent(which may have a particle size of the same order as particlescomprising the active ingredient).

Pharmaceutically acceptable compositions of the invention formulated forpulmonary delivery may provide the active ingredient in the form ofdroplets of a solution and/or suspension. Such formulations may beprepared, packaged, and/or sold as aqueous and/or dilute alcoholicsolutions and/or suspensions, optionally sterile, comprising the activeingredient, and may conveniently be administered using any nebulizationand/or atomization device. Such formulations may further comprise one ormore additional ingredients including, but not limited to, a flavoringagent such as saccharin sodium, a volatile oil, a buffering agent, asurface active agent, and/or a preservative such asmethylhydroxybenzoate. The droplets provided by this route ofadministration may have an average diameter in the range from about 0.1to about 200 nanometers.

The formulations described herein as being useful for pulmonary deliveryare useful for intranasal delivery of a pharmaceutically acceptablecomposition of the invention. Another formulation suitable forintranasal administration is a coarse powder comprising the activeingredient and having an average particle from about 0.2 to 500micrometers. Such a formulation is administered in the manner in whichsnuff is taken, i.e. by rapid inhalation through the nasal passage froma container of the powder held close to the flares.

Formulations suitable for nasal administration may, for example,comprise from about as little as 0.1% (w/w) and as much as 100% (w/w) ofthe active ingredient, and may comprise one or more of the additionalingredients described herein. A pharmaceutically acceptable compositionof the invention may be prepared, packaged, and/or sold in a formulationsuitable for buccal administration. Such formulations may, for example,be in the form of tablets and/or lozenges made using conventionalmethods, and may, for example, 0.1 to 20% (w/w) active ingredient, thebalance comprising an orally dissolvable and/or degradable compositionand, optionally, one or more of the additional ingredients describedherein. Alternately, formulations suitable for buccal administration maycomprise a powder and/or an aerosolized and/or atomized solution and/orsuspension comprising the active ingredient. Such powdered, aerosolized,and/or aerosolized formulations, when dispersed, may have an averageparticle and/or droplet size in the range from about 0.1 to about 200nanometers, and may further comprise one or more of the additionalingredients described herein.

A pharmaceutically acceptable composition of the invention may beprepared, packaged, and/or sold in a formulation suitable for ophthalmicadministration. Such formulations may, for example, be in the form ofeye drops including, for example, a 0.1/1.0% (w/w) solution and/orsuspension of the active ingredient in an aqueous or oily liquidcarrier. Such drops may further comprise buffering agents, salts, and/orone or more other of the additional ingredients described herein. Otheropthalmically-administrable formulations which are useful include thosewhich comprise the active ingredient in microcrystalline form and/or ina liposomal preparation. Ear drops and/or eye drops are contemplated asbeing within the scope of this invention.

General considerations in the formulation and/or manufacture ofpharmaceutical agents may be found, for example, in Remington: TheScience and Practice of Pharmacy 21^(st) ed., Lippincott Williams &Wilkins, 2005.

Although the descriptions of pharmaceutically acceptable compositionsprovided herein are principally directed to pharmaceutical compositionswhich are suitable for administration to humans, it will be understoodby the skilled artisan that such compositions are generally suitable foradministration to animals of all sorts. Modification of pharmaceuticallyacceptable compositions suitable for administration to humans in orderto render the compositions suitable for administration to variousanimals is well understood, and the ordinarily skilled veterinarypharmacologist can design and/or perform such modification with merelyordinary, if any, experimentation.

5. Kits

Still further encompassed by the invention are kits comprising one ormore compounds of the invention (or pharmaceutically acceptable salts orprodrugs thereof), and/or one or more pharmaceutically acceptablecompositions as described herein. Kits are typically provided in asuitable container (e.g., for example, a foil, plastic, or cardboardpackage).

In certain embodiments, an inventive kit may include one or morepharmaceutical excipients, pharmaceutical additives, therapeuticallyactive agents, and the like, as described herein. In certainembodiments, an inventive kit may include means for properadministration, such as, for example, graduated cups, syringes, needles,cleaning aids, and the like. In certain embodiments, an inventive kitmay include instructions for proper administration and/or preparationfor proper administration.

6. Methods of Treatment

The present invention also provides methods for treating anFAAH-mediated disease, disorder or condition by administering atherapeutically effective amount of a compound of any of formulae (I),(II), (III), (IV), (V), or (VI), or subgenera thereof, or apharmaceutically acceptable composition thereof, to a patient in needthereof.

Additionally, the present invention provides methods for inhibiting FAAHin a patient by administering a therapeutically effective amount of acompound of any of formulae (I), (II), (III), (IV), (V), or (VI), orsubgenera thereof, or a pharmaceutically acceptable composition thereof,to a patient in need thereof.

A patient to which administration is contemplated includes, but is notlimited to, humans (e.g., male, female, infant, child, adolescant,adult, elderly, etc.) and/or other primates; mammals, includingcommercially relevant mammals such as cattle, pigs, horses, sheep, cats,and/or dogs; and/or birds, including commercially relevant birds such aschickens, ducks, geese, and/or turkeys.

“Treating,” as used herein, refers to partially or completely inhibitingor reducing the condition from which the patient is suffering.

“Therapeutically effective amount,” as used herein, refers to theminimal amount or concentration of an inventive compound, orpharmaceutically acceptable composition thereof, that, whenadministered, is sufficient in treating the patient. Treating may be viaprophylactic or therapeutic therapy.

In other embodiments, the present invention provides a method forinhibiting FAAH in a biological sample comprising the step of contactingsaid sample with a compound of any of formulae (I), (II), (III), (IV),(V), or (VI), or subgenera thereof, or with a compound set forth in theExamples.

FAAH-mediated diseases, disorders or conditions include, but are notlimited to, painful conditions, inflammatory disorders, immunedisorders, depression, anxiety, anxiety-related disorders, sleepdisorders, feeding behaviors, movement disorders, glaucoma,neuroprotection and cardiovascular disease.

In certain embodiments, the FAAH-mediated disease, disorder or conditionis a painful condition, disease or disorder. As used herein, a “painfulcondition, disease or disorder” includes, but is not limited to,neuropathic pain (e.g., peripheral neuropathic pain), central pain,deafferentiation pain, chronic pain (e.g., chronic nociceptive pain, andother forms of chronic pain such as post-operative pain), stimulus ofnociceptive receptors, acute pain (e.g., phantom and transient acutepain), non-inflammatory pain, inflammatory pain, pain associated withcancer, wound pain, burn pain, post-operative pain, pain associated withmedical procedures, arthritic pain (e.g., pain associated withrheumatoid arthritis, osteoarthritis), lumbosacral pain,musculo-skeletal pain, headache, migraine, muscle ache, lower back andneck pain, toothache and the like.

In certain embodiments, the painful condition, disease or disorder isneuropathic pain. The term “neuropathic pain” refers to pain resultingfrom injury to a nerve. Neuropathic pain is distinguished fromnociceptive pain, which is the pain caused by acute tissue injuryinvolving small cutaneous nerves or small nerves in muscle or connectivetissue. Neuropathic pain typically is long-lasting or chronic and oftendevelops days or months following an initial acute tissue injury.Neuropathic pain can involve persistent, spontaneous pain as well asallodynia, which is a painful response to a stimulus that normally isnot painful. Neuropathic pain also can be characterized by hyperalgesia,in which there is an accentuated response to a painful stimulus thatusually is trivial, such as a pin prick. Neuropathic pain conditions candevelop following neuronal injury and the resulting pain may persist formonths or years, even after the original injury has healed. Neuronalinjury may occur in the peripheral nerves, dorsal roots, spinal cord orcertain regions in the brain. Neuropathic pain conditions include:diabetic neuropathy; sciatica; non-specific lower back pain; multiplesclerosis pain; fibromyalgia; HIV-related neuropathy; neuralgia, such aspost-herpetic neuralgia and trigeminal neuralgia; and pain resultingfrom physical trauma, amputation, cancer, chemotherapy-induced pain,chemotherapy, surgery, invasive medical procedures, toxins burns,infection, or chronic inflammatory conditions. Neuropathic pain canresult from a peripheral nerve disorder such as neuroma; nervecompression; nerve crush, nerve stretch or incomplete nervetranssection; mononeuropathy or polyneuropathy. Neuropathic pain canalso result from a disorder such as dorsal root ganglion compression;inflammation of the spinal cord; contusion, tumor or hemisection of thespinal cord; tumors of the brainstem, thalamus or cortex; or trauma tothe brainstem, thalamus or cortex.

The symptoms of neuropathic pain are heterogeneous and are oftendescribed as spontaneous shooting and lancinating pain, or ongoing,burning pain. In addition, there is pain associated with normallynon-painful sensations such as “pins and needles” (paraesthesias anddyscsthesias), increased sensitivity to touch (hyperesthesia), painfulsensation following innocuous stimulation (dynamic, static or thermalalodynia), in creased sensitivity to noxious stimuli (thermal, cold,mechanical hyperalgesia), continuing pain sensation after removal of thestimulation (hyperpathia) or an absence of or deficit in selectivesensory pathways (hypoalgesia).

In certain embodiments, the painful condition, disease or disorder isnon-inflammatory pain and/or inflammatory pain. The types ofnon-inflammatory pain include, without limitation, peripheralneuropathic pain (e.g., pain caused by a lesion or dysfunction in theperipheral nervous system), central pain (e.g., pain caused by a lesionor dysfunction of the central nervous system), deafferentation pain(e.g., pain due to loss of sensory input to the central nervous system),chronic nociceptive pain (e.g., certain types of cancer pain), noxiousstimulus of nociceptive receptors (e.g., pain felt in response to tissuedamage or impending tissue damage), phantom pain (e.g., pain felt in apart of the body that no longer exists, such as a limb that has beenamputated), pain felt by psychiatric patients (e.g., pain where nophysical cause may exist), and wandering pain (e.g., wherein the painrepeatedly changes location in the body). In certain embodiments,non-inflammatory pain and/or inflammatory pain are associated withdisorders such as inflammatory diseases (e.g., autoimmune disease).

In certain embodiments, the FAAH-mediated disease, disorder or conditionis an inflammatory disorder. The term “inflammatory disorders” refers tothose diseases or conditions that are characterized by signs of pain(dolor, from the generation of noxious substances and the stimulation ofnerves), heat (calor, from vasodilatation), redness (rubor, fromvasodilatation and increased blood flow), swelling (tumor, fromexcessive inflow or restricted outflow of fluid), and/or loss offunction (functio laesa, which may be partial or complete, temporary orpermanent). Inflammatory disorders include, without limitation, thoseaffecting the blood vessels (e.g., polyarteritis, temporal arteritis);joints (e.g, arthritis: crystalline, osteo-, psoriatic, reactive,rheumatoid, Reiter's syndrome); gastrointestinal tract (e.g, Crohn'sdisease, ulcerative colitis); skin (e.g, dermatitis); or multiple organsand tissues (e.g, systemic lupus erythematosus). Inflammatory disordersinclude, but are not limited to, inflammation associated with vasculardiseases, migraine headaches, tension headaches, arteritis, thyroiditis,aplastic anemia, Hodgkin's disease, scleroderma, rheumatic fever, type Idiabetes, myasthenia gravis, sarcoidosis, nephrotic syndrome, Behcet'ssyndrome, polymyositis, gingivitis, hypersensitivity, conjunctivitis,multiple sclerosis, and ischemia (e.g., myocardial ischemia), and thelike. The compounds and compositions may be useful for treatingneuroinflammation associated with brain disorders (e.g., Parkinson'sdisease and Alzheimer's disease) and chronic inflammation associatedwith cranial radiation injury. The compounds may be useful for treatingacute inflammatory conditions (e.g., conditions resulting frominfection) and chronic inflammatory conditions (e.g., conditionsresulting from asthma, arthritis and inflammatory bowel disease). Thecompounds may also be useful in treating inflammation associated withtrauma and non-inflammatory myalgia. Inflammation takes on many formsand includes, but is not limited to, acute, adhesive, atrophic,catarrhal, chronic, cirrhotic, diffuse, disseminated, exudative,fibrinous, fibrosing, focal, granulomatous, hyperplastic, hypertrophic,interstitial, metastatic, necrotic, obliterative, parenchymatous,plastic, productive, proliferous, pseudomembranous, purulent,sclerosing, seroplastic, serous, simple, specific, subacute,suppurative, toxic, traumatic, and/or ulcerative inflammation.

In certain embodiments, the FAAH-mediated disease, disorder or conditionis an immune disorder. Immune disorders, such as auto-immune disorders,include, but are not limited to, arthritis (including rheumatoidarthritis, spondyloarthopathies, gouty arthritis, degenerative jointdiseases such as osteoarthritis, systemic lupus erythematosus, Sjogren'ssyndrome, ankylosing spondylitis, undifferentiated spondylitis, Behcet'sdisease, haemolytic autoimmune anaemias, multiple sclerosis, amyotrophiclateral sclerosis, amylosis, acute painful shoulder, psoriatic, andjuvenile arthritis), asthma, atherosclerosis, osteoporosis, bronchitis,tendonitis, bursitis, skin inflammation disorders (e.g., psoriasis,eczema, burns, dermatitis), enuresis, eosinophilic disease,gastrointestinal disorders (e.g., inflammatory bowel disease (IBD),peptic ulcers, regional enteritis, diverticulitis, gastrointestinalbleeding, Crohn's disease, gastritis, diarrhea, irritable bowel syndromeand ulcerative colitis), and disorders ameliorated by a gastroprokineticagent (e.g., ileus, postoperative ileus and ileus during sepsis;gastroesophageal reflux disease (GORD, or its synonym GERD);eosinophilic esophagitis, gastroparesis such as diabetic gastroparesis;food intolerances and food allergies and other functional boweldisorders, such as non-ulcerative dyspepsia (NUD) and non-cardiac chestpain (NCCP, including costo-chondritis)).

In certain embodiments, the immune disorder is a gastrointestinaldisorder. In some embodiments, the immune disorder is inflammatory boweldisease (e.g., Crohn's disease and/or ulcerative colitis), pepticulcers, regional enteritis, diverticulitis, gastrointestinal bleeding,Crohn's disease, gastritis, diarrhea, irritable bowel syndrome andulcerative colitis. In other embodiments, the immune disorder isinflammatory bowel disease (IBD).

In certain embodiments, the FAAH-mediated disease, disorder or conditionis a skin disorder. In some embodiments, the skin disorder is pruritus(itch), psoriasis, eczema, burns or dermatitis. In certain embodiments,the skin disorder is psoriasis. In certain embodiments, the skindisorder is pruritis.

In certain embodiments, the FAAH-mediated disease, disorder or conditionis anxiety. “Anxiety,” as used herein, includes, but is not limited toanxiety and anxiety disorders or conditions, such as, for example,clinical anxiety, panic disorder, agoraphobia, generalized anxietydisorder, specific phobia, social phobia, obsessive-compulsive disorder,acute stress disorder, and post-traumatic stress disorder; andadjustment disorders with anxious features, anxiety disorders associatedwith depression, anxiety disorders due to general medical conditions,and substance-induced anxiety disorders. This treatment may also be toinduce or promote sleep in a patient (e.g., for example, a patient withanxiety).

In certain embodiments, the FAAH-mediated disease, disorder or conditionis a sleep disorder. “Sleep disorders” include, but are not limited to,insomia, sleep apnea, restless legs syndrome (RLS), delayed sleep phasesyndrome (DSPS), periodic limb movement disorder (PLMD), hypopneasyndrome, rapid eye movement behavior disorder (RBD), shift work sleepdisorder (SWSD), and sleep problems (e.g., parasomnias) such asnightmares, night terrors, sleep talking, head banging, snoring, andclenched jaw and/or grinding of teeth (bruxism).

In certain embodiments, the FAAH-mediated disease, disorder or conditionis depression. “Depression,” as used herein, includes, but is notlimited to, depressive disorders or conditions, such as, for example,major depressive disorders (unipolar depression), dysthymic disorders(chronic, mild depression) and bipolar disorders (manic-depression). Thedepression may be clinical or subclinical depression.

In certain embodiments, the FAAH-mediated disease, disorder or conditionis feeding behavior. “Feeding behavior,” as used herein, includes but isnot limited to, eating disorders (e.g., anorexias and cachexias ofvarious natures, over-eating leading to obesity), weight loss associatedwith cancer, weight loss associated with other general medicalconditions, weight loss associated with failure to thrive, and otherwasting conditions. The compounds disclosed herein can also be used toreduce body fat and for treating or preventing obesity in a mammal. Thecompounds disclosed herein can also be used for preventing or treatingthe diseases associated with these health conditions.

In certain embodiments, the FAAH-mediated disease, disorder or conditionis a movement disorder. In other embodiments, the FAAH-mediated disease,disorder or condition is glaucoma. In yet other embodiments, theFAAH-mediated disease, disorder or condition is neuroprotection. Instill yet other embodiments, the FAAH-mediated disease, disorder orcondition is cardiovascular disease.

In certain embodiments, the above methods provide administering acompound of any of formulae (I), (II), (III), (IV), (V), or (VI), orsubgenera thereof, or a pharmaceutically acceptable salt or prodrugthereof, to a patient in need thereof.

In some embodiments, the above methods provide administering a compoundof any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenerathereof, or a pharmaceutically acceptable salt or prodrug thereof, asprovided in the Examples.

In other embodiments, the above methods provide administering a compoundof any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenerathereof, or a pharmaceutically acceptable salt or prodrug thereof,having a K_(i) of less than or equal to 0.01 microM or having a K_(i) ofbetween 0.01 microM and 0.1 microM (i.e., compounds with activitiesdesignated “A” or “B”).

In yet other embodiments, the above methods provide administering acompound of any of formulae (I), (II), (III), (IV), (V), or (VI), orsubgenera thereof, or a pharmaceutically acceptable salt or prodrugthereof, having a K, of less than or equal to 0.01 microM (i.e.,compounds with activities designated “A”).

7. Administration

Provided compounds may be administered using any amount and any route ofadministration effective for treatment. The exact amount required willvary from subject to subject, depending on the species, age, and generalcondition of the subject, the severity of the infection, the particularcomposition, its mode of administration, its mode of activity, and thelike.

Compounds of the present invention are typically formulated in dosageunit form for ease of administration and uniformity of dosage. It willbe understood, however, that the total daily usage of the compositionsof the present invention will be decided by the attending physicianwithin the scope of sound medical judgment. The specific therapeuticallyeffective dose level for any particular subject or organism will dependupon a variety of factors including the disease, disorder, or conditionbeing treated and the severity of the disorder; the activity of thespecific active ingredient employed; the specific composition employed;the age, body weight, general health, sex and diet of the subject; thetime of administration, route of administration, and rate of excretionof the specific active ingredient employed; the duration of thetreatment; drugs used in combination or coincidental with the specificactive ingredient employed; and like factors well known in the medicalarts.

Provided compounds and compositions of the present invention may beadministered by any route. In some embodiments, provided compounds andcompositions are administered via a variety of routes, including oral,intravenous, intramuscular, intra-arterial, intramedullary, intrathecal,subcutaneous, intraventricular, transdermal, interdermal, rectal,intravaginal, intraperitoneal, topical (as by powders, ointments,creams, and/or drops), mucosal, nasal, bucal, enteral, sublingual; byintratracheal instillation, bronchial instillation, and/or inhalation;and/or as an oral spray, nasal spray, and/or aerosol. Specificallycontemplated routes are systemic intravenous injection, regionaladministration via blood and/or lymph supply, and/or directadministration to an affected site. In general the most appropriateroute of administration will depend upon a variety of factors includingthe nature of the agent (e.g., its stability in the environment of thegastrointestinal tract), the condition of the subject (e.g., whether thesubject is able to tolerate oral administration), etc. At present theoral and/or nasal spray and/or aerosol route is most commonly used todeliver therapeutic agents directly to the lungs and/or respiratorysystem. However, the invention encompasses the delivery of a providedpharmaceutically acceptable composition by any appropriate route takinginto consideration likely advances in the sciences of drug delivery.

The exact amount of a compound required to achieve a therapeuticallyeffective amount will vary from subject to subject, depending onspecies, age, and general condition of a subject, severity of the sideeffects or disorder, identity of the particular compound(s), mode ofadministration, and the like. The desired dosage may be delivered threetimes a day, two times a day, once a day, every other day, every thirdday, every week, every two weeks, every three weeks, or every fourweeks. In certain embodiments, the desired dosage may be delivered usingmultiple administrations (e.g., two, three, four, five, six, seven,eight, nine, ten, eleven, twelve, thirteen, fourteen, or moreadministrations).

In certain embodiments of the present invention, a therapeuticallyeffective amount of an inventive compound for administration one or moretimes a day to a 70 kg adult human may comprise about 0.0001 mg to about1000 mg of an inventive compound per unit dosage form. It will beappreciated that dose ranges as described herein provide guidance forthe administration of provided pharmaceutically acceptable compositionsto an adult. The amount to be administered to, for example, a child oran adolescent can be determined by a medical practitioner or personskilled in the art and can be lower or the same as that administered toan adult.

It will be also appreciated that an inventive compound or composition,as described above and herein, can be administered in combination withone or more additional therapeutically active agents.

By “in combination with,” it is not intended to imply that the agentsmust be administered at the same time and/or formulated for deliverytogether, although these methods of delivery are certainly within thescope of the invention. The compositions can be administeredconcurrently with, prior to, or subsequent to, one or more otheradditional therapeutically active agents. In general, each agent will beadministered at a dose and/or on a time schedule determined for thatagent. In will further be appreciated that the additionaltherapeutically active agent utilized in this combination may beadministered together in a single composition or administered separatelyin different compositions. The particular combination to employ in aregimen will take into account compatibility of the inventive compoundwith the additional therapeutically active agent and/or the desiredtherapeutic effect to be achieved.

In general, it is expected that additional therapeutically active agentsutilized in combination be utilized at levels that do not exceed thelevels at which they are utilized individually. In some embodiments, thelevels utilized in combination will be lower than those utilizedindividually.

By a “therapeutically active agent” or “active agent” refers to anysubstance that is useful for therapy, including prophylactic andtherapeutic treatment.

The invention encompasses the delivery of provided pharmaceuticallyacceptable compositions in combination with agents that may improvetheir bioavailability, reduce and/or modify their metabolism, inhibittheir excretion, and/or modify their distribution within the body. Itwill also be appreciated that therapy employed may achieve a desiredeffect for the same disorder (for example, an inventive compound may beadministered in combination with an anti-inflammatory, anti-anxietyand/or anti-depressive agent, etc.), and/or they may achieve differenteffects (e.g., control of any adverse side-effects).

Exemplary active agents include, but are not limited to, anti-canceragents, antibiotics, anti-viral agents, anesthetics, anti-coagulants,inhibitors of an enzyme, steroidal agents, steroidal or non-steroidalanti-inflammatory agents, antihistamine, immunosuppressant agents,anti-neoplastic agents, antigens, vaccines, antibodies, decongestant,ssedatives, opioids, pain-relieving agents, analgesics, anti-pyretics,hormones, prostaglandins, progestational agents, anti-glaucoma agents,ophthalmic agents, anti-cholinergics, anti-depressants, anti-psychotics,hypnotics, tranquilizers, anti-convulsants, muscle relaxants,anti-spasmodics, muscle contractants, channel blockers, miotic agents,anti-secretory agents, anti-thrombotic agents, anticoagulants,anti-cholinergics, β-adrenergic blocking agents, diuretics,cardiovascular active agents, vasoactive agents, vasodilating agents,anti-hypertensive agents, angiogenic agents, modulators ofcell-extracellular matrix interactions (e.g. cell growth inhibitors andanti-adhesion molecules), or inhibitors/intercalators of DNA, RNA,protein-protein interactions, protein-receptor interactions, etc. Activeagents include small organic molecules such as drug compounds (e.g.,compounds approved by the Food and Drugs Administration as provided inthe Code of Federal Regulations (CFR)), peptides, proteins,carbohydrates, monosaccharides, oligosaccharides, polysaccharides,nucleoproteins, mucoproteins, lipoproteins, synthetic polypeptides orproteins, small molecules linked to proteins, glycoproteins, steroids,nucleic acids, DNAs, RNAs, nucleotides, nucleosides, oligonucleotides,antisense oligonucleotides, lipids, hormones, vitamins and cells.

In certain embodiments, the additional therapeutically active agent is apain-relieving agent. In other embodiments, the additionaltherapeutically active agent is an anti-inflammatory agent.

8. Methods of Determining Biological Activity

Methods of determining the activity of compounds of the presentinvention for various therapeutic uses are well known in the art. Theseinclude, but are not limited to, high throughput screening to identifycompounds that bind to and/or modulate the activity of isolated FAAH, aswell as animal and cellular models of therapies.

Assays for compounds described herein are amenable to high throughputscreening. Assays useful for screening the compounds of the presentinvention may detect the binding of the inhibitor to FAAH or the releaseof a reaction product (e.g., fatty acid amide or ethanolamine) producedby the hydrolysis of a substrate such as oleoylethanolamide orananadamide. The substrate may be labeled to facilitate detection of thereleased reaction products. U.S. Pat. No. 5,559,410 discloses highthroughput screening methods for proteins, and U.S. Pat. Nos. 5,576,220and 5,541,061 disclose high throughput methods of screening forligand/antibody binding.

Methods for screening FAAH inhibitors for an antinociceptive effect arewell known to one of ordinary skill in the art. For instance, the testcompounds can be administered to the subject animals in the mousehot-plate test and the mouse formalin test and the nociceptive reactionsto thermal or chemical tissue damage measured (for example, see U.S.Pat. No. 6,326,156 which teaches methods of screening forantinociceptive activity; see also Cravatt et al. Proc. Natl. Acad. Sci.U.S.A. (2001) 98:9371-9376).

Two pharmacologically validated animal models of anxiety are theelevated zero maze test, and the isolation-induced ultrasonic emissiontest. The zero maze consists of an elevated annular platform with twoopen and two closed quadrants and is based on the conflict between ananimal's instinct to explore its environment and its fear of openspaces, where it may be attacked by predators (see, for example,Bickerdike, M. J. et al., Eur. J. Pharmacol., (994) 271, 403-411;Shepherd, J. K. et al., Psychopharmacology, (1994) 116, 56-64).Clinically used anxiolytic drugs, such as the benzodiazepines, increasethe proportion of time spent in, and the number of entries made into,the open compartments.

A second test for an anti-anxiety compound is the ultrasonicvocalization emission model, which measures the number of stress-inducedvocalizations emitted by rat pups removed from their nest (see, forexample, Insel, T. R. et al., Pharmacol. Biochem. Behay., 24, 1263-1267(1986); Miczek, K. A. et al., Psychopharmacology, 121, 38-56 (1995);Winslow, J. T. et al., Biol. Psychiatry, 15, 745-757 (1991).

The effect of the compound of the invention in the treatment ofdepression can be tested in the model of chronic mild stress inducedanhedonia in rats. This model is based on the observation that chronicmild stress causes a gradual decrease in sensitivity to rewards, forexample consumption of sucrose, and that this decrease isdose-dependently reversed by chronic treatment with antidepressants. Themethod has previously been described and more information with respectto the test appears from Willner, Paul, Psychopharmacology, 1997, 134,319-329.

Another test for antidepressant activity is the forced swimming test(Nature 266, 730-732, 1977). In this test, animals are administered anagent, preferably by the intraperitoneal route or by the oral route, 30or 60 minutes before the test. The animals are placed in a crystallizingdish filled with water and the time during which they remain immobile isclocked. The immobility time is then compared with that of the controlgroup treated with distilled water. Imipramine 25 mg/kg. can be used asthe positive control. The antidepressant compounds decrease theimmobility time of the mice thus immersed.

Another test for antidepressant activity is the caudal suspension teston the mouse (Psychopharmacology, 85, 367-370, 1985). In this test,animals are preferably treated with the study compound by theintraperitoneal route or by the oral route 30 or 60 minutes before thetest. The animals are then suspended by the tail and their immobilitytime is automatically recorded by a computer system. The immobilitytimes are then compared with those of a control group treated withdistilled water. Imipramine 25 mg/kg can be used as the positivecontrol. Antidepressant compounds decrease the immobility time of themice.

Animal models are available to one of ordinary skill in the art forstudying anticonvulsant activity of test compounds. See for instance,U.S. Pat. No. 6,309,406 and U.S. Pat. No. 6,326,156 which describemethods for performing such tests.

Inhibition of FAAH has been reported to induce sleep in test animals(U.S. Pat. No. 6,096,784). Methods for studying sleep inducing compoundsare well known to one of ordinary skill in the art. In particular,methods for testing the ability of a FAAH inhibitory compound to inducesleep or treat insomnia are disclosed in U.S. Pat. No. 6,096,784 andU.S. Pat. No. 6,271,015. Most obviously, the compounds can beadministered to a test animal (e.g., rat or mouse) or a human and thesubsequent time (e.g., onset, duration) spent sleeping (e.g., eyesclosed, motor quiescence) can be monitored. See also WO 98/24396.

Methods for screening FAAH inhibitors which induce catalepsy are alsowell known to one of ordinary skill in the art. See Quistand et al. inToxicology and Applied Pharmacology 173: 48-55 (2001). See Cravatt etal. Proc. Natl. Acad. Sci. U.S.A. 98:9371-9376 (2001).

Methods of assessing appetitive behavior arc known to one of ordinaryskill in the art. For instance, Maruani et al. (U.S. Pat. No. 6,344,474)teach two such assays. One method of assessing the effect on appetitebehavior is to administer a FAAH inhibitor to a rat and assess itseffect on the intake of a sucrose solution. This method is taught in W.C. Lynch et al., Physiol. Behay., 1993, 54, 877-880.

9. Covalent Complex Formation Between Serine-241 of FAAH and BoronicAcid Inhibitors

Compounds provided herein can form reversible covalent complexes withthe nucleophilic side chain of Ser-241 FAAH.

Thus, compounds of any of formulae (I), (II), (III), (IV), (V), or (VI),or subgenera thereof, as described above and herein, associated with(e.g., complexed with) a serine residue of a protein are also provided.

For example, in certain embodiments, compounds of any offormulae (III),(IV), (V), or (VI), or subgenera thereof, as described above and herein,are associated with a serine residue of a protein:

wherein Res₁-Ser-Res₂ is a protein having a length between about 400 toabout 600 residues.

By “Ser” is meant a serine residue. In certain embodiments, Ser isSer₂₄₁ of FAAH protein. In some embodiments, the protein is rat FAAH. Inother embodiments, the protein is human FAAH (SEQ ID NO. 1). In certainembodiments, the active site of the protein has a Lys at 142; a Ser at217; and a Ser at 241. In certain embodiments, the compound binds atSer₂₄₁.

By Res₁ is meant the residue(s) closer to the N-terminus than Ser. ByRes₂ is meant the residue(s) closer to the C-terminus than Ser. Incertain embodiments, Res₁ has a serine residue that is 24 amino acidscloser to the N terminus than (Ser) and a lysine residue that is 99amino acids closer to the N terminus than (Ser).

In certain embodiments, Z¹ and Z² are both —OH. Thus, in certainembodiments, the compound is a boronic acid compound.

10. Methods of Synthesis

A number of methods are known in the art to synthesize the compoundsprovided herein. A recognized method of synthesizing boronate esters isthe reaction of an organometallic species with an organic borate, suchas trimethyl borate. Suitable organometallic species include, but arenot limited to, alkyl lithium and Grignard reagents. Other methods forthe synthesis of boronates are employed when the boronate containssensitive functionality that may not tolerate alkyl lithium reagents orGrignard reagents. These methods include palladium coupling reactions ofaryl or akenyl halides and diboronates or dialkoxy boranes andhydroboration of alkenes or alkynes. Using these methods a diversecollection of boronates can be synthesized. Boronates can be readilytransformed in to boronic acids by hydrolyzing the boronate underaqueous acidic conditions using a suitable acid. Suitable acids include,but arc not limited to HCl, H₂SO₄, and HBr. Another method ofhydrolyzing boronates is an oxidative hydrolysis employing an oxidizingagent, such as NaIO₄, as exemplified in Example 5. The boronic acidcompounds of the present invention readily form boronic esters whenexposed to alcohols. The resulting boronic esters may also be used inthe methods provided herein. Cyclic boronates are formed when certaindiols (e.g., 1,2- and 1,3-diols) are used. Boronic acid compoundsprovided herein readily form oligomeric anhydrides by dehydration of theboronic acid moiety to form dimers, trimers, and tetramers, and mixturesthereof. These species in the presence of water and under physiologicalconditions convert back to the boronic acid by hydrolysis.

EXEMPLIFICATION

The invention now being generally described, it will be more readilyunderstood by reference to the following examples, which are includedmerely for purposes of illustration of certain aspects and embodimentsof the present invention, and are not intended to limit the invention.

Exemplary compounds are set forth in the Examples provided below.Compounds were assayed as inhibitors of human FAAH using the methoddescribed in detail in Example 286. Activity of exemplified compoundsare provided in the Examples, wherein activity designated as “A” refersto compounds having a K_(i) of less than or equal to 0.01 microM, “B”refers to compounds having a K_(i) of between 0.01 microM and 0.1microM, “C” refers to compounds having a K_(i) of between 0.1 microM and1 microM, and “D” refers to compounds having a K_(i) of greater than 1microM.

General Synthetic Methods Preparation of Boronic Acids:

Method 1

General conditions for the preparation of boronic acids: under an argonatmosphere, 0.1 M aryl bromide (1.0 equiv) dissolved in 4:1toluene/tetrahydrofuran was cooled to −78° C. Triisopropylborate (1.3equiv) was added, and the mixture was treated dropwise with nBuLi inhexanes (1.2 equiv). After stirring for 30 min, the mixture was warmedto 0° C. and stirred for an additional 30 min. The mixture was quenchedwith 2N aqueous HCl (10 equiv) and stirred for 1 h at 23° C. The mixturewas diluted with water and extracted with ethyl acetate. The organiclayer was washed with brine and then dried over sodium sulfate. Theresidue upon concentration was purified either byrecrystallization/trituration (heptanes, acetonitrile, or other) or byflash silica gel chromatography (1→10% methanol/dichloromethane) togenerally produce a white solid.

Method 2

General conditions for the preparation of boronic acids: under an argonatmosphere, 0.1 M aryl bromide (1.0 equiv) dissolved in 4:1toluene/tetrahydrofuran was cooled to −78° C. nBuLi in hexanes (2.5M,1.2 equiv) was added dropwise, and the mixture was stirred for 60 min.Triisopropylborate (1.3 equiv) was then added dropwise to the clearstirring solution. After 15 min, the mixture was warmed to 0° C. andstirred for an additional 30 min. The mixture was quenched with 2Naqueous HCl (10 equiv) and stirred for 1 h at 23° C. The mixture wasdiluted with water and extracted with ethyl acetate. The organic layerwas washed with brine and then dried over sodium sulfate. The residueupon concentration was purified either by recrystallization/trituration(heptanes, acetonitrile, or other) or by flash silica gel chromatography(1→10% methanol/dichloromethane) to generally produce a white solid.

Preparation of Boronic Acid Pinacol Esters:

Method 3

General conditions for the preparation of boronic acid pinacol esters: adry flask under argon atmosphere was charged with aryl bromide (1.0equiv), 1,1″-Bis(diphenylphosphino)-ferrocenedichloropalladium(II) (0.05equiv), potassium acetate (1.0 equiv), cesium carbonate (3 equiv), andbis(pinacolato)diboron (2.0 equiv). The mixture was suspended withdimethylsulfoxide (0.1 M with respect to aryl bromide) and heated at 80°C. for 2-8 h. Upon completion as judged by thin layer chromatographyanalysis, the reaction was split between water and ethyl acetate, andthe organic layer was washed with brine, dried over sodium sulfate, andconcentrated in vacuo. The concentrated reaction mixture was purified byflash silica gel chromatography (ethyl acetate/hexanes) to provideboronic acid pinacol ester.

Method 4

General conditions for the preparation of boronic acid pinacol esters: adry flask under argon atmosphere was charged with aryl bromide (1.0equiv), bis(triphenylphosphine)palladium(II) dichloride (0.05 equiv),potassium acetate (2.0 equiv), and bis(pinacolato)diboron (1.5 equiv).The mixture was suspended with 1,4-dioxane (0.1 M with respect to arylbromide) and heated at 80° C. for 2-8 h. Upon completion as judged bythin layer chromatography analysis, the reaction was split between waterand ethyl acetate, and the organic layer was washed with brine, driedover sodium sulfate, and concentrated in vacuo. The concentratedreaction mixture was purified by flash silica gel chromatography (ethylacetate/hexanes) to provide boronic acid pinacol ester.

Conversion of Boronate Esters to Boronic Acids:

Method 5

General conditions for the conversion of boronate esters to boronicacids: the boronate ester (1.0 eq), sodium periodate (5.0 eq) andammonium acetate (5.0 eq) were dissolved in acetone/water 2:1 (0.05 Mboronate ester) and stirred for 12 h at 23° C. until TLC or LCMSindicated conversion to the boronic acid was complete. One option forisolation is to precipitate the product by dilution of the mixture with1N aqueous HCl and collection by filtration of the solid boronic acid.Alternately, the mixture was split between water and ethyl acetate, andthe organic layer was washed with brine, dried over sodium sulfate, andconcentrated in vacuo. The residue was purified either byrecrystallization and trituration (heptane, acetonitrile, or othersolvents) or by flash silica gel chromatography (0.5%→10%methanol/dichloromethane) to afford pure boronic acid.

Method 6

General conditions for the conversion of boronate esters to boronicacids: the boronate ester was treated with concentrated sulfuric acid(0.2 M final ester concentration) and stirred until the mixture became aclear solution, about 10 min, at 23° C. The solution was diluted withwater 15 fold, and the precipitated boronic acid collected by filtrationand washed with water.

Preparation of Oxadiazoles:

Method 7

General conditions for the preparation of oxadiazoles: in a microwavereactor tube, (hydrazinocarbonyl)arylboronic acid pinacol ester (1.0equiv) and carboxylic acid (1.0 equiv) were dissolved in dryacetonitrile (0.1 M each). Polystyrene—supported triphenylphosphine (3.0equiv) and trichloroacetonitrile (2.0 equiv) were added, and the mixturewas sealed and heated in a microwave reactor at 130° C. for 2 hours. Theconcentrated reaction mixture was purified by flash silica gelchromatography (hexanes/ethyl acetate) to provide oxadiazole-arylboronic acid pinacol ester.

Method 8

General conditions for the preparation of oxadiazoles: the oxadiazolewas formed as in Method 7, except that the reactants are acarboxyarylboronic acid pinacol ester and either an alkyl or arylhydrazide.

Preparation of Thiadiazoles:

Method 9

General conditions for the preparation of thiadiazoles:(hydrazinocarbonyl)arylboronic acid pinacol ester (1.0 equiv) andcarboxylic acid (1 equiv) were dissolved in dry DCM (0.1 M each) andtreated with EDC (1.05 equiv) and DMAP (0.10 equiv). The mixture wasstirred for 6 h at 23° C., and then diluted into a separatory funnelwith DCM and washed twice each with 0.5 M aqueous citric acid andsaturated aqueous sodium bicarbonate. The organic layer was dried overmagnesium sulfate and concentrated to a clear oil.

This oil was dissolved in dry THF and 1.2 equiv Lawesson's reagentadded. The mixture was sealed in a tube and heated in a microwavereactor at 115° C. for 30 min. The concentrated reaction mixture waspurified by flash silica gel chromatography (hexanes/ethyl acetate) toprovide thiadiazole-aryl boronic acid pinacol ester.

Method 10

General conditions for the preparation of thiadiazoles: the thiadiazolewas formed as in Method 9, except that the reactants are acarboxyarylboronic acid pinacol ester and either an alkyl or arylhydrazide.

Preparation of quinoline-2-ethers:

Method 11

Conditions for the preparation of quinoline-2-ethers: substituted2-chloroquinolin e (1.0 eq.), alcohol (3.0 eq.), and crushed NaOH (2.0eq.) were suspended in NMP (0.3 M quinoline) and subjected to microwaveheating at a temperature of ca. 160° C. during 15 min. When done by 1c/ms, the reaction mixture was diluted into 0.1M NaOH and MTBE andseparated. The organic phase was washed with brine, dried on Na₂SO₄, andtreated with silica gel. After removal of the solvent, the residue waschromatographed (2→10% EtOAc/hexanes) to give clean ether product.

Preparation of Isoxazolines and Isoxazoles:

Method 12

General conditions for the preparation of isoxazolines and isoxazoles:Aldehyde (1.0 equiv.) was added to the solution of hydroxylaminehydrochloride (1.0 equiv.) in 1:1 t-BuOH: H2O (0.1 M aldehyde). To thiswas added NaOH to pH 5, and after being stirred for 30 min at ambienttemperature, TLC analysis indicated that oxime formation was complete.Chloramine-T trihydrate (1.0 equiv.) was added in small portions over 5min, followed by CuSO₄ (0.045 equiv.) and copper turnings (ca. 0.01equiv.). Alkene or alkyne (1.0 equiv.) was added, and the pH wasadjusted to ca. 6 by addition of a few drops of 1 M NaOH, and stirringwas continued for another 6 h. The reaction mixture was poured intoice/water, and dilute NH₄OH was added to remove all copper salts. Thedesired product was collected by filtration and purified by flash silicagel chromatography.

Preparation of Benzoxazoles:

Method 13

General conditions for the preparation of benzoxazoles: in a microwavereactor tube, aminophenol (1.0 equiv) and carboxylic acid (1.0 equiv)were dissolved in dry acetonitrile (0.1 M each). Polystyrene—supportedtriphenylphosphine (3.0 equiv) and trichloroacetonitrile (2.0 equiv)were added, and the mixture was sealed and heated in a microwave reactorat 150° C. for 2 hours. The concentrated reaction mixture was purifiedby flash silica gel chromatography (hexanes/ethyl acetate) to providethe desired benzoxazole.

Method 14

General conditions for the preparation of benzoxazoles: in a sealedtube, aminophenol (1.0 equiv) and carboxylic acid (1.0 equiv) weredissolved in dry acetonitrile (0.1 M each). Polystyrene—supportedtriphenylphosphine (4.0 equiv) and trichloroacetonitrile (2.0 equiv)were added, and the mixture was sealed and heated at 100° C. for 20-36h. The concentrated reaction mixture was purified by flash silica gelchromatography (hexanes/ethyl acetate) to provide the desiredbenzoxazole.

Preparation of Boronic Acid Pinacol Esters from Aryl Chlorides:

Method 15

General conditions for the preparation of boronic acid pinacol estersfrom aryl chlorides: a dry flask under argon atmosphere was charged witharyl chloride (1.0 equiv) and dissolved in tetrahydrofuran (0.1 M withrespect to aryl chloride). Bis(pinacolato)diboron (2.5 equiv) was addedfollowed by potassium acetate (2.5 equiv), palladium diacetate (0.2equiv) and 1,3-bis(2,6-di-iso-propylphenyl)imidazolium chloride (0.4equiv). The reaction was heated to 95° C. in a scaled tube for 14-36 h.Upon completion as judged by thin layer chromatography analysis themixture was then filtered through a plug of celite with some silica gelon top. The celite was washed with ethyl acetate. The combined solutionwas concentrated in vacuo and purified by flash silica gelchromatography(ethyl acetate/hexanes) to provide the desired boronic acid pinacolester.

Synthesis of Exemplary Compounds: Example 1

3-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid(470 mg, 1.77 mmol) and 2-aminoacetophenone hydrochloride (318 mg, 1.89mmol) were dissolved in 10 mL anhydrous dichloromethane. HOBt (286 mg,2.12 mmol) and EDC (406 mg, 2.12 mmol) were added followed bytriethylamine (741 uL, 5.30 mmol). The reaction was allowed to stir for12 h at room temperature after which point it was transferred to aseparatory funnel with excess dichloromethane and washed with 0.5 Mcitric acid (2×75 mL) and saturated NaHCO₃ (2×75 mL). The organic layerwas then dried over MgSO₄, filtered and concentrated to provide thedesired ketoamide as a yellow solid in quantitative yield (680 mg) whichwas used directly to form the oxazole the in the following step.

The crude ketoamide (100 mg, 0.261 mmol) was dissolved in 2 mLconcentrated H₂SO₄. The reaction solution first turns bright orange,then a brown solid forms. The reaction was allowed to stir at roomtemperature for 10 minutes after which it was poured into 75 mL water atwhich point a white solid forms that was isolated using vacuumfiltration. The solid was washed with excess water and dried undervacuum for 12 h to provide 45 mg of oxazole 1 in 61% yield. [M−H[=282.1m/z. Activity: B

Example 2

Oxazole 2 was prepared using conditions described for example 1.[M−H]⁻=264.1 m/z. Activity: B

Example 3

The ketoamide that was used to prepare 2 (223 mg, 0.58 mmol) wasdissolved in 5 mL anhydrous tetrahydrofuran and Lawesson's reagent (282mg, 0.70 mmol) was then added. The reaction was heated to 70° C. for 14h after which point it was loaded directly onto silica gel and purifiedusing silica gel chromatography using a gradient of 20-70% ethylacetate/hexanes to provide 200 mg of the desired thiazole in 90% yield.

The resulting pinacol ester(2-(3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-5-phenylthiazole)was then converted to thiazole 3 using Method 5 and was isolated afterprecipitation from the reaction mixture. [M−H]⁻=298.1 m/z. Activity: D

Example 4

6-Bromo-2-tetralone (4) was converted to its corresponding pincol esterboronate (5) using Method 3. This ketone(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydronaphthalen-2(1H)-one)(600 mg, 2.21 mmol) was dissolved in 10 mL 1:1 v/vmethanol/tetrahydrofuran and cooled to 0° C. in an ice bath. Sodiumborohydridc (250 mg, 6.63 mmol) was added portion wise and the reactionwas allowed to stir for 2 h after which point there was no more startingmaterial as indicated by TLC analysis. Saturated NaCl (100 mL) was addedto reaction and the mixture was transferred to a separatory funnel withexcess water and methylene chloride. The water layer was washed withmethylene chloride (2×75 mL). The organic layers were combined, washedwith saturated NaCl (1×75 mL), dried over Na₂SO₄ and concentrated underreduced pressure to provide the corresponding secondary alcohol inquantitative yield (600 mg).

This secondary alcohol (110 mg, 0.40 mmol) was dissolved in 2 mLanhydrous N,N-dimethylforamide and cooled to 0° C. in an ice bath.Sodium hydride (48 mg, 1.20 mmol, 60% in dispersion oil) was added withsome fizzing. After 10 min, benzyl bromide (95 μL, 0.80 mmol) was addedand the reaction was allowed to stir at room temperature for 2 h. Alarge amount of starting material was still remaining at this point sosodium hydride and benzyl bromide was added in 3 additional portions andthe reaction was allowed to stir for an additional 48 h. After thispoint, the reaction was quenched with saturated NH₄Cl (75 mL) andtransferred to a separatory funnel with excess water and ethyl acetate.The water layer was washed with ethyl acetate (2×75 mL). The combinedorganic layers were washed with saturated NaCl (2×75 mL), dried overMgSO₄, concentrated directly onto silica gel and purified by silica gelchromatography using a gradient of 5-10% ethyl acetate/hexanes toprovide the desired ether as an oil (57 mg) in 39% yield.

The resulting pinacol ester(2-(6-(benzyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane)was then converted to tetrahydronaphthalene 6 using Method 5 and wasisolated after precipitation from the reaction mixture. [M−H]⁻=281.1m/z. Activity: A

Example 5

The ketoamide used to prepare 2 (100 mg, 0.26 mmol) and ammonium acetate(1.00 g,13.0 mmol) was added to a 5 mL microwave reaction vial. Aceticacid (2 mL) is added and the reaction is heated for 30 min at 175° C. ina microwave reactor. Water (100 mL) is added to the crude reactionmixture at which point a small amount of solid crashes out which isisolated using vacuum filtration and dried under vacuum overnight toprovide 6 mg of imidazole 7 in 8% yield. [M−H]=281.1 m/z. Activity: D

Example 6

4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (160 mg,0.645 mmol) and 2-amino-1,4diphenylbutan-1-one hydrochloride (178 mg,0.645 mmol) were dissolved in 10 mL anhydrous dichloromethane. HOBt (105mg, 0.774 mmol) and EDC (148 mg, 0.774 mmol) were added followed bytriethylamine (270 uL, 1.94 mmol). The reaction was allowed to stir for12 h at room temperature after which point it was transferred to aseparatory funnel with excess dichloromethane and washed with 0.5 Mcitric acid (2×75 mL) and saturated NaHCO₃ (2×75 mL). The organic layerwas then dried over MgSO₄, filtered and concentrated to provide thedesired ketoamide as a white solid in 93% yield (281 mg) which was useddirectly to form the thiazole in the following step.

The ketoamide (140 mg, 0.298 mmol) was dissolved in 4 mL anhydroustetrahydrofuran and followed by the addition of Lawesson's reagent (145mg, 0.358 mmol). The reaction was heated to 115° C. in a microwavereactor for 90 min after which point the crude mixture was loadeddirectly onto silica gel and purified using a gradient of 25-50% ethylacetate/hexanes to isolate 90 mg of the desired compound in 65% yield.The resulting pinacol ester(4-phenethyl-5-phenyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)thiazole)was then converted to thiazole 8 by Method 5 and was isolated afterprecipitation from the reaction mixture. [M−H]⁻=384.1 m/z. Activity: D

Example 7

Oxadiazole 9 was prepared in 2 steps starting with oxadiazole formationbetween 5-bromopicolic acid and hexanoic hydrazide using Method 7followed by the lithiation conditions of Method 1. [M−H]=260.1 m/z.Activity: A

Example 8

Oxadiazole 10 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzohydrazide and3-(2-oxo-pyrrolidin-1-yl)-propionic acid using Method 7 followed byMethod 5 and was isolated after precipitation from the reaction mixture.[M−H]⁻=300.1 m/z. Activity: C

Example 9

Oxadiazole 11 was prepared in 2 steps starting with oxadiazole formationbetween 2-bromo-5-(trifluoromethyl)benzoic acid and acetic hydrazideusing Method 7 followed by lithiation using Method 1. [M−H]⁻=271.0 m/z.Activity: C

Example 10

Oxadiazole 12 was prepared in 2 steps starting with oxadiazole formationbetween 5-bromopicolic acid and benzoic hydrazide using Method 7followed by lithiation using Method 1. [M−H]⁻=266.1 m/z. Activity: B

Example 11

Oxadiazole 13 was prepared by Method 8 followed by Method 5.[M−H]−—231.1 m/z. Activity: D

Example 12

Part A

2-Bromo-5-hydroxybenzaldehyde 14 (1.0 g, 5 mmol. 1.0 equiv), phenethylbromide (2.76 g, 15 mmol, 3.0 equiv), and potassium carbonate (2.75 g,20 mmol, 4.0 equiv) were suspended in dimethylformamide (15 ml) andheated at 80° C. for 14 h. The mixture was cooled and split betweenwater (150 ml) and ethyl acetate (150 ml), and the organic layer waswashed with brine and dried over sodium sulfate. The oil fromconcentration in vacuo was purified by flash silica gel chromatography(1→30% ethyl acetate/hexanes) to give phenethyl ether 15 as a clear oil(550 mg).

Part B

Bromobcnzaldchydc 15 (3.0 g, 9.83 mmol, 1.0 equiv) dissolved in 2:1tetrahydrofuran/water (75 ml) was treated with 2-methyl-2-butene (6.9 g,98 mmol, 10 equiv), sodium phosphate monobasic, dihydrate, (4.6 g, 29.5mmol, 3.0 equiv), and sodium chlorite (2.1 g, 24 mmol, 2.4 equiv). Themixture was stirred at 23° C. for 6 h and was then split between ethylacetate (200 ml) and 1N aqueous HCl (100 ml). The organic layer waswashed with brine (100 ml) and concentrated in vacuo. The resulting oilwas purified by flash silica gel chromatography (1→30% ethylacetate/hexanes) to give the carboxylic acid 16 (56% yield).

The acid 16 was converted to the oxadiazole-arylboronic acid 17 byMethod 8 followed by Method 1. [M−H]⁻=351.1 m/z. Activity: A

Example 13

Oxadiazole 18 was prepared in 2 steps starting with oxadiazole formationbetween 2-bromo-5-phenethoxybenzoic acid 16 and furoic hydrazide usingMethod 7 followed by lithiation using Method 1. [M−H]⁻=375.1 m/z.Activity: A

Example 14

Oxadiazole 19 was prepared in 2 steps starting with oxadiazole formationbetween 2-bromo-5-phenethoxybenzoic acid 16 and acetic hydrazide usingMethod 7 followed by lithiation using Method 1. [M−H]⁻=323.1 m/z.Activity: A

Example 15

Oxadiazole 20 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzohydrazide and4,4,5,5,5-pentafluoropentanoic acid using Method 7 followed by Method 5and was isolated after precipitation from the reaction mixture.[M−H]⁻=335.1 m/z. Activity: A

Example 16

Oxadiazole 21 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid andnicotinic hydrazide using Method 8 followed by Method 6. [M−H]⁻=266.1m/z. Activity: A

Example 17

Oxadiazole 22 was prepared in 2 steps by first forming the oxadiazolefrom 4-fluoro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoicacid and butyric hydrazide using Method 8 followed by Method 5 and wasisolated after precipitation from the reaction mixture followed bypurification using flash silica gel chromatography. [M−H]=249.1 m/z.Activity: D

Example 18

Oxadiazole 23 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid and(2-methyl-thiazol-4-yl)acetic acid hydrazide using Method 8 followed byMethod 6. [M−H]⁻=300.1 m/z. Activity: B

Example 19

Oxadiazole 24 was prepared in 2 steps from the corresponding arylbromide using Method 3 followed by Method 5 and was isolated afterprecipitation from the reaction mixture. [M−H]⁻=231.1 m/z. Activity: A

Example 20

Oxadiazole 25 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzohydrazide and2-hexenoic acid using Method 7 followed by Method 5 and was isolatedafter precipitation from the reaction mixture. [M−H]⁻=257.1 m/z.Activity: A

Example 21

Oxadiazole 26 was prepared in 2 steps by first forming the oxadiazolefrom 3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoicacid and hexanoic hydrazide using Method 8 followed by Method 5 and wasisolated after precipitation from the reaction mixture. [M−H]⁻=279.1m/z. Activity: A

Example 22

Oxadiazole 27 was prepared in 2 steps by first forming the oxadiazolefrom4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophene-2-carboxylicacid and hexanoic hydrazide using Method 8 followed by Method 5 and wasisolated after precipitation from the reaction mixture. [M−H]⁻=265.1m/z. Activity: A

Example 23

Oxadiazole 28 was prepared in 2 steps by first forming the oxadiazolefrom(E)-3-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acrylicacid and acetic hydrazide using Method 8 followed by Method 5 and wasisolated after precipitation from the reaction mixture. [M−H]⁻=229.1m/z. Activity: C

Example 24

Oxadiazole 29 was prepared in 2 steps by first forming the oxadiazolefrom 3-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoicacid and hexanoic hydrazide using Method 8 followed by Method 5 and wasisolated after precipitation from the reaction mixture. [M−H]⁻=293.1m/z. Activity: A

Example 25

Oxadiazole 30 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzohydrazide andhexanoic acid using Method 7 followed by Method 5 and was isolated afterprecipitation from the reaction mixture. [M−H]⁻=259.1 m/z. Activity: A

Example 26

Oxadiazole 31 was prepared in 2 steps by first forming the oxadiazolefrom 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid andbenzoic hydrazide using Method 8 followed by Method 5 and was isolatedafter precipitation from the reaction mixture followed by purificationusing flash silica gel chromatography. [M−H]⁻=265.1 m/z. Activity: D

Example 27

Oxadiazole 32 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzohydrazide and4-methylhexanoic acid using Method 7 followed by Method 5 and wasisolated after precipitation from the reaction mixture. [M−H]⁻=273.1m/z. Activity: A

Example 28

Oxadiazole 33 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzohydrazide and3-cyclopentylpropionic acid using Method 7 followed by Method 5 and wasisolated after precipitation from the reaction mixture. [M−H]=285.1 m/z.Activity: A

Example 29

Oxadiazole 34 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzohydrazide and2-methylhexanoic acid using Method 7 followed by Method 5 and wasisolated after precipitation from the reaction mixture. [M−H]⁻=273.1m/z. Activity: A

Example 30

Oxadiazole 35 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzohydrazide andcyclopentylacetic acid using Method 7 followed by Method 5 and wasisolated after precipitation from the reaction mixture. [M−H]⁻=271.1m/z. Activity: A

Example 31

Oxadiazole 36 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzohydrazide and3-cyclohexylpropionic acid using Method 7 followed by Method 5 and wasisolated after precipitation from the reaction mixture. [M−H]⁻=299.1m/z. Activity: A

Example 32

Oxadiazole 37 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzohydrazide andheptanoic acid using Method 7 followed by Method 5 and was isolatedafter precipitation from the reaction mixture. [M−H]⁻=273.1 m/z.Activity: A

Example 33

Oxadiazole 38 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzohydrazide and5-methylhexanoic acid using Method 7 followed by Method 5 and wasisolated after precipitation from the reaction mixture. [M−H]⁻=273.1m/z. Activity: A

Example 34

Oxadiazole 39 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid andbutyric hydrazide using Method 8 followed by Method 5 and was isolatedafter precipitation from the reaction mixture. [M−H]=231.1 m/z.Activity: A

Example 35

Oxadiazole 40 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzohydrazide and5,5,5-trifluoropentanoic acid using Method 7 followed by Method 5 andwas isolated after precipitation from the reaction mixture. [M−H]⁻=299.1m/z. Activity: A

Example 36

Oxadiazole 41 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzohydrazide and5-fluoronicotinic acid using Method 7 followed by Method 6. [M−H]⁻=284.1m/z. Activity: B

Example 37

Oxadiazole 42 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid andvaleric hydrazide using Method 8 followed by Method 5 and was isolatedafter precipitation from the reaction mixture. [M−H]⁻=245.1 m/z.Activity: A

Example 38

Oxadiazole 43 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzohydrazide and1,4-benzodioxan-5-carboxylic acid using Method 7 followed by Method 5and was isolated after precipitation from the reaction mixture.[M−H]⁻=323.1 m/z. Activity: A

Example 39

Oxadiazole 44 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzohydrazide and2,3-dimethoxybenzoic acid using Method 7 followed by Method 5 and wasisolated after precipitation from the reaction mixture. [M−H]⁻=325.1m/z. Activity: A

Example 40

Oxadiazole 45 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzohydrazide andpiperonylic acid using Method 7 followed by Method 5 and was isolatedafter precipitation from the reaction mixture. [M−H]⁻=309.0 m/z.Activity: A

Example 41

Oxadiazole 46 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzohydrazide and2,3-dihydro-1-benzofuran-7-carboxylic acid using Method 7 followed byMethod 5 and was isolated after precipitation from the reaction mixture.[M−H]⁻=307.1 m/z. Activity: A

Example 42

Oxadiazole 47 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzohydrazide and3-trifluoromethylbenzoic acid using Method 7 followed by Method 6.[M−H]⁻=333.0 m/z. Activity: A

Example 43

Thiadiazole 48 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzohydrazide and3-trifluoromethylbenzoic acid using Method 9 followed by Method 6.[M−H]⁻=349.1 m/z. Activity: A

Example 44

Thiadiazole 49 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid andnicotinic hydrazide using Method 9 followed by Method 6. [M−H]=282.1m/z. Activity: A

Example 45

Thiadiazole 50 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzohydrazide and3-trifluoromethylbenzoic acid using Method 9 followed by Method 5 andwas isolated after precipitation from the reaction mixture. [M−H]=325.1m/z. Activity: A

Example 46

Oxadiazole 51 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzohydrazide and1-methyl-1H-indole-4-carboxylic acid using Method 7 followed by Method 5and was isolated after precipitation from the reaction mixture.[M−H]=318.1 m/z. Activity: A

Example 47

Oxadiazole 52 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzohydrazide and2,2-difluoro-1,3-benzodioxole-4-carboxylic acid using Method 7 followedby Method 5 and was isolated after precipitation from the reactionmixture. [M−H]⁻=345.1 m/z. Activity: A

Example 48

Oxadiazole 53 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzohydrazide and1,3-benzodioxole-4-carboxylic acid using Method 7 followed by Method 5and was isolated after precipitation from the reaction mixture.[M−H]⁻=309.1 m/z. Activity: A

Example 49

Oxadiazole 54 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid and1-methyl-1H-imidazole-5-carbohydrazide using Method 8 followed by Method6. [M−H]⁻=269.1 m/z. Activity: B

Example 50

Oxadiazole 55 was prepared in 2 steps by first forming the oxadiazolefrom5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophene-2-carboxylicacid and phenylacetic hydrazide using Method 8 followed by Method 5 andwas isolated after precipitation from the reaction mixture. [M−H]⁻=285.1m/z. Activity: B

Example 51

Oxadiazole 56 was prepared in 2 steps by first forming the oxadiazolefrom5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophene-2-carboxylicacid and benzoic hydrazide using Method 8 followed by Method 5 and wasisolated after precipitation from the reaction mixture. [M−H]⁻=271.1m/z. Activity: B

Example 52

Oxadiazole 57 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid and3-phenylpropionic acid hydrazide using Method 8 followed by Method 5 andwas isolated after precipitation from the reaction mixture. [M−H]⁻=293.1m/z. Activity: A

Example 53

Oxadiazole 58 was prepared in 2 steps by first forming the oxadiazolefrom4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophene-2-carboxylicacid and 3-phenylpropionic acid hydrazide using Method 8 followed byMethod 5 and was isolated after precipitation from the reaction mixture.[M−H]⁻=299.1 m/z. Activity: A

Example 54

Oxadiazole 59 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid and2-(3-thienyl)ethanohydrazide using Method 8 followed by Method 5 and wasisolated after precipitation from the reaction mixture. [M−H]⁻=285.1m/z. Activity: A

Example 55

Oxadiazole 60 was prepared in 2 steps by first forming the oxadiazolefrom4-(4,4,5,5-tetra-methyl-1,3,2-dioxaborolan-2-yl)thiophene-2-carboxylicacid and phenylacetic hydrazide using Method 8 followed by Method 5 andwas isolated after precipitation from the reaction mixture. [M−H]⁻=285.1m/z. Activity: A

Example 56

Oxadiazole 61 was prepared in 2 steps by first forming the oxadiazolefrom4-(4,4,5,5-tetra-methyl-1,3,2-dioxaborolan-2-yl)thiophene-2-carboxylicacid and benzoic hydrazide using Method 8 followed by Method 5 and wasisolated after precipitation from the reaction mixture. [M−H]⁻=271.1m/z. Activity: B

Example 57

Thiadiazole 62 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetra-methyl-1,3,2-dioxaborolan-2-yl)benzohydrazide andbenzoic acid using Method 9 followed by Method 5 and was isolated afterprecipitation from the reaction mixture. [M−H]⁻=281.1 m/z. Activity: A

Example 58

Oxadiazole 63 was prepared in 2 steps by first forming the oxadiazolefrom 3-(4,4,5,5-tetra-methyl-1,3,2-dioxaborolan-2-yl)benzoic acid andbenzoic hydrazide using Method 8 followed by Method 5 and was isolatedafter precipitation from the reaction mixture. [M−H]⁻=265.1 m/z.Activity: C

Example 59

Oxadiazole 64 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane)phenylacetic acid andbenzoic hydrazide using Method 8 followed by Method 5 and was isolatedafter precipitation from the reaction mixture. [M−H]⁻=279.1 m/z.Activity: B

Example 60

Oxadiazole 65 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid and2-picolinyl hydrazide using Method 8 followed by Method 6. [M−H]⁻=266.1m/z. Activity: B

Example 61

Oxadiazole 66 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid and3-methoxybenzoic hydrazide using Method 8 followed by Method 5 and wasisolated after precipitation from the reaction mixture. [M−H]⁻=295.1m/z. Activity: A

Example 62

Oxadiazole 67 was prepared in 2 steps by first forming the oxadiazolefrom 2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoicacid and benzoic hydrazide using Method 8 followed by Method 5 and wasisolated after precipitation from the reaction mixture. [M−H]⁻=283.1m/z. Activity: B

Example 63

Oxadiazole 68 was prepared in 2 steps by first forming the oxadiazolefrom 2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoicacid and benzoic hydrazide using Method 8 followed by Method 5 and wasisolated after precipitation from the reaction mixture. ESI-MS[M+H]⁺=301.2 m/z. Activity: A

Example 64

Oxadiazole 69 was prepared in 2 steps by first forming the oxadiazolefrom 3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoicacid and phenylacetic hydrazide using Method 8 followed by Method 5 andwas isolated after precipitation from the reaction mixture. [M−H]⁻=297.1m/z. Activity: B

Example 65

Oxadiazole 70 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid andphenylacetic hydrazide using Method 8 followed by Method 5 and wasisolated after precipitation from the reaction mixture. [M−H]⁻=279.0m/z. Activity: A

Example 66

Oxadiazole 71 was prepared in 2 steps by from the corresponding arylbromide using Method 1 followed by Method 6. [M−H]⁻=265.1 m/z. Activity:A

Example 67

Oxadiazole 72 was prepared in 2 steps by first forming the oxadiazolefrom2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophene-3-carboxylicacid and butyric hydrazide using Method 8 followed by Method 5.[M−H]⁻=237.1 m/z. Activity: D

Example 68

Oxadiazole 73 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid and2-hydroxyisobutryic hydrazide using Method 8 followed by Method 5.[M−H]⁻=247.1 m/z. Activity: B

Example 69

Oxadiazole 74 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic hydrazideand ethoxyacetic acid using Method 7 followed by Method 5. [M−H]⁻=247.1m/z. Activity: B

Example 70

Oxadiazole 75 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic hydrazideand methoxyacetic acid using Method 7 followed by Method 5. [M−H]⁻=233.1m/z. Activity: A

Example 71

Oxadiazole 76 was prepared in 2 steps by first forming thebis-oxadiazole from bromobenzene-2,4-dicarboxylic acid and butryichydrazide using Method 8 followed by Method 1. [M−H]⁻=341.1 m/z.Activity: A

Example 72

Oxadiazole 77 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid andpivaloic hydrazide using Method 8 followed by Method 5. [M−H]⁻=245.1m/z. Activity: A

Example 73

Oxadiazole 78 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic hydrazideand 5-hexenoic acid using Method 7 followed by Method 5. [M−H]⁻=257.1m/z. Activity: A

Example 74

Oxadiazole 79 was prepared in 2 steps by first forming the oxadiazolefrom 3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoicacid and benzoic hydrazide using Method 8 followed by Method 5 and wasisolated after precipitation from the reaction mixture. [M−H]⁻=283.1m/z. Activity: B

Example 75

Oxadiazole 80 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid andfuroic hydrazide using Method 8 followed by Method 5 and was isolatedafter precipitation from the reaction mixture. [M−H]⁻=255.0 m/z.Activity: A

Example 76

In a microwave reactor tube, 4-chloro-2-(trifluoromethyl)benzoic acid(300 mg, 1.34 mmol) and benzoic hydrazide (182 mg, 1.34 mmol) weredissolved in dry acetonitrile (6 mL). Polystyrene—supportedtriphenylphosphine (3.0 equiv, 1.80 g, 2.23 mmol/g loading) andtrichloroacetonitrile (270 uL, 2.68 mmol) were added, and the mixturewas sealed and heated in a microwave reactor at 130° C. for 2 hours. Thereaction was then filtered and the resin was washed with excesstetrahydrofuran and methylene chloride. The filtrate was concentratedonto silica gel and purified by column chromatography using a gradientof 25-50% ethyl acetate/hexanes to provide the 300 mg of the desiredoxadiazole in 70% yield.

2-(4-Chloro-2-(trifluoromethyl)phenyl)-5-phenyl-1,3,4-oxadiazole (296mg, 0.921 mmol) was dissolved in 6 mL anhydrous tetrahydrofuran in amicrowave reaction tube. Bis(pinacolato)diboron (278 mg, 1.09 mmol) wasadded followed by potassium acetate (206 mg, 2.10 mmol), palladium(II)acetate (12 mg, 0.055 mmol) and1,3-bis(2,6-di-isopropylphenyl)imidazolium chloride (46 mg, 0.11 mmol).The reaction was heated in a microwave reactor was heated to 110° C. for20 min. A slurry of palladium(II) acetate and the imidazolum catalyst in1 mL tetrahydrofuran was then added and the reaction was reheated underthe same conditions. This was repeated a third time after which pointthe reaction was filtered through a plug of slica gel using 1:1 ethylacetate/hexanes (v/v) as eluent. The filtrate was then concentrated ontosilica gel and purified by column chromatography using a gradient of25-50% ethyl acetate/hexanes to provide the 300 mg of the desiredoxadiazole in 79% yield.

The resulting pinacol ester(2-phenyl-5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)phenyl)-1,3,4-oxadiazole)was then converted to boronic acid 81 using Method 5 and was isolatedafter precipitation from the reaction mixture. [M−H]⁻=333.1 m/z.Activity: C

Example 77

4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzohydrazide (300 mg,1.15 mmol) and N-Boc-β-alanine (227 mg, 1.20 mmol) were dissolved in 10mL anhydrous dichloromethane. HOBt (187 mg, 1.37 mmol) and EDC (263 mg,1.37 mmol) were added followed by triethylamine (480 uL, 3.43 mmol). Thereaction was allowed to stir for 12 h at room temperature after whichpoint it was transferred to a separatory funnel with excessdichloromethane and washed with 0.5 M citric acid (2×75 mL) andsaturated NaHCO₃ (2×75 mL). The organic layer was then dried over MgSO₄,filtered and concentrated to provide the desired diacyl hydrazone as awhile foamy solid in 93% yield (461 mg) which was used directly to formthe oxadiazole in the following step.

The diacyl hydrazone (461 mg, 1.06 mmol) was dissolved in anhydroustetrahydrofuran. Burgess' reagent (355 mg, 1.60 mmol) was added and thereaction was heated to 60° C. in a sealed tube for 20 h. After thispoint, the reaction was allowed to cool and transferred to a separatoryfunnel with excess saturated NaHCO₃ (50 mL) and ethyl acetate (50 mL).The organic layer is washed with saturated NaCl (50 mL), dried overMgSO₄, and concentrated under vacuum to provide a crude oil that ispurified using silica gel chromatography with a gradient of 20-70%ethyl/hexanes to provide the 187 mg of the desired oxadiazole in 43%yield.

The resulting pinacol ester (tert-butyl2-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,3,4-oxadiazol-2-yl)ethylcarbamate)was then converted to boronic acid 82 using Method 5 and was isolatedafter precipitation from the reaction mixture. [M−H]⁻=332.1 m/z.Activity: B

Example 78

Carbamate 83 was prepared using the analogous procedure as Example 77except that N-Boc glycine was used in place of N-Boc-β-alanine[M−H]⁻=318.1 m/z. Activity: B

Example 79

Carbamate 82 (20 mg, 0.060 mmol) was dissolved in 5 mL methylenechloride. Excess trifluoroacetic acid (5 mL) was added and the reactionwas allowed to stir at room temperature for 10 min. The reaction wasthen diluted with toluene (40 mL) and azeotroped under vacuum to removethe excess acid. This was repeated 2 times and the resultant solid wasdried under vacuum overnight to provide the desired amine 84 inquantitative yield (14 mg). [M−H]⁻=232.1 m/z. Activity: D

Example 80

Amine 84 (17 mg, 0.050 mmol) was suspended in 5 mL methylene chloride.Acetic anhydride (49 μL, 0.49 mmol) was added followed by NaHCO₃ (29 mg,0.25 mmol) and allowed to stir at room temperature for 10 min. Anadditional 49 uL of acetic anhydride and 29 mg of NaHCO₃ were then addedand the reaction was allowed to stir for an additional hour at whichpoint the reaction was determined to be complete by LC/MS. Methanol (1mL) was added and the mixture was allowed to stir at room temperaturefor 20 min. The reaction mixture was then filtered and concentrated toprovide 6 mg of amide 85 in 45% yield. [M−H]⁻=274.1 m/z. Activity: C

Example 81

Tert-butyl2-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,3,4-oxadiazol-2-yl)ethylcarbamate(187 mg, 0.450 mmol) was dissolved in 10 mL 2N HCl in dioxane andallowed to stir at room temperature for 2 h. After this point thesolvent was removed under vacuum to provide the desired free amine inquantitative yield as the HCl salt. A portion of this free amine (63 mg,0.18 mmol) was dissolved in 3 ml, anhydrous THF. Methyl chloroformate(18 μL, 0.23 mmol) was added followed by diisopropylethylamine (83 μL,0.47 mmol) and the reaction was allowed to stir at room temperature for2 h at which point there is no more starting material visible by LC/MS.Water (30 ml,) was added and the mixture is acidified to pH<4 with 0.5 Mcitric acid. The solid that remains was collected via vacuum filtrationand washed with excess water to provide the desired pinacol ester in 12%yield (8.0 mg).

The resulting pinacol ester (methyl2-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,3,4-oxadiazol-2-yl)ethylcarbamate)was then converted to amide 86 using Method 5 and was isolated afterprecipitation from the reaction mixture. [M−H]⁻=290.1 m/z. Activity: B

Example 82

Benzothiazole 87 was prepared in two steps from the corresponding arylbromide using Method 3 followed by Method 5 and purified using flashsilica gel chromatography. [M−H]⁻=254.1 m/z. Activity: D

Example 83

Benzothiazole 88 was prepared in two steps from the corresponding arylbromide using Method 3 followed by Method 5 and purified using flashsilica gel chromatography. [M−H]⁻=192.0 m/z. Activity: C

Example 84

Thiazole 89 was prepared in two steps from the corresponding arylbromide using Method 3 followed by Method 5 and purified using flashsilica gel chromatography. [M−H]⁻=218.1 m/z. Activity D

Example 85

Oxazole 90 was prepared in two steps from the corresponding aryl bromideusing Method 3 followed by Method 5 and purified using flash silica gelchromatography. [M−H]⁻=188.1 m/z. Activity: B

Example 86

Pyrazole 92 was prepared in 5 steps from3-(4-bromophenyl)-1-phenylpyrazole-4-propionic acid (1.00 g, 2.69 mmol)starting with the methylation of the free acid usingtrimethylsilyl-diazomethane (4.0 equiv in hexanes) in 1:1toluene/methanol (0.05 M) for 1 h after which point the reaction wasconcentrated and dried under vacuum. The crude mixture was thenredissolved in THF (0.15 M) and cooled to 0° C. in an ice bath under N₂.DIBAL (3.5 equiv, 1.0 M in toluene) was added drop wise and the reactionwas allowed to warm to room temperature and allowed to stir for 2 h. Thereaction was then quenched methanol (20 mL) followed by the addition ofa saturated solution of Rochelle's salt (100 mL) After 1 h, the reactionwas transferred to a separatory funnel with excess ethyl acetate andwater after which the water layer was washed with ethyl acetate (2×75mL). The organic layers were combined and washed with brine (2×75 mL),dried over MgSO₄, and concentrated to provide the desired product as acrude oil in quantitative yield.

The crude alcohol (340 mg, 0.95 mmol) was then redissolved in anhydrousN,N-dimethylforamide (0.20 M) and cooled to 0° C. in an ice bath. Sodiumhydride (3.0 equiv) was added portion wise and allowed to stir for 10min after which point iodomethane (2.0 equiv) was added and the reactionwas allowed to stir for 2 h at room temperature. The reaction was thenquenched with saturated NH₄Cl and was transferred to a separatory funnelwith excess ethyl acetate and water after which the water layer waswashed with ethyl acetate (2×75 mL). The organic layers were combinedand washed with brine (2×75 mL), dried over MgSO₄, and concentrated toprovide the desired ether as a crude oil in quantitative yield.

The resulting methyl ether was then converted to the desired pyrazole 92using Method 3 followed by Method 5 and purified using flash silica gelchromatography. [M−H]⁻=335.1 m/z. Activity: D

Example 87

Part A

At 0° C., aldehyde 93 (15) (1.8 mmol, 1.0 equiv) was dissolved in 1:1tetrahydrofuran/methanol (14 ml) and treated with sodium borohydride(136 mg, 3.6 mmol, 2.0 equiv). After stirring for 2 h, the mixture wasdiluted with water (100 ml) and extracted with ethyl acetate (100 ml).The organic layer was washed with brine, dried over sodium sulfate, andconcentrated in vacuo. The resulting oil was purified by flash silicagel chromatography (5→30% ethyl acetate/hexanes) to give a colorless oil(500 mg).

Part B

Benzylic alcohol 94 (185 mg, 0.6 mmol, 1.0 equiv) and iodomethane (128mg, 0.9 mmol, 1.5 equiv) were dissolved in dimethylformamide (3 ml) and,at 0° C., were treated with sodium hydride (36 mg, 0.9 mmol, 1.5 equivof a 60% dispersion in mineral oil). The mixture was stirred for 2 h andthen quenched by addition of saturated aqueous ammonium chloride (1 ml).The mixture was split between water (100 ml) and extracted with ethylacetate (100 ml). The organic layer was washed with brine, dried oversodium sulfate, and concentrated in vacuo. Purification by flash silicagel chromatography (1→5% ethyl acetate/hexanes) to give a colorless oil(143 mg). The resulting aryl bromide was converted to the boronic acid95 by Method 1. [M−H]⁻=285.1 m/z. Activity: B

Example 88

Benzyl alcohol 96 was prepared by reduction of the benzaldehyde-boronicacid as described for 94 and purified by flash silica gel chromatography(1→5% methanol/dichloromethane). [M−H]⁻=257.1 m/z. Activity: D

Example 89

The benzyl ether 97 was made according to the procedures described for95. [M−H]⁻=361.2 m/z. Activity: D

Example 90

The bromobenzaldehyde 93 (15) (500 mg, 1.6 mmol, 1.0 equiv) and ethyleneglycol (712 mg, 11.5 mmol, 7.0 equiv) with toluenesulfonic acid (9 mg, 3mol %) were dissolved in toluene (35 ml) and heated at reflux 24 h withazeotropic removal of water with a Dean-Stark apparatus. After cooling,the mixture was split between 5% aqueous sodium bicarbonate (100 ml),and the organic layer was then washed with water (100 ml) and then brine(50 ml), dried over sodium sulfate, and concentrated in vacuo. Theresultant clear oil was purified by flash silica gel chromatography(1→5% ethyl acetate/hexanes) to give a colorless oil (534 mg).

This pure acetal was then converted to the boronic acid 98 by Method 1.It was important to stir the mixture after the quench with 2N aqueousHCl for 1 h to ensure full hydrolysis of the acetal. [M−H]=269.1 m/z.Activity: A

Example 91

Benzaldehyde-boronic acid 98 (500 mg, 1.85 mmol, 1 equiv) and pinacol(263 mg, 2.2 mmol, 1.2 equiv) were heated at reflux in benzene (12 ml)for 5 h, with azeotropic removal of water using a Dean-Stark apparatus.The solution was concentrated and purification by flash silica gelchromatography (1→10% ethyl acetate/hexanes) gave pinacol ester (436mg).

The product ester and methyl (triphenylphosphoranylidene)acetate (540mg, 1.6 mmol, 1.3 equiv) were heated at 90° C. in dry toluene for 18 h.The mixture was cooled and split split between water (150 ml) and ethylacetate (150 ml), and the organic layer was washed with brine and driedover sodium sulfate. The oil from concentration in vacuo was purified byflash silica gel chromatography (1→30% ethyl acetate/hexanes) to give aclear oil (70% yield). The pinacol ester was cleaved by Method 5 toproduce boronic acid 100. [M−H]⁻=325.1 m/z. Activity: A

Example 92

The thienyl—unsaturated ester boronic acid 101 was prepared by conditionsimilar to those for compound 100. [M−H]⁻=211.0 m/z. Activity: C

Example 93

Bromobenzaldehyde 93 (15) (420 mg, 1.4 mmol, 1.0 equiv) and methyl(triphenylphos-phoranylidene)acetate (690 mg, 2.1 mmol, 1.5 equiv) wereheated at 90° C. in dry toluene for 18 h. The mixture was cooled andsplit split between water (150 ml) and ethyl acetate (150 ml), and theorganic layer was washed with brine and dried over sodium sulfate. Theoil from concentration in vacuo was purified by flash silica gelchromatography (1→10% ethyl acetate/hexanes) to give a clear oil (55%yield).

The unsaturated ester (276 mg, 0.764, 1.0 equiv) in dry methanol (10 ml)was stirred under nitrogen atmosphere with magnesium turnings (279 mg,11.5 mmol, 15 equiv) for 6 h at 23° C. The mixture was filtered, dilutedwith ethyl acetate (100 ml) and then washed with 1N aqueous HCl (100 ml)and brine (100 ml). The residue from concentration in vacuo was purifiedby flash silica gel chromatography (1→10% ethyl acetate/hexanes) to givethe saturated ester (70% yield). The resulting aryl bromide wasconverted to the boronic acid pinacol ester 102 by Method 3 and theresultant pinacol ester cleaved by method 5. [M−H]⁻=327.1 m/z. Activity:B

Example 94

The pinacol ester of compound 100 (442 mg, 1.1 mmol, 1.0 equiv) wasdissolved in 3:1 tetrahydrofuran/water (8 ml) and stirred with lithiumhydroxide (78 mg, 3.25 mmol, 3.0 equiv) at 50° C. for 3 h. The mixturewas diluted with ethyl acetate (50 ml), washed with 1N aqueous HCl (50ml) and then brine (25 ml) and concentrated in vacuo. Purification byflash silica gel chromatography (1→20% ethyl acetate/hexanes) gaveproduct (60% yield) which was used directly in the next step.

Carboxylic acid (133 mg, 0.34 mmol, 1.0 equiv) was dissolved in drydichloromethane (5 ml) and treated with EDC-HCl (78 mg, 0.41 mmol, 1.2equiv), HOBt (55 mg, 0.41 mmol, 1.2 equiv), iPr₂EtN (130 mg, 1.02 mmol,3.0 equiv), dimethylamine (0.4 ml of a 2 M solution in tetrahydrofuran,0.56 mmol, 2.2 equiv), and DMAP (2 mg, 0.02 mmol, 0.05 equiv). Themixture was stirred at 23° C. for 16 h and then split between 5% aqueoussodium bicarbonate and ethyl acetate (100 ml each). The organic layerwas washed with brine (50 ml) and concentrated in vacuo. Purification byflash silica gel chromatography (1→10% methanol/dichloromethane) gavethe desired amide (84% yield) which was cleaved by Method 5 to producethe arylboronic acid 103. [M−H]⁻=338.2 m/z. Activity: B

Example 95

Benzaldehydeboronic acid 98 (240 mg, 0.89 mmol, 1.0 equiv) was suspendedin water (10 ml) with hydroxylamine hydrochloride (195 mg, 2.80 mmol,3.0 equiv) and sodium acetate (230 mg, 2.80 mmol, 3.0 equiv). Themixture was heated at 60° C. for 16 h and then cooled to roomtemperature. Addition of 1N HCl to achieve pH 1 produced (104) as awhite precipitate that was collected and washed with water (64% yield).[M−H]⁻=266.1 m/z. Activity: B

Example 96

4-(Benzyloxy)-2-formylphenylboronic acid (72 mg, 0.28 mmol) wassuspended in water (10 mL) followed by the addition of hydroxylaminehydrochloride (62 mg, 0.89 mmol). The pH was adjusted to 4 with 1N NaOHand the reaction was heated to 60° C. for 16 h after which point LC/MSanalysis showed only the desired product. Additional water is added (50mL) and the pH is adjusted to <2 with 6N HCl. The resultant solid isisolated using vacuum filtration, washed with excess water and driedunder vacuum to provide 55 mg of benzoazaborine 105 in 77% yield.[M−H]⁻=252.1 m/z. Activity: B

Example 97

4-(Benzyloxy)-2-formylphenylboronic acid (100 mg, 0.391 mmol) wasdissolved in 20 mL water/ethanol (1:1 v/v) followed by the addition ofN-benzylhydroxylamine hydrochloride (62 mg, 0.391 mmol). The reactionwas basified to pH=7 with 1N NaOH and stirred at room temperature for 6h after which point there was no more starting material remaining byLC/MS analysis. The ethanol was removed under a stream of N₂ and 100 mL1N HCl was added. The white solid that precipitated was collected usingvacuum filtration, washed with excess water and dried under vacuum toprovide 55 mg of nitrone 106 in 39% yield. [M−H]⁻=360.2 m/z. Activity: C

Example 98

2-Formyl-4-phenethoxyphenylboronic acid (111 mg, 0.411 mmol) and2-hydroxyethyl hydrazine (33 mL, 0.43 mmol) are dissolved in 10 mLethanol and heated to 50° C. for 12 h. The reaction is allowed to cooland the solvent is removed under a stream of N₂ until there is only 2 mLof ethanol left. 1N HCl (50 mL) is then added until a solid crashes outwhich is isolated using vacuum filtration and washed with excess water.The resultant solid is dried under vacuum overnight to provide 10 mg ofbenzodiazoborine 107 in 8% yield. [M−H]⁻=309.1 m/z. Activity: D

Example 99

Benzodiazoborine 108 was prepared using the analogous procedure asexample 98 except that N-methyhydrazine was used in place of2-hydroxyethyl hydrazine. [M−H]⁻=279.1 m/z. Activity: D

Example 100

Benzodiazoborine 109 was prepared using the analogous procedure asexample 98 except that N-benzylhydrazine was used in place of2-hydroxyethyl hydrazine. [M−H]⁻=341.2 m/z. Activity: B

Example 101

4-(Benzyloxy)-2-formylphenylboronic acid (78 mg, 0.31 mmol) is dissolvedin 5 mL methylene chloride. N-Methyl-N-benzylamine (41 μL, 0.32 mmol) isadded and the mixture is allowed to stir at room temperature for 20 min.Sodium triacetoxyborohydride (68 mg, 0.32 mmol) is then added and thereaction is allowed to stir at room temperature for 30 min after whichpoint there is no starting material visible by LC/MS. The solvent isevaporated under a stream of N₂. The resultant solid is resuspended in asolution of 2% acetic acid in water (50 mL). The solid that forms isisolated using vacuum filtration, washed with excess water, and driedunder vacuum to provide 93 mg of amine 110 in 85% yield. [M−H]⁻=360.2m/z. Activity: C

Example 102

Amine 111 was prepared using the analogous procedure as example 101except that benzylamine was used in place of N-methyl-N-benzylamine.[M−H]⁻=364.2 m/z. Activity: C.

Example 103

(E)-3-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acrylicacid (80 mg, 0.29 mmol) was dissolved in 10 mL anhydrous dichloromethaneand benzylamine (33 μL, 0.31 mmol) was added. HOBt (47 mg, 0.35 mmol)and EDC (67 mg, 0.35 mmol) were then added followed by triethylamine (59uL, 58 mmol). The reaction was allowed to stir for 12 h at roomtemperature after which point it was transferred to a separatory funnelwith excess dichloromethane and washed with 0.5 M citric acid (2×75 mL)and saturated NaHCO₃ (2×75 mL). The organic layer was then dried overMgSO₄, filtered and concentrated to provide the desired ketoamide as awhite solid in 94% yield (100 mg) which was used directly in thefollowing step.

The resulting pinacol ester((E)-N-benzyl-3-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acrylamide)was then converted to amide 112 using Method 5 and was isolated afterprecipitation from the reaction mixture. [M−H]⁻=280.1 m/z. Activity: C

Example 104

Amide 113 was prepared using the analogous procedure as example 103except that N-Boc-m-phenylenediamine was used in place of benzylamine.[M−H]⁻=381.2 m/z. Activity: D

Example 105

Amide 114 was prepared using the analogous procedure as example 103except that N-methyl-N-benzylamine was used in place of benzylamine[M−H]⁻=294.1 m/z. Activity: C

Example 106

4-(Benzyloxy)-2-formylphenylboronic acid (100 mg, 0.39 mmol) andO-benzylhydroxylamine hydrochloride (62 mg, 0.39 mmol) were dissolved in5 mL ethanol. The reaction was allowed to stir at room temperature for14 h. The reaction was then added to 1N HCl (75 mL) and a solid crashedout which was collected via vacuum filtration and washed with excesswater to provide 92 mg of the benzyloxyimine 115 after drying undervacuum overnight. [M−H]⁻=360.1 m/z. Activity: B

Example 107

2-Formylphenylboronic acid (150 mg, 1.0 mmol) and 3-phenylpropionichydrazide (164 mg, 1.0 mmol) were dissolved in 5 mL ethanol. Thereaction was heated to 50° C. for 14 h after which point there was morestarting material by LC/MS analysis. The reaction was allowed to coolafter which point 100 mL 1N HCl was added to the reaction and the solidwhich crashes out is collected by vacuum filtration and washed withexcess water. The solid is dried under vacuum overnight to provide 200mg of acyl hydrazone 116 as a white solid in 68% yield. [M−H]⁻=295.1m/z. Activity: D

Example 108

Acyl hydrazone 117 was prepared using the analogous procedure as example107 except that N-Boc glycine hydrazide was used in place of3-phenylpropionic hydrazide and 2-formyl-4-benzyloxyphenylboronic acidwas used in place of 2-formylphcnylboronic acid. [M−H]=426.1 m/z.Activity: B

Example 109

Acyl hydrazone 117 (58 mg, 0.14 mmol) is suspended in 10 mL ethylacetate saturated with HCl. The reaction is allowed to stir for 30 min.The solvent is then removed under a stream of N₂ over the course of 1.5h. The resulting oil is triturated with tert-butyl methylether until asolid forms, which is filtered and washed with excess tert-butylmethylether to provide 35 mg of acyl hydrazone 118 as the hydrochloridesalt in 70% yield. [M−H]⁻=326.1 m/z. Activity: D

Example 110

Acyl hydrazone 119 was prepared using the analogous procedure as example107 except that 3-maleimidopropionic hydrazide was used in place of3-phenylpropionic hydrazide and 2-formyl-4-phenethoxyphenylboronic acidwas used in place of 2-formylphenylboronic acid. [M−H]⁻=434.1 m/z.Activity: A

Example 111

Acyl hydrazonc 120 was prepared using the analogous procedure as example107 except that acetic hydrazide was used in place of 3-phenylpropionichydrazide and 2-formyl-4-benzyloxyphenylboronic acid was used in placeof 2-formylphenylboronic acid. [M−H]⁻=325.1 m/z. Activity: A

Example 112

Acyl hydrazone 121 was prepared using the analogous procedure as example107 except that pheylacetic hydrazide was used in place of3-phenylpropionic hydrazide. [M−H]⁻=281.1 m/z. Activity: D

Example 113

Acyl hydrazone 122 was prepared using the analogous procedure as example107 except that indole-3-acetic acid hydrazide was used in place of3-phenylpropionic hydrazide. [M−H]=320.1 m/z. Activity: D

Example 114

Acyl hydrazone 123 was prepared using the analogous procedure as example107 except that (2-methyl-thiazol-4-yl)acetic acid hydrazide was used inplace of 3-phenylpropionic hydrazide. [M−H]⁻=302.1 m/z. Activity: D

Example 115

Acyl hydrazone 124 was prepared using the analogous procedure as example107 except that pheylacetic hydrazide was used in place of3-phenylpropionic hydrazide and 2-formyl-4-benzyloxyphenylboronic acidwas used in place of 2-formylphenylboronic acid. [M−H]⁻=387.2 m/z.Activity: B

Example 116

Acyl hydrazone 125 was prepared using the analogous procedure as example107 except 2-picolinyl hydrazide was used in place of 3-phenylpropionichydrazide and 2-formyl-4-benzyloxyphenylboronic acid was used in placeof 2-formylphenylboronic acid. [M−H]⁻=374.1 m/z. Activity: B

Example 117

A mixture of 4-ethynylbenzeneboronic acid (42 mg, 0.289 mmol, 1.0equiv), benzyl azide (38.5 mg, 0.289 mmol, 1.0 equiv), copper sulfate(0.5 mg, 0.003 mmol, 1 mol %), and sodium ascorbate (5 mg, 0.03 mmol,0.1 equiv) were stirred in 2:1 tert-butanol/water (3 ml) for 14 h at 23°C. The mixture was split between ethyl acetate (25 ml) and water (25ml), and the organic layer was washed with brine (20 ml) and dried oversodium sulfate. The residue upon concentration was purified by flashsilica gel chromatography (1→30% methanol/dichloromethane) to give awhite solid (70% yield). [2M−H₂0]⁻=539.1 m/z. Activity: A

Example 118

Compound 127 was prepared by methods described for Example 117.[M−H]⁻=346.1.1 m/z. Activity: C

Example 119

Compound 128 was prepared by methods described for Example 117.[M−H]⁻=308.1 m/z. Activity: B

Example 120

Compound 129 was prepared by methods described for Example 117.[M−H]⁻=292.1 m/z. Activity: A

Example 121

A mixture of 4-ethynylbenzeneboronic acid (180 mg, 1.23 mmol, 1.45equiv), phenyl azidc (100 mg, 0.84 mmol, 1.0 equiv), copper powder (0.5mg, 0.003 mmol, 1 mol %), and sodium ascorbate (16 mg, 0.08 mmol, 0.1equiv) were stirred in 1:1 tert-butanol/water (6 ml) for 14 h at 23° C.The mixture was split between ethyl acetate (25 ml) and water (25 ml),and the organic layer was washed with brine (20 ml) and dried oversodium sulfate. The residue upon concentration was purified by flashsilica gel chromatography (1→10% methanol/dichloromethane) to give 130as a white solid (30% yield). [M−H]⁻=264.1 m/z. Activity: B

Example 122

A 6 ml DMF solution of 4-bromomethylphenylboronic acid pinacol ester(150 mg, 0.5 mmol, 1.0 equiv) was heated with sodium azide (164 mg, 2.5mmol, 5 equiv) at 60° C. for 24 h. The mixture was diluted with water(50 ml) and extracted with ethyl acetate (50 ml). The organic layer waswashed with water (50 ml), then brine (30 ml) and then dried over sodiumsulfate.

The clear oil produced upon concentration was then stirred withphenylacetylene (62 mg, 0.6 mmol, 1.0 equiv), copper sulfate (1 mg, 1mol %), and sodium ascorbate (12 mg, 0.06 mmol, 0.1 equiv) in 2:1tert-butanol/water (6 ml) for 16 h at 23° C. The mixture was dilutedwith water (50 ml) and extracted with ethyl acetate (50 ml). The organiclayer was washed with water (50 ml), then brine (30 ml) and then driedover sodium sulfate. The residue from concentration in vacuo waspurified by flash silica gel chromatography (5→60% ethylacetate/hexanes) to give the pinacol ester as a clear oil. Thisresultant pinacol ester was cleaved by Method 5. [M−H]⁻=278.1 m/z.Activity: B

Example 123

Part A

A flame—dried flask equipped with a rubber septum was charged with4-bromo-3-fluoroiodobenzene (1.0 g, 3.3 mmol, 1.0 equiv), copper(I)iodide (63 mg, 0.33 mmol. 0.1 equiv), andbis(triphenylphosphine)palladium(II) dichloride (117 mg, 0.17 mmol, 0.05equiv). Under argon atmosphere, the solids were suspended in dry THF (8ml), and triethylamine (1.15 ml, 8.3 mmol, 2.5 equiv) andtrimethylsilylacetylene (490 mg, 5 mmol, 1.5 equiv) were added. Themixture was stirred at 23° C. for 4 h, turning from orange to black, andwas then split between ethyl acetate (50 ml) and water (50 ml). Theorganic layer was washed with brine (25 ml) and dried over sodiumsulfate. The residue from concentration in vacuo was restored inmethanol (15 ml) and stirred with potassium carbonate (1.4 g, 10 mmol,3.0 equiv) for 1 h. The mixture was split between ethyl acetate (50 ml)and water (50 ml) and the organic layer was washed with brine (25 ml)and then dried over sodium sulfate and concentrated in vacuo.Purification by flash silica gel chromatography (hexanes) gave acetylene132 as a pale yellow solid (60% yield).

Part B

4-Bromo-3-fluorophenylacetylene (132) (400 mg, 2.0 mmol, 1.0 equiv),copper powder (126 mg, 2.0 mmol, 1.0 equiv), copper sulfate (6 mg, 0.1mmol, 0.05 equiv), and sodium ascorbate (40 mg, 0.2 mmol, 0.1 equiv) in2:1 tert-butanol/water (6 ml) were stirred for 16 h at 23° C. Themixture was diluted with water (50 ml) and extracted with ethyl acetate(50 ml). The organic layer was washed with water (50 ml), then brine (30ml) and then dried over sodium sulfate. The residue from concentrationin vacuo was purified by flash silica gel chromatography (5→60% ethylacetate/hexanes) to give the triazole 133 as a white solid (35 mg).

Part C

The aryl bromide 133 was converted to arylboronic acid 134 by Method 1.[M−H]⁻=282.1 m/z. Activity: B

Example 124

Part A

4-Bromo-3-fluorophenylacetylene (900 mg, 4.5 mmol, 1.0 equiv) and benzylazide (600 mg, 4.5 mmol, 1.0 equiv) were suspended in water (15 ml) andheated in a sealed tube at 120° C. for 24 h. The mixture was cooled andextracted with ethyl acetate (50 ml), and the organic layer was washedwith brine and dried over sodium sulfate. The 1,5-triazole 135 (10%yield) was precipitated from 40% ethyl acetate/hexanes, and the1,4-triazole 136 (25% yield) was isolated after purification of themother liquor by flash silica gel chromatography (5→60% ethylacetate/hexanes).

Part B

The 1,4 isomer 136 was converted to boronic acid 137 by Method 4 andMethod 5. [M−H]⁻=296.1 m/z. Activity: B

Example 125

The 1,5-triazole-arylbromide 135 was converted to the arylboronic acid138 by Method 1. [M—H]⁻=296.1 m/z. Activity: C

Example 126

Part A

4-Bromo-3-fluoroaniline (1.0 g, 5.26 mmol, 1.0 equiv) was dissolved in25 ml of CH3-CN and cooled to 0° C. With stirring, tert-BuONO (1.04 ml,7.9 mmol, 1.5 equiv) was added portionwise over 5 minutes, followed bydropwise addition of trimethylsilylazide (0.67 g, 5.8 mmol, 1.2 equiv).The resulting pale-yellow solution was stirred at 23° C. for 1.5 h. Themixture was then diluted with water (50 ml) and extracted with ethylacetate (50 ml). The organic layer was washed with water (50 ml), thenbrine (30 ml) and then dried over sodium sulfate. Concentration in vacuogave a yellow oil used without purification.

Crude azide (490 mg, 2.25 mmol, 1.0 equiv) and phenylacetylene (231 mg,2.25 mmol, 1.0 equiv) were suspended in water (15 ml) and heated in asealed tube at 120° C. for 24 h. The mixture was cooled and extractedwith ethyl acetate (50 ml), and the organic layer was washed with brineand dried over sodium sulfate. The 1,5-triazole 140 (25% yield) wasprecipitated from 40% ethyl acetate/hexanes, and the 1,4-triazole 139(45% yield) was isolated after purification of the mother liquor byflash silica gel chromatography (5→60% ethyl acetate/hexanes).

Part B

The 1,4-regioisomer 141 was converted to the arylboronic acid by Method4. [M−H]⁻=282.1 m/z. Activity: B

Example 127

The 1,5-triazole-arylbromide 142 was converted to the arylboronic acidby Method 1. [M−H]=282.1 m/z. Activity: C

Example 128

1,4-Triazole 143 was prepared according to the procedure described inexample 126. [M−H]⁻=264.1 m/z. Activity: A

Example 129

1,5-Triazole 144 was prepared according to the procedure described inexample 127. [M−H]⁻=264.1 m/z. Activity: B

Example 130

Part A

A flask is charged with 4-bromo-3-fluorobenzylaldehyde (1.5 g, 7.5 mmol,1.0 equiv) in MeOH-THF (3:1, 20 mL) was added an aqueous solution ofhydroxylamine (0.67 g, 1.3 equiv. in 2 mL water) in one portion. The phwas adjusted to 9 with 6N KOH, and stirred at rt for 2 h. After thedisappearance of the aldehyde by TLC analysis, sodium cyanoborohydride(0.93 g, 2 equiv.) was added and the solution was acidified to pH 2-3using concentrated HCl. The solution was allowed to stir over night. Thesolution was basified with 2N KOH to a pH of 11, extracted with DCM(3×50 mL), dried, concentrated in vacuo to afford a off white solidhydroxylamine 145 (1.4 g).

Part B

The mixture of 145 (500 mg, 1.0 equiv.), 146 (820 mg, 3 equiv.), 147(400 mg, 1.5 equiv.) and 1 g of 4 A molecular sieves in 5 mL of1,2-dichloroethane was heated at reflux for 14 h. TLC analysis showed nomore starting material remaining The mixture was cooled to rt andfiltered to remove sieves and wash solid with ethyl acetate. The organicmixtures were washed with brine, dried and concentrated. Purification onsilica gel (0-30% ethyl acetate in hexanes) gave isoxazolidinc as ayellow oil (470 mg). Conversion to the boronic acid 148 was achieved byMethods 3 and 5. [M−H]⁻=372.1 m/z. Activity: B

Example 131

(8-Bromo-1-naphthyl)methanol 149 (210 mg, 1.0 equiv.), phenol 150 (130mg, 1.3 equiv.), triphenylphosphine (465 mg, 2.0 equiv.), triethylamine(0.25 mL, 2.0 equiv.) were dissolved in 2 mL THF and cooled to 0° C.under nitrogen. Diisopropyl azodicarboxylate (0.34 mL, 2.0 equiv.) wasadded dropwise and the mixture was warmed to rt and stirred overnight.The mixture was concentrated and purified using flash silica gelchromatography (12 g, 0-10% EtOAc in hexanes) to provide coupled product100 mg. Conversion to boronic acid 151 was achieved by Method 1.[M−H]⁻=295.1 m/z. Activity: D

Example 132

Compound 152 was synthesized via Method 12 from 152 and 153.[M−H]⁻=266.1 m/z. Activity: A

Example 133

Compound 156 was synthesized via Method 12 from 152 and 155.[M−H]⁻=264.1 m/z. Activity: A

Example 134

Compound 159 was synthesized via Method 12 from 157 and 158.[M−H]⁻=266.1 m/z. Activity: A

Example 135

Compound 160 was synthesized via Method 12 from phenylacetylene and 157.[M−H]⁻=264.1 m/z. Activity: A

Example 136

Compound 161 was synthesized via Method 12 from 1-heptene and 157.[M−H]⁻=260.2 m/z. Activity: A

Example 137

Compound 162 was synthesized via Method 12 from 2-methyl-1-heptene and157. [M−H]⁻=274.2 m/z. Activity: A

Example 138

Compound 163 was synthesized via Method 12 from β-propylstyrene and 157.[M−H]⁻=308.2 m/z. Activity: C

Example 139

Compound 164 was synthesized via Method 12 from 2-pentyl-1-hexene and157. [M−H]⁻=330.2 m/z. Activity: C

Example 140

Compound 165 was synthesized via Method 12 from 3-vinylpyridine and 157.[M−H]⁻=267.1 m/z. Activity: B

Example 141

Compound 166 was synthesized via Method 12 from 3-pyridylacetylene and157. [M−H]⁻=265.1 m/z. Activity: A

Example 142

Compound 167 was synthesized via Method 12 from 2-bromobenzaldehdye and1-pentene, followed by methods 5 and 3. [M−H]⁻=232.1 m/z. Activity: B

Example 143

Compound 168 was synthesized via Method 12 from 2-bromobenzaldehdye and1-pentyne, followed by methods 5 and 3. [M−H]⁻=230.1 m/z. Activity: D

Example 144

A mixture of 1,3-dihydroxypropane 170 (340 mg, 2 mmol, 1.0 equiv.),4-bromo-3-fluorobenzaldehyde 169 (450 mg, 2 mmol, 1.0 equiv.), andp-tolucncsulfonic acid (0.1 g, 0.25 equiv.) in toluene (30 mL) wasrefluxed for 24 h with a Dean-Stark trap attached for removal of water.The mixture was diluted with EtOAc, washed with sat. sodium bicarbonateand brine, dried and concentrated. The crude mixture was purified on asilica gel column (5-20% EtOAc in hexane) to give major isomer 171 (210mg) and minor isomer 172 (70 mg). Compound 173 was synthesized from 171according to Method 1. [M−H]⁻=301.1 m/z. Activity: A

Example 145

Compound 174 was synthesized from 172 according to Method 1.[M−H]⁻=301.1 m/z. Activity: A

Example 146

Compound 175 was synthesized from 4-bromobenzaldehyde by methodsdescribed for example 145. [M−H]⁻=283.1 m/z. Activity: A

Example 147

Step A

To a mixture of diol 176 (540 mg, 3.9 mmol, 1.0 equiv.),4-bromobenzaldehyde (795 mg, 4.3 mmol, 1.1 equiv.), andp-toluenesulfonic acid (1 g, 5.3 mmol, 1.3 equiv) in toluene (6 mL) wasadded crushed molecular sieves 1.2 g. The mixture was stirred at rt for3.5 h, then 10 ml of sat. NaHCO₃ was added. The mixture was filteredthrough celite, washed with EtOAc. The combined organic layers werewashed with water, brine, dried and concentrated. The crude was purifiedon a silica gel column (hexane to 5-20% EtOAc in hexane) to give transproduct 177 590 mg and cis product 178 540 mg.

Step B

Compound 179 was synthesized from 177 by Method 1. [M−H]⁻=269.1 m/z.Activity: A

Example 148

Compound 180 was synthesized from 178 by Method 1. [M−H]⁻=269.1 m/z.Activity: A

Example 149

Boronic acid 181 was prepared by methods described for example 147.[M−H]⁻=269.1 m/z. Activity: A

Example 150

Boronic acid 182 was prepared by methods described for example 148.[M−H]⁻=269.1 m/z. Activity: A

Example 151

To the suspension of propyltriphenylphosphonium bromide (140 mg, 1.1equiv.) in 3 mL of THF is added drop wise 0.16 mL of a 2.5 M solution ofBuLi in hexanes under nitrogen at 0 C. After 15 min, the red solution iscooled at −78° C. and treated with benzaldehyde 93 (100 mg, 1 equiv.) in1 mL THF. After an additional 15 min, the solution was slowly warmed tort for 1 h, then water (2 ml) and brine (10 ml) are added followed by anextractive workup using ethyl acetate (100 ml). The organic extract isdried (MgSO₄), filtered, concentrated, and purified to give desiredproduct olefin as 1:3 trans to cis mixture. The mixture was dissolved in2 ml toluene, AIBN (5 mg) and PhSH (5 μl) were added. The solution washeated to 80° C. for 2 h, cooled to rt and filtered through short silicagel column. Hexanes was used to wash the product out and the combinedsolution was concentrated to give the aryl bromide as a single transisomer. The aryl bromide was converted by Method 1 to boronic acid 183.[M−H]⁻=295.1 m/z. Activity: B

Example 152

Compound 184 was by methods described for example 151, using3-phenylpropyl triphenylphosphonium bromide in place ofpropyltriphenylphosphonium bromide. [M−H]=371.2 m/z. Activity: C

Example 153

6-Bromo-2-naphthol (2.8 g, 12.5 mmol), 2-chloropyridine (1.7 g, 15 mmol,1.2 eq.), and NaOH (750 mg, 19 mmol, 1.5 eq.) were combined in NMP (15mL) and heated in the microwave at 220° C. during 15 min. The reactionmixture was diluted with water and extracted into MTBE; the organicphase was dried on Na₂SO₄ and concentrated. Chromatography on silica(1→10% EtOAe/hexanes) gave 6-bromonaphthalene-2-(2-pyridyl)ether as awhite solid, 3.31 g. This material was converted to the6-pinacolboronate via Method 3 and the free boronate via Method 5,giving compound 185 as a white solid (1.11 g, 38%). [M−H]⁻=264.1 m/z.Activity: A

Example 154

6-Hydroxynaphthalene-2-boronic acid (1.5 g, 8 mmol) was dissolved inMTBE (75 mL) and stirred with pinacol (943 mg, 8 mmol) for 1h, thendried on Na₂SO₄ and concentrated to crude pinacol ester which was usedwithout further purification.

This crude ester (220 mg, 0.81 mmol), NaOH (150 mg, 3.7 mmol, 4.5 eq.),and chloropyrazine (215 uL, 2.4 mmol, 3 eq.) were dissolved in DMF (3mL) and heated via microwave at 160° C. for 15 min. Dilution with waterand extraction into EtOAc, followed by purification via chromatographyon silica gel (4→20% EtOAc/hexanes) gave the pinacol ester as a yellowoil. This was deprotected to the free boronic acid via Method 5 to give186 as a yellowish solid (172 mg, 79%), approx. 90% pure by rp-hplc.[M−H]⁻=265.1 m/z. Activity: A

Example 155

6-Bromo-2-chloroquinoline (2.5 g, 10.3 mmol) was converted, via Methods11, 3, and 5, to compound 187 (1.31 g, 47%) as a white solid.[M−H]⁻=264.1 m/z. Activity: A

Example 156

7-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) was converted, via Methods11, 3, and 5, to compound 188 (113 g, 41%) as a white solid.[M−H]⁻=264.1 m/z. Activity: A

Example 157

6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and 3-methoxyphenol (330uL, 3. eq.) were converted, via Methods 11, 3, and 5, to compound 189(141 mg, 46%) as a white solid. [M−H]⁻=294.1 m/z. Activity: A

Example 158

6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and potassium tert-butoxide(230 mg, 2.0 eq.) were dissolved in cyclopentanol (3 mL) and heated bymicrowave at 150° C. for 30 min. Extraction from water into MTBE anddrying on Na₂SO₄ gave the crude ether. This was converted, via Methods 3and 5, to compound 190 (66 mg, 25%) as a yellow waxy solid. [M−H]⁻=256.1m/z. Activity: A

Example 159

6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and potassium tert-butoxide(230 mg, 2.0 eq.) were dissolved in n-butanol (3 mL) and heated bymicrowave at 150° C. for 30 min. Extraction from water into MTBE anddrying on Na₂SO₄ gave the crude ether. This was converted, via Methods 3and 5, to compound 191 (74 mg, 29%). [M−H]⁻=244.1 m/z. Activity: A

Example 160

6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and potassium tert-butoxide(230 mg, 2.0 eq.) were dissolved in cyclohexanol (3 mL) and heated at120° C. for 16 hours. Extraction from water into MTBE and drying onNa₂SO₄ gave the crude ether. This was converted, via Methods 3 and 5, tocompound 192 (156 mg, 57%).[M−H]⁻=270.1 m/z. Activity: B

Example 161

6-Bromo-2-chloroquinoline (200 mg, 0.8 mmol) and NaH (40 mg, 2.0 eq.)were dissolved in BnOH (2 mL) and heated at 120° C. for 16 hours.Extraction from water into MTBE and drying on Na₂SO₄ gave the crudeether. This was converted, via Methods 3 and 5, to compound 193 (40 mg,18%).[M−H]⁻=278.1 m/z. Activity: A

Example 162

6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and 3-(dimethylamino)phenol(3 mmol, 3.0 eq.) were converted, via Methods 11, 3, and 5, to compound194 (140 mg, 44%).[M−H]⁻=307.1 m/z. Activity: A

Example 163

6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and 3-nitrophenol (3 mmol,3.0 eq.) were converted, via Methods 11, 3, and 5, to compound 195 (83mg, 26%).[M−H]⁻=309.1 m/z. Activity: A

Example 164

6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and 2-chlorophenol (3 mmol,3.0 eq.) were converted, via Methods 11, 3, and 5, to compound 196 (132mg, 43%). [M−H]⁻=298.1 m/z. Activity: A

Example 165

6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and 3-chlorophenol (3 mmol,3.0 eq.) were converted, via Methods 11, 3, and 5, to compound 197 (93mg, 30%). [M−H]⁻=298.1 m/z. Activity: A

Example 166

6-Bromo-2-chloroquinolinc (250 mg, 1.0 mmol) and 3-cyanophcnol (3 mmol,3.0 eq.) were converted, via Methods 11, 3, and 5, to compound 198 (46mg, 15%). [M−H]⁻=289.1 m/z. Activity: A

Example 167

6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and catechol (3 mmol, 3.0eq.) were converted, via Methods 11, 3, and 5, to compound 199 (78 mg,28%). [M−H]⁻=280.2 m/z. Activity: A

Example 168

6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and guaiacol (3 mmol, 3.0eq.) were converted, via Methods 11, 3, and 5, to compound 200 (159 mg,61%). [M−H]⁻=294.1 m/z. Activity: A

Example 169

6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and 4-chlorophenol (3 mmol,3.0 eq.) were converted, via Methods 11, 3, and 5, to compound 201 (63mg, 21%). [M−H]⁻=298.1 m/z. Activity: A

Example 170

6-Bromo-2-chloroquinoline (200 mg, 0.8 mmol) and 25% methanolic NaOMe (2mL) were heated at 50° C. for 16 hours. Extraction from water into EtOAcand drying on Na₂SO₄ gave the crude ether. This was converted, viaMethods 3 and 5, to compound 202 (110 mg, 66%). [M−H]⁻=202.1 m/z.Activity: B

Example 171

Ethoxyquinoline 203 was prepared by methods used for example 170. (110mg, 66%). [M−H]⁻=215.1 m/z. Activity: B

Example 172

6-Bromo-2-chloroquinoline (200 mg, 0.8 mmol) and N-methylbenzylamine (2mL) were heated at 120° C. for 16 hours. Extraction from 2M NaOH intoDCM and drying on Na₂SO₄ gave the crude 2-aminoquinoline. This wasconverted, via Methods 3 and 5, to compound 204 (110 mg, 46%).[M−H]⁻=291.1 m/z. Activity: A

Example 173

6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and N-methylaniline (2 mL)were heated at 120° C. for 16 hours. Extraction from 2M NaOH into DCMand drying on Na₂SO₄ gave the crude 2-aminoquinoline. This wasconverted, via Methods 3 and 5, to compound 205 (88 mg, 31%).[M−H]⁻=277.0 m/z. Activity: B

Example 174

6-Bromo-2-chloroquinoline (1 g, 4.1 mmol) and aniline (8 mL) were heatedat 100° C. for 16 hours. Some dark color was removed by pushing througha plug of silica gel with MTBE. The eluent was taken up in hexanes,washed with water, and concentrated; the residue was shaken with water(100 mL) and hexanes (20 mL), giving a beige solid which was collectedby filtration and washed with water. This material was converted, viaMethods 3 and 5, to compound 206 (647 mg, 60%). [M−H]⁻=263.1 m/z.Activity: A

Example 175

6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and tetrahydroquinoline (2mL) were heated at 120° C. for 16 hours. The material was taken up inDCM (20 mL) and treated with NEt₃ (6 mL) and Ac₂O (3 mL) for 2 h, thenextracted from 0.1 M NaOH into DCM. Drying on Na₂SO₄ and concentrationgave a crude residue which was converted, via Methods 3 and 5, tocompound 207 (151 mg, 48%). [M−H]⁻=303.1 m/z. Activity: B

Example 176

6-hydroxynaphthalene-2-boronic acid (1.5 g, 8 mmol) was dissolved inMTBE (75 mL) and stirred with pinacol (943 mg, 8 mmol) for 1 h, thendried on Na₂SO₄ and concentrated to crude pinacol ester which was usedwithout further purification.

This crude ester (220 mg, 0.81 mmol), NaOH (150 mg, 3.7 mmol, 4.5 eq.),and 2-bromo-pyrimidine (390 mg, 2.4 mmol, 3.0 eq.) were dissolved in DMF(3 mL) and heated via microwave at 160° C. for 15 min. Dilution withwater and extraction into EtOAc, followed by purification viachromatography on silica gel (4→20% EtOAc/hexanes) gave the pinacolester as a yellow oil. This was deprotected to the free boronic acid viaMethod 5 to give 208 (54 mg, 25%). [M−H]⁻=265.1 m/z. Activity: A

Example 177

6-Bromo-2-chloroquinoline (250 mg, 1.0 mmol) and 3-hydroxypyridine (3mmol, 3. eq.) were converted, via Methods 11, 3, and 5, to compound 209(69 mg, 26%). [M−H]⁻=265.1 m/z. Activity: A

Example 178

A solution of 4-bromoaniline (9.0 g, 52.3 mmol) in PhMe (100 mL) andpyridine (8.5 mL, 110 mmol, 2.0 eq.) was cooled in an ice bath andslowly treated with propionyl chloride (5.5 mL, 63 mmol, 1.2 eq.). After2 h, the reaction mixture was added to 0.1 M HCl and extracted intoEtOAc. Concentration followed by recrystallization of the residue fromEtOH/water gave N-propionyl-4-bromoaniline (10.64 g, 89%). [M−H]⁻=278.1m/z.

Phosphorous oxychloride (3 mL, excess) was treated with DMF (650 uL, 8.7mmol, 1.5 eq.) and the solution allowed to return to ambienttemperature. N-propionyl-4-bromoaniline (1.32 g, 5.8 mmol, 1 eq.) wasadded and the mixture heated at 85° C. for 4 h. The hot mixture waspoured onto ice (100 g), stirred until melted, and the solids werecollected by filtration. Washing with water and drying in vacuo gaveclean 6-bromo-2-chloro-3-methylquinoline (914 mg, 61%).

This intermediate (250 mg, 1.0 mmol) and phenol (3 mmol, 3. eq.) wereconverted, via Methods 11, 3, and 5, to compound 210 (118 mg, 42%).[M−H]⁻=278.1 m/z. Activity: A

Example 179

2-Quinoxalinol (2.9 g, 20 mmol) and silver sulfate (3.1 g, 10 mmol, 0.5eq.) in sulfuric acid (20 mL) were treated with bromine (1.03 mL, 20mmol, 1.0 eq.). After stirring at ambient temperature for 18 h, thereaction mixture was diluted with carbon tetrachloride (50 mL), heatedto 50° C., and filtered. The filtrate was poured onto ice and the solidscollected by filtration and recrystallized from HOAc, giving6-bromo-2-quinoxalinol (1.8 g, 40%).

6-Bromo-2-quinoxalinol (631 mg) in POCl₃ (6.3 mL) was refluxed for 2 h,then poured onto ice. The solution was neutralized to pH 7 by additionof NH₄OH, and the resulting solid collected by filtration. Washing withwater and drying in vacuo gave 6-bromo-2-chloroquinoxaline (627 mg,92%).

This intermediate (250 mg, 1.0 mmol) and phenol (3 mmol, 3.0 eq.) wereconverted, via Methods 11, 3, and 5, to compound 211 (4.4 mg, 2%).[M−H]⁻=265.1 m/z. Activity: B

Example 180

4-Bromo-2-methylaniline (1.8 g, 10 mmol) in PhMe (25 mL) was treatedwith ethyl acetoacetate (1.3 mL, 11 mmol, 1.1 eq.) and refluxed during18 h. Upon cooling a precipitate ofN-acetoacetyl-4-bromo-2-methylaniline (1.59 g, 60%) formed, which wascollected by filtration and used without further purification.

This acetoacetamide (1 g, 3.7 mmol) was dissolved in sulfuric acid (5mL) and heated at 120° C. during 2 h. The hot solution was poured ontoice (100 g), giving a white solid which was collected by filtration,washed with water, and dried in vacuo to give6-bromo-4,8-dimethyl-2-quinolone (418 mg, 45%).

This quinolone (410 mg, 1.6 mmol) in POCl₃ (5 mL) was refluxed for 2 h,then poured onto ice. The solution was neutralized to pH 7 by additionof NH₄OH, and the resulting solid collected by filtration. Washing withwater and drying in vacuo gave 6-bromo-2-chloro-4,8-dimethyl-quinoline(407 mg, 93%).

This intermediate (200 mg, 0.74 mmol) and phenol (3 mmol, 3.0 eq.) wereconverted, via Methods 11, 3, and 5, to compound 212 (141 mg, 65%).[M−H]⁻=292.1 m/z. Activity: B

Example 181

Compound 213 was produced in a manner analogous to compound 212, using4-bromoaniline in place of 4-bromo-2-methylaniline. Yield 131 mg.[M−H]⁻=278.1 m/z. Activity: A

Example 182

A solution of 6-bromobenzothiazolin-2-one (500 mg, 2.2 mmol) in POCl₃ (5mL) was refluxed during 18 h, then poured onto ice. The solution wasneutralized to pH 9 by addition of NH₄OH, and the resulting solidcollected by filtration. Washing with water and drying in vacuo gave6-bromo-2-chlorobenzothiazole (450 mg, 83%).

This intermediate (200 mg, 0.8 mmol) and phenol (3 mmol, 3.0 eq.) wereconverted, via Methods 11, 3, and 5, to compound 214 (25 mg, 12%).[M−H]⁻=270.1 m/z. Activity: A

Example 183

6-Bromo-2-chloroquinoline (500 mg, 2.0 mmol) and 2-hydroxypyridine (3mmol, 3.0 eq.) were converted, via Methods 11, 3, and 5, to compound 215(35 mg, 7%). [M−H]=265.1 m/z. Activity: A

Example 184

6-Hydroxynaphthalene-2-boronic acid (1.5 g, 8 mmol) was dissolved inMTBE (75 mL) and stirred with pinacol (943 mg, 8 mmol) for 1 h, thendried on Na₂SO₄ and concentrated to crude pinacol ester which was usedwithout further purification.

Phenylboronic acid (140 mg, 1.1 mmol, 2.0 eq.) was coevaporated withPhMc twice to produce the anhydride. This was treated with crude6-hydroxynaphthalene-2-boronic acid pinacol ester (150 mg, 0.56 mmol),DCM (5 mL), NEt₃ (400 uL, 3 mmol, 5 eq.), and cupric acetate (100 mg,0.53 mmol, 0.95 eq.) and stirred at ambient temperature during 16 h. Themixture was extracted from 0.1M NaOH into DCM, dried on Na₂SO₄,concentrated, and chromatographed on silica gel (0→2% EtOAc/hexanes) togive 6-phenoxynaphthalene-2-boronic acid pinacol ester, which wasdeprotected via Method 5 to provide compound 216 (54 mg, 37%).[M−H]⁻=263.1 m/z. Activity: A

Example 185

The corresponding pinacol ester (22 mg, 0.066 mmol) was cleavedaccording to Method 5 to give compound 217 (17 mg, quant.). [M−H]⁻=251.1m/z. Activity: A

Example 186

The corresponding bromide (256 mg, 1.0 mmol) was reacted according toMethod 2 to give compound 218 (37 mg, 17%). [M−H]=214.1 m/z. Activity: D

Example 187

The corresponding bromide (336 mg, 1.1 mmol) was converted via Methods 3and 5 to compound 219 (77 mg, 26%). [M−H]⁻=273.1 m/z. Activity: B

Example 188

The corresponding pinacol ester (200 mg, 0.8 mmol) was cleaved accordingto Method 5 to give compound 220 (89 mg, 66%). [M−H]=181.1 m/z.Activity: C

Example 189

6-Bromoquinaldine (1 g, 4.5 mmol) in CCl₄ (6 mL) was treated with NBS(750 mg, 4.2 mmol, 0.95 eq.) and a few crystals of benzoyl peroxide andrefluxed during 2 h. The hot solution was filtered, the filtratedcooled, and the resulting crystals collected by filtration and usedwithout further purification.

A solution of phenol (60 mg, 0.63 mmol, 2.0 eq.) in NMP was treated with60% NaH dispersion (25 mg, 0.63 mmol, 2.0 eq.) and the dibromoquinaldineproduced in the previous step (150 mg, 0.31 mmol). After stirring atambient temperature for 18 h, the reaction was extracted from 0.1M NaOHinto MTBE, dried on Na₂SO₄, concentrated, and chromatographed on silicagel (0→10% EtOAc/hexanes) to give a-phenoxy-6-bromoquinaldine (93 mg,94%).

This bromide was converted via Methods 3 and 5 to compound 221 (48 mg,58%). [M−H]⁻=278.1 m/z. Activity: B

Example 190

4-Bromoiodobenzene (460 mg, 1.6 mmol, 1.5 eq.),1-isoamylpyrazole-4-boronic acid (200 mg, 1.1 mmol), potassium acetate(100 mg, 1.0 eq.), Pd(dppf)Cl₂ (100 mg, 0.1 eq.), and Cs₂CO₃ (1 g, 3.0eq.) in DMSO (5 mL) were heated under argon at 80° C. during 1 h. Thereaction mixture was extracted from water into ether, dried Na₂SO₄,concentrated, and chromatographed on silica gel (0→10% EtOAc/hexanes) togive 1-isoamyl-4-(4-bromophenyl)pyrazole (263 mg, 82%).

This bromide was converted via Methods 3 and 5 to compound 222 (147 mg,64%). [M−H]=257.2 m/z. Activity: A

Example 191

The corresponding iodide (125 mg, 0.4 mmol) was converted via Methods 3and 5 to compound 223 (9 mg, 10%). [M−H]⁻=237.1 m/z. Activity: D

Example 192

2-(4-Iodophenyl)benzimidazole (200 mg, 0.6 mmol) was methylated withiodomethane (180 mg, 1.2 mmol, 2.0 eq.) and NaH (45 mg, 1.8 mmol, 3 eq.)in DMF (3 mL) for 18 h. Dilution with diethyl ether, washing with water,drying over Na₂SO₄, and chromatography (10→25% EtOAc/hexanes) gave1-methyl-2-(4-iodophenyl)benzimidazole (124 mg, 59%).

This iodide was converted via Method 2 to compound 224 (9 mg, 10%).Activity: D

Example 193

4-Bromo-3-fluoroiodobenzene (250 mg, 0.7 mmol, 1.2 eq.),4-methyl-2-phenylthiazole-5-boronic acid pinacol ester (170 mg, 0.6mmol), potassium acetate (70 mg, 1.0 eq.), Pd(dppf)Cl₂ (70 mg, 0.1 eq.),and Cs₂CO₃ (700 mg, 3.0 eq.) in DMSO (5 mL) were heated under argon at80° C. during 1 h. The reaction mixture was extracted from water intodiethyl ether, dried over Na₂SO₄, concentrated, and chromatographed onsilica gel (5→10% EtOAc/hexanes) to give the corresponding bromide to225 (169 mg, 85%).

This bromide was converted via Methods 3 and 5 to compound 225 (15 mg,10%). Activity: B

Example 194

4-Bromo-3-fluoroiodobenzene (250 mg, 0.8 mmol, 1.2 eq.),1-benzylpyrazole-4-boronic acid pinacol ester (200 mg, 0.7 mmol),potassium acetate (70 mg, 1 eq.), Pd(dppf)Cl₂ (70 mg, 0.1 eq.), andCs₂CO₃ (700 mg, 3.0 eq.) in DMSO (5 mL) were heated under argon at 80°C. during 1 h. The reaction mixture was extracted from water intodiethyl ether, dried over Na₂SO₄, concentrated, and chromatographed onsilica gel (5→10% EtOAc/hexanes) to give the corresponding bromide to226 (193 mg, 83%).

This bromide was converted via Methods 3 and 5 to compound 226 (13 mg,8%). [M−H]⁻=295.1 m/z. Activity: A

Example 195

4-Bromo-iodobenzene (240 mg, 0.8 mmol, 1.2 eq.),1-benzylpyrazole-4-boronic acid pinacol ester (200 mg, 0.7 mmol),potassium acetate (70 mg, 1 eq.), Pd(dppf)Cl₂ (70 mg, 0.1 eq.), andCs₂CO₃ (700 mg, 3.0 eq.) in DMSO (5 mL) were heated under argon at 80°C. during 1 h. The reaction mixture was extracted from water intodiethyl ether, dried over Na₂SO₄, concentrated, and chromatographed onsilica gel (5→10% EtOAc/hexanes) to give1-benzyl-4-(4-bromophenyl)pyrazole (218 mg, 99%).

This bromide was converted via Methods 3 and 5 to compound 227 (142 mg,73%). [M−H]⁻=277.1 m/z. Activity: A

Example 196

4-Bromo-iodobenzene (250 mg, 0.9 mmol, 1.2 eq.),2-methoxynaphthalene-6-boronic acid (150 mg, 0.7 mmol), potassiumacetate (70 mg, 1.0 eq.), Pd(dppf)Cl₂ (70 mg, 0.1 eq.), and Cs₂CO₃ (700mg, 3.0 eq.) in DMSO (5 mL) were heated under argon at 80° C. during 1h. The reaction mixture was extracted from water into diethyl ether,dried over Na₂SO₄, concentrated, and chromatographed on silica gel(5→20% EtOAc/hexanes) to 2-methoxy-6-(4-bromophenyl)naphthalene (131 mg,56%).

This bromide was converted via Methods 3 and 5 to compound 228 (47 mg,41%). [M−H]⁻=277.1 m/z. Activity: B

Example 197

4-Bromo-3-fluoroiodobenzene (250 mg, 0.8 mmol, 1.2 eq.),quinoline-5-boronic acid (120 mg, 0.7 mmol), potassium acetate (70 mg, 1eq.), Pd(dppf)Cl₂ (70 mg, 0.1 eq.), and Cs₂CO₃ (700 mg, 3.0 eq.) in DMSO(5 mL) were heated under argon at 80° C. during 1 h. The reactionmixture was extracted from water into ether, dried over Na₂SO₄,concentrated, and chromatographed on silica gel (5→20% EtOAc/hexanes) togive 5-(4-bromo-3-fluorophenyl)quinoline (220 mg, quant.).

This bromide was converted via Methods 3 and 5 to compound 229 (39 mg,20%). [M−H]⁻=266.1 m/z. Activity: B

Example 198

4-Bromo-3-fluoroiodobenzene (250 mg, 0.8 mmol, 1.2 eq.),indole-4-boronic acid (110 mg, 0.7 mmol), potassium acetate (70 mg, 1eq.), Pd(dppf)Cl₂ (70 mg, 0.1 eq.), and Cs₂CO₃ (700 mg, 3 eq.) in DMSO(5 mL) were heated under argon at 80° C. during 1 h. The reactionmixture was extracted from water into ether, dried Na₂SO₄, concentrated,and chromatographed on silica gel (5→15% EtOAc/hexanes) to give4-(4-bromo-3-fluorophenyl)indole (164 mg, 83%).

This bromide was converted via Methods 3 and 5 to compound 230 (77 mg,53%). [M−H]⁻=254.1 m/z. Activity: B

Example 199

2-Phelylmalondialdehyde (200 mg, 1.4 mmol) in EtOH (10 mL) was treatedwith 4-bromophenylhydrazine HCl (300 mg, 1.4 mmol) and NEt₃ (200 uL, 1.4mmol) and refluxed for 1 h. The solution was diluted slightly withwater, chilled, and the resulting precipitate of1-(4-bromophenyl)-4-phenylpyrazole collected by filtration (179 mg,44%).

This bromide was converted via Methods 3 and 5 to compound 231 (35 mg,23%). [M−H]⁻=263.1 m/z. Activity: A

Example 200

2-(4-Bromophenyl)malondialdehyde (250 mg, 1.1 mmol) in EtOH (10 mL) wastreated with phenylhydrazine (110 uL, 1.1 mmol) and refluxed for 1 h.The solution was diluted slightly with water, chilled, and the resultingprecipitate of 4-(4-bromophenyl)-1-phenylpyrazole collected byfiltration (270 mg, 82%).

This bromide was converted via Methods 3 and 5 to compound 232 (155 mg,68%). [M−H]⁻=263.0 m/z. Activity: A

Example 201

4-(4-Bromophenyl)piperidine HCl (1 g, 3.7 mmol) in DCM (6 mL) wastreated with K₂CO₃ (1.3 g, 9 mmol, 2.5 eq.) and Boc2O (1.35 g, 6 mmol,1.6 eq). The mixture was diluted with water, extracted with MTBE, washedwith brine, dried on Na₂SO₄, and concentrated. Chromatography on silicagel (2>8% EtOAc/hexanes) gave 1 Boc 4 (4-bromophenyl)piperidine (944 mg,76%). This bromide was converted via Method 3 to1-Boc-4-(4-boronophenyl)piperidine pinacol ester (1.16 g, quant.).

A portion of this ester (270 mg) was deprotected via Method 5 to givecompound 233 (144 mg, 68%). [M−H]⁻=304.2 m/z. Activity: A

Example 202

4-Bromophenethylamine (2 mL, 13 mmol) in DCM (12 mL) was treated withK₂CO₃ (2.7 g, 20 mmol, 1.5 eq.) and Boc2O (3.1 g, 14 mmol, 1.1 eq.). Themixture was diluted with water, extracted with MTBE, washed with brine,dried on Na₂SO₄, and concentrated to give cleanN-Boc-4-bromophenethylamine (4 g, quant.).

This carbamate was dissolved in DMF (40 mL) and treated with 60% NaHdispersion (1.7 g, 42 mmol, 3.0 eq.) and MeI (1.7 mL, 28 mmol, 2.0 eq.).After stirring at ambient temperature 18 h, the reaction mixture isextracted from 0.1M NaOH into MTBE, dried on Na₂SO₄, and concentrated toclean N-Boc-N-methyl-bromophenethylamine (4.67 g, quant.). 1 g of thisbromide (3.2 mmol) was converted via Method 3 toN-Boc-N-methyl-4-boronophenethylamine pinacol ester (981 mg, 85%).

A portion of this ester (150 mg) was deprotected via Method 5 to givecompound 234 (95 mg, 82%). [M−H]⁻=278.1 m/z. Activity: A

Example 203

A solution of 4-bromodihydrocinnamic acid (1.5 g, 6.6 mmol) in THF (10mL) and DMF (10 mL) was treated with 2.0M methylamine in THF (10 mL, 3.0eq.) and HBTU (2.75 g, 7.2 mmol, 1.1 eq.) The mixture was diluted withwater, extracted with MTBE, washed with brine, dried on Na₂SO₄, andpushed through a pad of silica gel using 50% EtOAc/hexanes, givingN-methyl-4-bromodihydrocinnamide.

This amide was dissolved in THF (20 mL) and treated withborane-dimethylsulfide complex (1.25 mL, 13 mmol, 2.0 eq.) and refluxedfor 3 h. The reaction was quenched with MeOH, then treated with 6M HClto a pH of 1 and concentrated in vacuo. The residue was extracted from1M NaOH into DCM, dried Na₂SO₄, and concentrated toN-methyl-3-(4-bromophenyl)propylamine (562 mg, 38%) which is usedwithout further purification.

This amine in DCM (5 mL) was treated with K₂CO₃ (500 mg, 3.7 mmol, 1.5eq.) and Boc2O (900 mg, 4 mmol, 1.6 eq.). The mixture was diluted withwater, extracted with MTBE, washed with brine, dried on Na₂SO₄,concentrated, and chromatographed to give cleanN-Boc-N-methyl-3-(4-bromophenyl)propylamine (546 mg, 68%). This bromidewas converted via Method 3 toN-Boc-N-methyl-3-(4-boronophenyl)propylamine pinacol ester (594 mg,95%).

A portion of this ester (100 mg) was deprotected via Method 5 to givecompound 235 (59 mg, 76%). [M−H]⁻=292.2 m/z. Activity: A

Example 204

1-Boc-4-(4-boronophenyl)piperidine pinacol ester (887 mg, 2.3 mmol),prepared in the synthesis of compound 233, was dissolved in TFA (10 mL),stirred for 1 h, and coevaporated with twice with PhMe to givedeprotected salt with pinacol ester intact (by NMR and LC). 190 mg ofthis salt (0.47 mmol) in DCM (5 mL) was treated with NEt₃ (250 uL, 1.8mmol, 3.8 eq.) and benzenesulfonyl chloride (75 uL, 0.57 mmol, 1.2 eq.).After stirring at ambient temperature 16 h, the reaction mixture wasdiluted with DCM and concentrated onto silica gel. Chromatography (3→45%EtOAc/hexanes) gave 1-benzenesulfonyl-4-(4-boronophenyl)piperidinepinacol ester. Deprotection of this ester via Method 5 gave compound 236(80 mg, 49%). [M−H]⁻−344.1 m/z. Activity: B

Example 205

N-Boc-N-methyl-4-boronophenethylamine pinacol ester (430 mg), preparedin the synthesis of compound 234, was dissolved in TFA (5 mL), stirredfor 1 h, and coevaporated with twice with PhMe to give deprotected saltwith pinacol ester intact (by NMR and LC). 208 mg of this salt (0.55mmol) in DCM (5 mL) was treated with NEt₃ (250 uL, 1.8 mmol, 3.3 eq.)and benzenesulfonyl chloride (85 uL, 0.67 mmol, 1.2 eq.). After stirringat ambient temperature 16 h, the reaction mixture was diluted with DCMand concentrated onto silica gel. Chromatography (2→15% EtOAc/hexanes)gave N-benzenesulfonyl-N-methyl-4-boronophenethylamine pinacol ester.Deprotection of this ester via Method 5 gave compound 237 (117 mg, 66%).[M−H]⁻=318.1 m/z. Activity: A

Example 206

N-Boc-N-methyl-3-(4-boronophenyl)propylamine pinacol ester (494 mg),prepared in the synthesis of compound 235, was dissolved in TFA (5 mL),stirred for 1 h, and coevaporated with twice with PhMe to givedeprotected salt with pinacol ester intact (by NMR and LC). 256 mg ofthis salt (0.66 mmol) in DCM (5 mL) was treated with NEt₃ (300 uL, 2.2mmol, 3.3 eq.) and benzenesulfonyl chloride (100 uL, 0.79 mmol, 1.2eq.). After stirring at ambient temperature 16 h, the reaction mixturewas diluted with DCM and concentrated onto silica gel. Chromatography(2→15% EtOAc/hexanes) gaveN-benzenesulfonyl-N-methyl-3-(4-boronophenyl)propylamine pinacol ester.Deprotection of this ester via Method 5 gave compound 238 (135 mg, 62%).[M−H]⁻=332.1 m/z. Activity: A

Example 207

Oxadiazole 239 was prepared in 2 steps by first forming the oxadiazolefrom 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzohydrazide and4-oxo-4-(1-piperidinyl)butanoic acid using Method 7 followed by Method 5and was isolated after precipitation from the reaction mixture.[M−H]⁻=328.1 m/z. Activity: B

Example 208

Oxadiazole 60 was prepared in 2 steps by first forming the oxadiazolefrom 5-(4,4,5,5-tetra-methyl-1,3,2-dioxaborolan-2-yl)furan-3-carboxylicacid and hexanoic hydrazide using Method 8 followed by Method 5 and wasisolated after precipitation from the reaction mixture. [2M−H₂O]⁻=481.0m/z. Activity: B

Example 209

Benzoxazole 241 was prepared in 3 steps by first forming the benzoxazolefrom 2-amino-5-chlorophenol and phenyl acetic acid using Method 13followed by conversion to the boronate ester using Method 15 followed byMethod 5. [M−H]⁻=252.0 m/z. Activity: A

Example 210

Benzoxazole 242 was prepared in 3 steps by first forming the benzoxazolefrom 2-amino-4-bromophenol and 3-phenylpropionic acid using Method 13followed by conversion to the boronate ester using Method 3 followed byMethod 5. [M−H]⁻=266.1 m/z. Activity: A

Example 211

Benzoxazole 243 was prepared in 3 steps by first forming the benzoxazolefrom 2-amino-5-chlorophenol and 3-phenylpropionic acid using Method 13followed by conversion to the boronate ester using Method 15 followed byMethod 5. [M−H]⁻=266.1 m/z. Activity: A

Example 212

Benzoxazole 244 was prepared in 3 steps by first forming the benzoxazolefrom 2 amino-5-chlorophenol and butyric acid using Method 13 followed byconversion to the boronate ester using Method 15 followed by Method 5.[M−H]⁻=204.1 m/z. Activity: A

Example 213

Benzoxazole 245 was prepared in 3 steps by first forming the benzoxazolefrom 2-amino-5-chlorophenol and hexanoic acid using Method 13 followedby conversion to the boronate ester using Method 15 followed by Method5. [M−H]⁻=233.9 m/z. Activity: A

Example 214

Benzoxazole 246 was prepared in 3 steps by first forming the benzoxazolefrom 2-amino-5-chlorophenol and 5,5,5-trifluoropentanoic acid usingMethod 13 followed by conversion to the boronate ester using Method 15followed by Method 5. [M−H]⁻=272.1 m/z. Activity: A

Example 215

Benzoxazole 247 was prepared in 3 steps by first forming the benzoxazolefrom 2-amino-5-chlorophenol and 4-oxo-4-(1-piperidinyl)butanoic acidusing Method 13 followed by conversion to the boronate ester usingMethod 15 followed by Method 5. [M−H]⁻=301.1 m/z. Activity: B

Example 216

Benzoxazole 248 was prepared in 3 steps by first forming the benzoxazolefrom 2-amino-5-chlorophenol and 5-oxo-1-phenyl-pyrrolidine-3-carboxylicacid using Method 13 followed by conversion to the boronate ester usingMethod 15 followed by Method 5. [M−H]⁻=321.1 m/z. Activity: B

Example 217

Benzoxazole 249 was prepared in 3 steps by first forming the benzoxazolefrom 2-amino-5-chlorophenol and 5-oxo-1-phenyl-pyrrolidine-3-carboxylicacid using Method 13 followed by conversion to the boronate ester usingMethod 15 followed by Method 5. [M−H]=335.1 m/z. Activity: B

Example 218

Part A

5-Fluoro-2(3H)-benzoxazolone 250 (0.50 g, 1.0 equiv) and phosphoruspentachloride (1.36 g, 2.0 equiv) were placed in a microwave reactorvial. The reaction was sealed and heated to 175° C. in a microwavereactor for 45 min. The reaction was then quenched with excess saturatedsodium bicarbonate (100 mL) which resulted in significant fuming. Thereaction mixture was then transferred to a separatory funnel with excesswater and ethyl acetate at which point the water layer was washed withethyl acetate (2×50 mL). The organic layers were combined, dried overMgSO₄ and concentrated under vacuum to provide 500 mg of the desiredproduct 251 that was taken on directly to the next step.

Compound 251 (0.50 g, 1.0 equiv) was suspended in 10 mL of water in amicrowave reactor vial. Sodium hydroxide (1.60 g, 15.0 equiv) was addedand the mixture was stirred at room temperature until all the sodiumhydroxide dissolved. The reaction was then heated to 150° C. in amicrowave reactor for 20 min after which 1N HCl was added until a solidcrashes out (pH ˜7). The solid is isolated via vacuum filtration, washedwith excess water and dried on the high vac to provide 300 mg of thedesired aminophenol 252 (70% yield).

Part B

Benzoxazole 253 was prepared in 3 steps by first forming the benzoxazolefrom 2-amino-5-chloro-4-fluorophenol 252 and 3-phenylpropionic acidusing Method 13 followed by conversion to the boronate ester usingMethod 15 followed by Method 5. [M−H]=284.1 m/z. Activity: A

Example 219

Benzodiazoborine 254 was prepared using the analogous procedure asexample 98 except that N-benzylhydrazine was used in place of2-hydroxyethyl hydrazine and (2-formyl-4,5-methylenedioxy)phenylboronicacid was used in place of benzene boronic acid 98. [M−H]=279.1 m/z.Activity: D

Example 220

Benzodiazoborine 255 was prepared using the analogous procedure asexample 98 except that N-benzylhydrazine was used in place of2-hydroxyethyl hydrazine and 5-methoxy-2-formylphenylboronic acid wasused in place of benzene boronic acid 98. [M−H]⁻=265.1 m/z. Activity: D

Example 221

Benzodiazoborine 256 was prepared using the analogous procedure asexample 98 except that N-benzylhydrazine was used in place of2-hydroxyethyl hydrazine and 3-formylthiophene-2-boronic acid was usedin place of benzene boronic acid 98. [M−H]⁻=241.1 m/z. Activity: D

Example 222

Benzodiazoborine 257 was prepared using the analogous procedure asexample 98 except that N-benzylhydrazine was used in place of2-hydroxyethyl hydrazine and 4-formylthiophene-3-boronic acid was usedin place of benzene boronic acid 98. [M−H]=241.1 m/z. Activity: D

Example 223

Benzodiazoborine 258 was prepared using the analogous procedure asexample 98 except that hydrazine was used in place of 2-hydroxyethylhydrazine and 4-(benzyloxy)-2-formylphenylboronic acid was used in placeof benzene boronic acid 98. [M−H]⁻=251.1 m/z. Activity: D

Example 224

Benzoxazole 259 was prepared in 2 steps by first forming the benzoxazolefrom 2-amino-3-hydroxypyridine and 2-bromo benzoic acid using Method 13followed by conversion to the boronic acid using Method 1. [M−H]=239.0m/z. Activity: D

Example 225

Oxadiazole 260 was prepared in 2 steps starting with oxadiazoleformation between 2-bromo-5-methoxybenzoic acid and butyric hydrazideusing Method 8 followed by lithiation using Method 1. [M−H]⁻=261.1 m/z.Activity: D

Example 226

Oxadiazole 261 was prepared in 2 steps starting with oxadiazoleformation between 2-bromo-5-fluorobenzoic acid and butyric hydrazideusing Method 8 followed by lithiation using Method 1. [M−H]⁻=249.0 m/z.Activity: D

Example 227

Oxadiazole 262 was prepared in 2 steps starting with oxadiazoleformation between 2-bromo-6-fluorobenzoic acid and butyric hydrazideusing Method 8 followed by lithiation using Method 1. [M−H]⁻=249.2 m/z.Activity: D

Example 228

Oxadiazole 263 was prepared in 2 steps by first forming the oxadiazolefrom 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzohydrazide and3-(2-oxo-pyrrolidin-1-yl)-propionic acid using Method 7 followed byMethod 5 and was isolated after precipitation from the reaction mixture.[M−H]⁻=300.1 m/z. Activity: D

Example 229

Oxadiazole 264 was prepared in 2 steps by first forming the oxadiazolefrom 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid andfuroic hydrazide using Method 8 followed by Method 5 and was isolatedafter precipitation from the reaction mixture. [M−H]−455.1 m/z.Activity: D.

Example 230

Oxadiazole 265 was prepared in 2 steps by first forming the oxadiazolefrom 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid and3-phenylpropionic hydrazide using Method 8 followed by Method 5 and wasisolated after precipitation from the reaction mixture. [M−H]⁻=293.1m/z. Activity: D

Example 231

Thiadiazole 266 was prepared in 2 steps by first forming the thiadiazolefrom 2-bromobenzoic acid and butyric hydrazide using Method 9 followedby lithiation using Method 1. [M−H]⁻=247.1 m/z. Activity: D.

Example 232

Thiadiazole 267 was prepared in 2 steps starting with thaidiazoleformation between 2-bromo-5-phenethoxybenzoic acid 16 and propionichydrazide using Method 9 followed by lithiation using Method 1.[M−H]⁻=267.1 m/z. Activity: A

Example 233

Oxadiazole 268 was prepared in 2 steps starting with oxadiazoleformation between 2-bromo-5-phenethoxybenzoic acid 16 and1-methyl-1H-imidazole-5-carbohydrazide using Method 7 followed bylithiation using Method 1. [M−H]⁻=389.0 m/z. Activity: B.

Example 234

Oxadiazole 269 was prepared in 2 steps starting with oxadiazoleformation between 2-bromo-5-phenethoxybenzoic acid 16 and2-methyl-1,3-thiazole-4-carbohydrazide using Method 7 followed bylithiation using Method 1. [M+H]⁺−408.3 m/z. Activity: C.

Example 235

Oxadiazole 271 was prepared in analogous fashion to the oxadiazole 17 inexample 12 except that 1-bromobutane was used in the place ofphenethylbromide in part A to synthesize 2-bromo-5-butoxybenzaldehyde270. Aldehyde 270 was then converted to the desired oxadiazole using theoxidation, cyclization and lithiation steps in part B. [M−H]⁻=303.2 m/z.Activity: B

Example 236

Oxadiazole 272 was prepared in analogous fashion to the oxadiazole 17 inexample 12 except that 1-bromobutane was used in the place ofphenethylbromide in part A to synthesize 2-bromo-5-butoxybenzaldehyde270 and that acetic hydrazide was used in place of butyric hydrazideduring the cyclization step in part B. [M−H]⁻=275.1 m/z. Activity: B

Example 237

In a microwave reactor tube,4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (300 mg, 1.0equiv), polystyrene—supported triphenylphosphine (3.0 equiv) andtrichloroacetonitrile (0.18 mL, 2.0 equiv) were added, and the mixturewas sealed and heated in a microwave reactor at 100° C. for 30 min.N-Hydroxy-butyramidine (0.14 mL, 1.1 equiv) was then added followed byN,N-diisopropyl ethylamine (0.43 mL, 2.0 equiv) and the reaction wasreheated in a microwave reactor to 150° C. for 1 h. The concentratedreaction mixture was purified by flash silica gel chromatography(hexanes/ethyl acetate) to provide oxadiazole-aryl boronic acid pinacolester in 32% yield. The boronate was then converted the boronic acid 272using Method 5. [M−H]=231.1 m/z. Activity: A.

Example 238

Oxadiazole 273 was prepared in two steps first using the analogousprocedure as example 238 except that 2-bromo-5-phenethoxybenzoic acid 16was used in place of4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid. Theresultant oxadiazole was then converted to the corresponding boronicacid using the lithiation conditions in Method 1. [M−H]⁻=351.2 m/z.Activity: B

Example 239

Thiazole 276 was prepared in 3 steps from 2-bromo-5-phenethoxybenzoicacid 16. Acid 16 (700 mg, 1.0 equiv) and 1-aminopentan-2-onehydrochloride (390 mg, 1.3 equiv) were dissolved in 20 mL anhydrousdichloromethane. HOBt (353 mg, 1.2 equiv) and EDC (501 mg, 1.2 equiv)were added followed by triethylamine (940 uL, 3.0 equiv). The reactionwas allowed to stir for 12 h at room temperature after which point itwas transferred to a separatory funnel with excess dichloromethane andwashed with 0.5 M citric acid (2×75 mL) and saturated NaHCO₃ (2×75 mL).The organic layer was then dried over MgSO₄, filtered and concentratedto provide the desired ketoamide 274 as a yellow solid in quantitativeyield (880 mg) which was used directly to form the thiazole the in thefollowing step.

Ketoamide 274 (308 mg, 1.0 equiv) was added to a microwave reactor vialand dissolved in 5 mL anhydrous tetrahydrofuran after which Lawesson'sreagent (462 mg, 1.5 equiv) was then added. The reaction was heated to115° C. for 90 min in a microwave reactor after which point it wasloaded directly onto silica gel and purified using flash silica gelchromatography using a gradient of 20-70% ethyl acetate/hexanes toprovide 230 mg of the desired thiazole 275 in 50% yield.

The resultant thiazole 275 was then converted to the correspondingboronic acid using the lithiation conditions in Method 1. [M+H]⁺=368.2m/z. Activity: B

Example 240

Benzodiazoborine 277 was prepared in 3 steps by first preparing thecorresponding boronic acid aldehyde in analogous fashion to example 90except that aldehyde 270 used in place of aldehyde 93. Benzodiazoborine277 was then prepared using the analogous procedure as example 96 exceptthat 4-butoxy-2-formylphenylboronic acid was used in the place of 98.[M−H]⁻=218.1 m/z. Activity: C.

Example 241

Benzothiazole 278 was prepared in 3 steps by first forming thebenzothiazole from 2-amino-5-chlorothiophenol and 3-phenylpropionic acidusing Method 13 followed by conversion to the boronate ester usingMethod 15 followed by Method 5. [M−H]⁻=282.2 m/z. Activity: A.

Example 242

Piperidine 279 was prepared in 3 steps starting from1-Boc-4(4-boronophenyl)piperidine pinacol ester 233 which was firstdeprotected as described in Example 204. This salt (150 mg, 0.374 mmol)was dissolved in tetrahydrofuran (5 mL) and treated with triethylamine(41.6 mg, 0.411 mmol, 1.1 eq.) and benzaldehyde (43.6 mg, 0.411 mmol,1.1 eq.) and stirred for 30 minutes while being cooled in an ice bath.To this solution sodium triacetoxyborohydride (87 mg, 0.411 mmol, 1.1eq.) was added in portions and the reaction was allowed to warm toambient temperature and stir for 16 h. The reaction was diluted withethyl acetate (50 mL) and washed with water (2×15 mL). The organic layerwas dried over magnesium sulfate, filtered and evaporated onto silicagel. Purification using silica gel chromatography (gradient of 0 to 20%ethyl acetate/hexanes) gave 1-benzyl-4-(4-boronophenyl)piperidinepinacol ester. Deprotection of this ester via Method 5 gave compound 279(30 mg, 30%). [M H]⁻=294.2 m/z. Activity: C.

Example 243

Piperidine 280 was prepared using the analogous procedure as example 242except that 4-isopropylbenzaldehyde was used in place of benzaldehyde.[M−H]⁻=336.3 m/z. Activity: B.

Example 244

Oxadiazole 281 was prepared in 2 steps by first forming the oxadiazolefrom 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid andhexanoic hydrazide using Method 8 followed by Method 5 and was isolatedand purified by using flash silica gel chromatography. [M−H]⁻=259.1 m/z.Activity: D

Example 245

2-Bromobenzhydrazide (1.03 g, 4.8 mmol, 1.0 equiv) and1,1′-carbonyldiimidazole (1.01 g, 6.23 mmol, 1.3 equiv) were heated in1,4-dioxane (20 mL) for 4 h at 80° C. The mixture was concentrated invacuo, and the resulting residue split between ethyl acetate and water(100 mL each). The organic layer was washed with brine, dried oversodium sulfate, and concentrated in vacuo to afford a white solid (1.1g, 95% yield). A portion of this intermediate oxadiazolidinone (820 mg,3.4 mmol, 1.0 equiv) was suspended in a solution of dimethylamine (2.0 Min THF, 20 mL) and stirred at 23° C. overnight. The resulting solutionwas concentrated in vacuo; the residue was re-suspended in drydichloromethane (30 mL) and concentrated in vacuo. This residue wasagain re-suspended in dry dichloromethane (5 mL) and treated withp-toluenesulfonyl chloride (681 mg, 3.57 mmol, 1.05 equiv) andtriethylamine (1.2 ml, 8.5 mmol, 2.5 equiv). After stirring at 23° C.for 16 h, the mixture was split between ethyl acetate and water (50 mLeach), and the organic layer was washed with brined and dried oversodium sulfate. Concentration in vacuo gave a residue which, uponpurification by silica gel chromatography (30→100% ethylacetate/hexanes) gave dimethylamino-oxadiazole as a white solid. Thisbromide was converted to the boronic acid by Method 1, and was isolatedand purified by using flash silica gel chromatography to provide 282 asa white solid. [2M−H₂0]⁻=447.1 m/z. Activity: D

Example 246

2-Bromobenzhydrazide (500 mg, 2.32 mmol, 1.0 equiv) and isobutyrylchloride (372 mg, 3.49 mmol, 1.5 equiv) were stirred with sodiumbicarbonate (590 mg, 7.0 mmol, 3.0 equiv) in water and 1,4-dioxane (10mL each), at 0° C. for 1 h. The mixture was split between ethyl acetateand water (50 mL each), and the organic layer was washed with brine,dried over sodium sulfate, and concentrated in vacuo to a white solid.This solid was dissolved in dry dichloromethane (5 mL), and the solutionwas concentrated to 2.5 mL in vacuo. This solution was treated withp-toluenesulfonyl chloride (465 mg, 2.44 mmol, 1.05 equiv) andtriethylamine (0.8 ml, 5.8 mmol, 2.5 equiv) and stirred at 23° C. for 16h. The mixture was split between ethyl acetate and water (50 mL each),and the organic layer was washed with brine, dried over sodium sulfate,and concentrated in vacuo to give oxadiazole as a clear oil. Thisbromide was converted to the boronic acid by Method 1, and was isolatedand purified by using flash silica gel chromatography to provide 283 asa white solid. [M−H]⁻=231.1 m/z. Activity: D

Example 247

Oxadiazole 284 was prepared using the analogous procedure as example 246except that isovaleryl chloride was used in place of isobutyrylchloride. [M−H]⁻=245.1 m/z. Activity: D.

Example 248

Oxadiazole 285 was prepared in 2 steps by first forming the oxadiazolefrom 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzhydrazide and3,3,3-trifluorobutanoic acid using Method 7 followed by Method 5 and wasisolated and purified by using flash silica gel chromatography.[M−H]⁻=285.0 m/z. Activity: D

Example 249

2-Bromobenzhydrazide (500 mg, 2.32 mmol, 1.0 equiv) and ethylchloroformate (359 mg, 2.88 mmol, 1.2 equiv) were stirred with sodiumbicarbonate (605 mg, 7.2 mmol, 3.0 equiv) in water and 1,4-dioxane (10mL each), at 0° C. for 1 h. The mixture was split between ethyl acetateand water (50 mL each), and the organic layer was washed with brine,dried over sodium sulfate, and concentrated in vacuo to a white solid.This solid was dissolved in dry dichloromethane (5 mL), and the solutionwas concentrated to 2.5 mL in vacuo. This solution was treated withp-toluenesulfonyl chloride (480 mg, 2.52 mmol, 1.05 equiv) andtriethylamine (0.84 ml, 6.0 mmol, 2.5 equiv) and stirred at 23° C. for16 h. The mixture was split between ethyl acetate and water (50 mLeach), and the organic layer was washed with brine, dried over sodiumsulfate, and concentrated in vacuo to give oxadiazole as a clear oil.This bromide was converted to the boronic acid by Method 3 followed bymethod 5, and purification using silica gel chromatography gave the 286as a white solid. [2M−H₂0]⁻=488.8 m/z. Activity: D

Example 250

The pinacol ester of compound 100 (18 mg, 0.04 mmol, 1.0 equiv) wasdissolved in 3:1 tetrahydrofuran/water (1.2 mL) and stirred with lithiumhydroxide (6 mg, 0.26 mmol, 6.0 equiv) at 50° C. for 2 h. The mixturewas diluted with ethyl acetate (50 mL), washed with 1N aqueous HCl (100mL) and then brine (15 mL) and concentrated in vacuo to yield 17 mg ofcrude carboxylic acid, which was used in the next step withoutpurification.

Carboxylic acid (8 mg, 0.02 mmol, 1.0 equiv) was dissolved in drydichloromethane (1 mL) and treated with 3-aminomethyl pyridine (4 mg,0.04 mmol, 2.0 equiv), HBTU (8 mg, 0.03 mmol, 1.5 equiv) and iPr₂EtN (8mg, 0.06 mmol, 3.0 equiv). The mixture was stirred at 23° C. for 16 hand then split between 5% aqueous sodium bicarbonate and ethyl acetate(20 mL each). The organic layer was concentrated in vacuo to yield 10 mgcrude product. The crude product was cleaved by Method 5 to produce thearylboronic acid 287 after HPLC purification. [M−H]⁻=401.2 m/z.Activity: D

Example 251

Boronic acid 288 was prepared using the analogous procedure as example250 except 2-furylmethylamine was used in place of isobutyryl chloride.[M−H]⁻=390.2 m/z. Activity: D.

Example 252

A mixture of 1-bromo-2-fluoro-4-iodobenzene (460 mg, 1.5 mmol, 1.0equiv), 3-isopropylphenyl-boronic acid (250 mg, 1.5 mmol, 1.0 equiv),Pd(PPh₃)₂Cl₂ (35 mg, 0.05 mmol, 0.03 equiv) and NaHCO₃ (640 mg, in 4 mLwater) were added to a flask and dioxane (4 mL) was added. The mixturewas purged with argon for 5 min, and then stirred at 80° C. under anargon atmosphere for 6 h. The reaction was diluted with ethyl acetate(200 mL), washed with 60 mL water, then 40 mL brine, dried andconcentrated. Purification via silica gel column chromatography with(gradient of 0-2.5% ethyl acetate/hexanes) gave desired the biphenylbromide as yellow oil 340 mg. The biphenyl bromide was converted to 289by Method 1. [M−H]=357.1 m/z. Activity: A

Example 253

Part A

To a solution of 2-amino-4-bromophenol (2 g, 8.9 mmol, 1.0 equiv) in HCl(5 M, 12.5 mL, 7.0 equiv) was added drop-wise a solution of sodiumnitrite (0.62 g, 8.9 mmol, 1.0 equiv) in water (5 mL) at 0° C. Themixture was stirred at this temperature for 30 min after which a cooledsolution of KI (1.5 g, 8.9 mmol, 1.0 equiv) in H₂O (14 mL) was slowlyadded at 0° C. The mixture was then allowed to warm to room temperatureand stirred overnight. The reaction mixture was diluted with ethylacetate (200 mL) and the separated aqueous phase was extracted withethyl acetate (100 mL×3). The combined organic fraction was washed withNa₂S₂O₃ (10%, 40 mL), water (100 mL×2) and brine (40 mL), dried overNa₂SO₄ and concentrated to dryness. The residue was purified by flashsilica gel chromatography (ethyl acetate/hexanes) to afford 1.1 g4-bromo-2-iodo-pheno as a yellow solid.

Part B

4-Phenyl-1-pentyne (131 mg, 1.0 mmol, 1.0 equiv) was added to asuspension of 4-bromo-2-iodophenol (300 mg, 1.0 mmol, 1.0 equiv) andCu₂O (85 mg, 0.6 mmol) in dry pyridine (4 mL). The mixture was refluxedunder nitrogen for 4 h. The mixture was filtered through celite andwashed with ethyl acetate. The pyridine was evaporated under reducedpressure, and the residue was purified by chromatography (combiflash,hexane) gave partially pure desired product 290 (276 mg). The benzofuranbromide 290 was converted to desired boronic acid 291 by Method 3followed by Method 5. [M−H]⁻=265.0 m/z. Activity: A.

Example 254

Part A

6-Chloro-2-phenethylbenzofuran 292 was prepared using the analogousprocedure as example 253 except 2-amino-5-chlorophenol hydrochloride wasused in place of 2-amino-4-bromophenol.

Part B

Benzofuran 293 was synthesized from 292 according to the followingprocedure: 292 (160 mg, 0.6 mmol, 1.0 equiv), tetramethyl dioxaborolane(160 mg, 1.2 mmol, 2.0 equiv), phospine ligand and palladium diacetatewere added together in to 8 mL toluene. The mixture was purged with Arfor 5 min, and then was heated to 80° C. for 5 h. The reaction wascooled to room temperature and water (20 mL) was added after whichdiethyl ether (3×50 mL) was used to extract the product. The organiclayer was washed with brine, dried (Na₂SO₄), and concentrated.Purification on combiflash (10-15-20% ethyl acetate in hexanes) gave 50mg of the desired pinacol ester. This was converted to compound 293 byMethod 5. [M−H]⁻=265.2 m/z. Activity: A.

Example 255

Part A

A mixture of 3-iodopyridine (980 mg, 4.8 mmol, 1.0 equiv),2-bromo-5-hydroxybenzaldehyde (960 mg, 4.8 mmol, 1.0 equiv), cesiumcarbonate (3.11 g, 9.6 mmol, 2.0 equiv), copper iodide (182 mg, 0.96mmol, 0.2 equiv), and N,N-dimethylglycine HCl salt (533 mg, 3.8 mmol,0.8 equiv) are suspended in 10 mL of dioxane in a sealed tube and heatedto 90° C. under a nitrogen atmosphere. After 16 h, the cooled mixturewas filtered through a bed of celite with small amount of silica gel ontop of it. Ethyl acetate (3×20 mL) was used to wash the celite. Thefiltrate was concentrated in vacuo. The residual oil was loaded on asilica gel column and eluted with ethyl acetate/hexanes (15-20%) toafford 0.4 g of the corresponding aldehyde.

A solution of the aldehyde (160 mg, 0.58 mmol, 1.0 equiv) intetrahydrofuran (10 mL) is placed in a flask with stir bar and isoprene(404 mg, 5.8 mmol, 10 equiv), 2.7M phosphate buffer (1.7 mL, 4.6 mmol,8.0 equiv), and NaClO₂ (208 mg, 2.3 mmol, 4.0 equiv) are added. Thereaction is stirred at room temperature for 2 h and stopped by theaddition of water (30 mL), acidification to pH 1 with 6M HCl, andextraction (3×50 mL methylene chloride). The organic layers are dried onNa₂SO₄ and concentrated to give 294 as a white foam (182 mg), which isused without further purification.

Part B

A solution of the acid 294 (140 mg, 0.48 mmol, 1.0 equiv) in methylenechloride (5 mL) is treated with oxalyl chloride (91 mg, 0.71 mmol, 1.5equiv) followed by a drop of N,N-dimethylforamide and stirred 23° C. for3 h. The mixture was concentrated in vacuo and resuspended in methylenechloride (6 mL). To this mixture were treated with triethylamine (96 mg,0.96 mmol, 2.0 equiv) followed by butyric hydrazide (73 mg, 0.71 mmol,1.5 equiv) and catalytic DMAP. After 20 min at 23° C., the reactionmixture was split between water and methylene chloride. The aqueouslayer was back extracted again with methylene chloride. The combinedorganics were washed with 5% NaHCO₃ and then brine, dried over sodiumsulfate and concentrated in vacuo to yield 150 mg crude material. Thecrude material was suspended in POCl₃ (6 mL) and heated at 90° C. for 2h after which point the mixture was poured into ice water. Methylenechloride was used to extract the aqueous layer and the organic layer waswashed with brine, dried over sodium sulfate, and concentrated in vacuo.HPLC purification (FA 10-80) gave oxadiazole 295 (8 mg), which wasconverted to compound 296 by Method 1. [M+H]⁺=326.0 m/z. Activity: B.

Example 256

4-Bromo-3-fluorophenol (200 mg, 1.0 mmol, 1.0 equiv),5-fluoropyridin-3-ylboronic acid (221 mg, 1.5 mmol, 1.5 equiv), copper(II) acetate (190 mg, 0.481 mmol, 1.0 equiv) and 4A MS were suspended in10 mL methylene chloride. Triethylamine (530 mg, 5.0 mmol, 5.0 equiv)was then added after which point the reaction turned from blue to brownand was stirred at room temperature for 16 h under ambient atmosphereafter which point the reaction turned back blue. The slurry was filteredthrough a small pad of celite and washed with 30% ethyl acetate inhexanes. The combined filtrate was concentrated in vacuo. Purificationusing flash silica gel chromatography gave the desired biaryl bromide(45 mg) which was converted to boronic acid 297 by Method 1.[M−H]⁻=250.1 m/z. Activity: A.

Example 257

Biaryl boronic acid 298 was prepared using the analogous procedure asexample 256 except that 4-fluoropyridin-3-ylboronic acid was used inplace of 5-fluoropyridin-3-ylboronic acid. [M−H]⁻=250.1 m/z. Activity:A.

Example 258

1-Boc-piperidin-4-ylacetic acid (1.7 g, 7.0 mmol, 1.0 equiv) and4-chloro aminophenol (1.0 g, 7.0 mmol, 1.0 equiv) were added to a sealedflask. Acetonitrile (20 mL) was added followed by triphenylphosphineresin (11.1 g, 1.88 mmol/g, 4.0 equiv) and trichloroacetonitrile (2.0 g,14 mmol, 2.0 equiv). The flask was scaled and heated at 100° C. for 20 hand cooled to room temperature. The resin was rinsed with excesstetrahydrofuran/methylene chloride (1:1). The resulting filtrate wasthen concentrated to yield the corresponding Boc-deprotected benzoxazolechloride. The solid was washed with 30% ethyl acetate in hexanes to getrid of the non polar impurities and used directly in next step.

To a solution of the amine (1.2 g, 4.8 mmol, 1.0 equiv) andtriethylamine (1.5 g, 14.4 mmol, 4.0 equiv) in 70 mL of methanol wasadded di-tert-butyl dicarbonate (1.3 g, 5.7 mmol, 1.2 equiv) and themixture stirred at room temperature for 24 h. The solvent was evaporatedand the residue was suspended in 100 mL of ethyl acetate. The mixturewas washed with a saturated sodium bicarbonate solution (50 mL) andsubsequently with water (2×100 mL). The organic layer was dried withanhydrous sodium sulfate and concentrated. The Boc-protected benzoxazolechloride 1.2 g was obtained as yellow oil and was used directly in theconversion to the boronate ester using Method 15 to provide pinacolester 300 followed by Method 5 to provide 299. [M−H]⁻=359.1 m/z.Activity: A.

Example 259

Boc protected benzoxazole pinacol ester 300 (600 mg, 1.4 mmol, 1.0equiv) is stirred in trifluoroacetic acid (6 mL) for 1 h, after whichpoint the solution was evaporated under reduced pressure. The crudematerial was azeotroped twice with toluene (75 mL) after which point thepiperidine salt was used directly in the next step.

The crude amine TFA salt (200 mg, 0.45 mmol, 1.0 equiv) is dissolved in4 mL dry methylene chloride. Triethylamine (181 mg, 1.82 mmol, 4.0equiv) and 4-isopropylbenzaldehyde (135 mg, 0.9 mmol, 2.0 equiv) wereadded followed by the addition of sodium triacetoxyborohydride (386 mg,1.82 mmol, 4.0 equiv). The reaction was stirred at room temperature for20 h then concentrated. Methanol was added to the residue to quench theunreacted borohydride after which point the crude material was directlypurified with HPLC (FA 10-80) to give 50 mg of pure pinacol ester, whichwas converted to compound 301 by Method 5. [M−H]⁻=391.2 m/z. Activity: B

Example 260

Benzoxazole 302 was prepared using the analogous procedure as example259 except that benzaldehyde was used in place of4-isopropylbenzaldehyde. [M−H]⁻=349.2 m/z. Activity: B.

Example 261

Benzoxazole 303 was prepared using the analogous procedure as example259 except that propionaldehyde was used in place of4-isopropylbenzaldehyde. [M−H]⁻=301.2 m/z. Activity: C.

Example 262

Benzoxazole 304 was prepared using the analogous procedure as example259 except that isobutyraldehyde was used in place of4-isopropylbenzaldehyde. [M−H]⁻=315.2 m/z. Activity: D.

Example 263

Boc-protected benzoxazole pinacol ester 300 is deprotected as in example259 and the crude amine TFA salt (190 mg, 0.43 mmol, 1.0 equiv) isdissolved in 5 mL dry methylene chloride. Triethylamine (175 mg, 1.73mmol, 4.0 equiv) followed by benzenesulfonyl chloride (153 mg, 0.86mmol, 2.0 equiv) were added. The reaction was stirred at roomtemperature for 20 h and then concentrated under reduced pressure.Methanol was added to the residue and the crude material was directlypurified with HPLC (FA 10-80) to give 70 mg pure sulfonamide pinacolester product, which was converted to compound 305 by Method 5.[M−H]⁻=399.0 m/z. Activity: B.

Example 264

Boc-protected benzoxazole pinacol ester 300 is deprotected as in example259 and the crude amine TFA salt (200 mg, 0.45 mmol, 1.0 equiv) isdissolved in 5 mL dry methylene chloride. Triethylamine (181 mg, 1.8mmol, 4.0 equiv) and hydrocinnamoyl chloride (154 mg, 0.9 mmol, 2.0equiv) were added. The reaction was stirred at room temperature for 20 hand then concentrated. Methanol was added to the residue and the crudematerial was directly purified with HPLC (FA 10-80) to give 60 mg pureamide pinacol ester product, which was converted to compound 306 byMethod 5. [M−H]⁻=391.1 m/z. Activity: A.

Example 265

5-Bromophthalic anhydride (1.0 g, 4.4 mmol) in ethanol (10 mL) wastreated with n-amylamine (562 uL, 4.9 mmol, 1.1 eq.) and heated atreflux overnight. The mixture was diluted into 0.1M HCl (100 mL) and theresulting white solid collected by filtration, washed with water, anddried in vacuo to give 136 mg of the corresponding phthalimide as awhite solid. The filtrate was diluted with brine and chilled at −20° C.for 2d. A second crop of precipitate was collected, washed with water,and dried in vacuo to give another 116 mg phthalimide as a white solid.The crops are identical by NMR and combined to give a total yield of 252mg (0.85 mmol, 19%). This material was used without furtherpurification.

This precipitated phthalimide (250 mg, 0.84 mmol) was converted usingmethods 3 followed by method 5, to form boronic acid 307 (22 mg, 10%) asa white solid. [M−H]⁻=260.1 m/z. Activity: A.

Example 266

5-Bromo-2-benzylphthalimide was produced from 5-bromophthalic anhydride(1.0 g, 4.4 mmol) using the analogous procedure as example 265 exceptthat benzylamine was used in the place of n-amylamine, to provide 421 mg(30%) of product as a white crystals.

This precipitated phthalimide (200 mg, 0.63 mmol) was converted usingmethods 3 followed by method 5, to form boronic acid 308 (67 mg, 38%) asan off-white solid. Activity: A.

Example 267

5-Bromo-2-phenethylphthalimide was produced from 5-bromophthalicanhydride (1.0 g, 4.4 mmol) using the analogous procedure as example 265except that phenethylamine was used in the place of n-amylamine, toprovide 521 mg (36%) of product as a white crystals.

This precipitated phthalimide (270 mg, 0.82 mmol) was converted usingmethods 3 followed by method 5, to form boronic acid 309 (106 mg, 44%)as a brownish powder. [M−H]⁻=294.0 m/z. Activity: A.

Example 269

3-Fluoro-4-bromotoluene (5.0 g, 27 mmol) in carbon tetrachloride (50 mL)was treated with N-bromosuccinimide (7.0 g, 40 mmol, 1.5 eq) and heatedto 80° C. Benzoyl peroxide (65 mg, 0.27 mmol, 0.01 eq.) was added andheating was continued for 1 h. The reaction was then cooled to ambienttemperature and filtered, and the filtercake was washed sparingly withchloroform. The filtrate was washed with water and brine, dried overNa₂SO₄, and concentrated to give crude 3-fluoro-4-bromobenzyl bromide asa clear oil which was used without further purification.

This crude benzyl bromide (27 mmol) and sodium cyanide (2.38 g, 54 mmol,2.0 eq.) were combined in ethanol (100 mL) and heated at 80° C. for 2 h.The reaction mixture was concentrated to dryness in vacuo, suspended inwater, and extracted with ethyl acetate. Washing with brine and dryingover Na₂SO₄ gave, after removal of the solvent, a red oil which waspurified using silica gel chromatography (gradient of 2→12% ethylacetate/hexanes) to provide 3-fluoro-4-bromophenylacetonitrile as whiteneedles (1.96 g, 35% over 2 steps).

A solution of lithium aluminum hydride (1M in THF, 14 mL, 14 mmol, 3.0eq.) was chilled in an ice bath and slowly treated with sulfuric acid(390 uL, 7.0 mmol, 1.5 eq.). After the visible reaction was complete, asolution of the nitrile produced above (1.0 g, 4.7 mmol) intetrahydrofuran (10 mL) was dripped in to the mixture slowly. Themixture was stirred at 0° C. for 20 min, then refluxed for 30 min. Aftercooling to room temperature, the excess reagents were quenched with2-propanol, followed by 4M NaOH. After stirring to assure completereaction, the resulting suspension was filtered through celite and thefiltercake was washed well with 2-propanol. The filtrate wasconcentrated to give crude 3-fluoro-4-bromophenethylamine as a clear oilwhich was used without further purification.

This crude material (4.7 mmol) was dissolved in methylene chloride (10mL) and treated with potassium carbonate (1.0 g, 7.0 mmol, 1.5 eq.) anddi-tert-butyldicarbonate (1.15 g, 5.2 mmol, 1.1 eq). The mixture wasstirred at ambient temperature for 2 days, then diluted with water,extracted into MTBE, washed with brine, dried over Na₂SO₄, andconcentrated to a white solid which contains excess dicarbonate reagent.The material was taken up in ethanol (20 mL) and treated with imidazole(200 mg). After stirring for a few minutes, the solvent was removedunder vacuum and the residue dissolved in methylene chloride, washedseveral times with 1% HCl, and concentrated to give crudeN-Boc-3-fluoro-4-bromophenethylamine as a yellow solid which was usedwithout further purification.

This crude material (4.7 mmol) was dissolved in N,N-dimethylforamide (10mL) and chilled in an ice bath. Sodium hydride dispersion (60% inmineral oil, 560 mg, 14 mmol, 3.0 eq.) was added and stirring continueduntil gas evolution ceased, then iodomethane (580 uL, 9.4 mmol, 2.0 eq,)was added and the mixture allowed to warm to room temperature. Afterstirring overnight, the mixture is diluted with MTBE, washed with waterand brine, dried over Na₂SO₄, and concentrated to give crudeN-methyl-N-Boc-3-fluoro-4-bromophenethylamine (916 mg, 59% over 3steps).

This material (916 mg, 2.76 mmol) was converted to thepinacolatoboronate (351 mg, 34%) using Method 3. This boronate ester (70mg) was converted, via Method 5, to provide boronic acid 311 (52 mg) asa colorless oil. [M−H]⁻=296.2 m/z. Activity: A.

Example 270

N-Methyl-N-Boc-3-fluoro-4-bromophenethylamine from Example 269 wasconverted to the corresponding boronate ester using method 3. Thiscompound (280 mg, 0.74 mmol) was dissolved in trifluoroacetic acid (4mL) and stirred for 1 h. The acid was removed under vacuum, and was thenazeotroped twice with toluene, to give the crude trifluoroacetate saltof N-methyl-3-fluoro-4-pinacolboronato-phenethylamine as a clear viscousoil.

This crude salt (100 mg, 0.25 mmol) was taken up in methylene chloride(5 mL) and treated with triethylamine (150 uL, 1.0 mmol, 4.0 eq.).Benzenesulfonyl chloride (40 uL, 0.31 mmol, 1.2 eq.) was added and thesolution stirred at ambient temperature overnight. The mixture wasdiluted with methylene chloride and treated with silica gel.Concentration and purification using silica gel chromatography (gradientof 2→18% ethyl acetate/hexanes) provided the benzenesulfonamidederivative as a clear oil.

This material was converted, via Method 5, to provide boronic acid 312(29 mg, 34%) as a white solid. [M−H]⁻=336.3 m/z. Activity: A.

Example 271

A solution of 2-fluoro-4-bromobenzaldehyde (5.09 g, 25 mmol) wasdissolved in glyme (25 mL) and slowly treated over 10 minutes withanhydrous hydrazine (25 mL, 0.8 mol, 32 eq.). The resulting biphasicmixture was then held at reflux overnight. The reflux condenser wasreplaced with a short-path distillation head and about half the solventdistilled, at which time the reaction flask showed one phase and twophases were evident in the distillate. The undistilled residue wascooled and treated with water (25 mL), forming a white precipitate. Thissolid was collected by filtration, washed thoroughly with water, anddried in vacuo to give 6-bromoindazole (4.21 g, 85%) as white crystals.

6-Bromoindazole (3.63 g, 18 mmol) was suspended in dioxane (15 mL) andbenzyl bromide (2.65 mL, 22 mmol, 1.2 eq.) was added. The reaction washeated to reflux overnight, then allowed to cool to 80° C. after whichpoint ethyl acetate (50 mL) added. The cake was broken up with a spatulaand after stirring for 20 min, the solids were filtered off and washedwith ethyl acetate, giving glossy white crystals of the hydrobromidesalt of 2-benzyl-6-bromoindazole. These were suspended in ethyl acetate(100 mL) and shaken with saturated NaHCO₃ (150 mL) until dissolution.The layers were separated and the aqueous layer was extracted with ethylacetate (50 mL). The combined organic layers were concentrated to anoff-white powder which was recrystallized from 66% ethanol (40 mL).Washing with water and drying in vacuo gave 2-benzyl-6-bromoindazole(3.30 g, 62%) as shiny white plates.

This material (3.0 g, 10.3 mmol) was converted to boronic acid 313 (1.8g, 69%) as a white powder using method 3 followed by method 5.[M−H]⁻=251.1 m/z. Activity: A.

Example 272

6-Bromoindazole, produced in example 271 (300 mg, 1.5 mmol) and sodiumhydroxide (90 mg, 2.3 mmol, 1.5 eq.) were suspended in dioxane (3 mL)and phenethyl bromide (500 uL, 3.6 mmol, 2.4 eq). was added. Thereaction was heated to 80° C. for 4 h. The product was extracted fromwater into MTBE, washed with brine, and dried with Na₂SO₄. Silica gelwas added and the solvent removed after which purification using silicagel chromatography (gradient of 0→12% ethyl acetate/hexanes) separatedtwo products, 1-phenethyl-6-bromoindazole (122 mg) and2-phenethyl-6-bromoindazole (273 mg, 60%).

2-Phenethyl-6-bromoindazole (273 mg, 0.9 mmol) was converted to boronicacid 314 (152 mg, 63%) as an off-white foam using method 3 followed bymethod 5. [2M−H₂O]⁻=513.0 m/z. Activity: A.

Example 273

5-Bromoindazole, (300 mg, 1.5 mmol) and sodium hydroxide (90 mg, 2.3mmol, 1.5 eq.) were suspended in dioxane (2 mL) and phenethyl bromide(500 uL, 3.6 mmol, 2.4 eq). was added. The reaction was heated to 80° C.for 4 h. The product was extracted from water into MTBE, washed withbrine, and dried with Na₂SO₄. Silica gel was added and the solventremoved after which purification using silica gel chromatography(gradient of 0→15% ethyl acetate/hexanes) separated two products,1-phenethyl-5-bromoindazole (134 mg) and 2-phenethyl-5-bromoindazole(228 mg, 50%).

2-Phenethyl-5-bromoindazole (228 mg, 0.76 mmol) was converted to boronicacid 315 (131 mg, 65%) as a tan foam using method 3 followed by method5. [2M−H₂O]⁻=513.1 m/z. Activity: A.

Example 274

5-Bromoindazole, (500 mg, 2.5 mmol), tetrabutylammonium iodide (100 mg,0.25 mmol, 0.1 eq.) and sodium hydroxide (150 mg, 3.8 mmol, 1.5 eq.)were suspended in para-xylene (10 mL) and benzyl bromide (360 uL, 3mmol, 1.2 eq) was added. The reaction was heated to 130° C. overnight.The mixture was diluted with MTBE, washed with water and brine, anddried with Na₂SO₄. After partial concentration in vacuo to a xylenesolution purification using silica gel chromatography (gradient of 0→10%ethyl acetate/hexanes) separated two products, 1-benzyl-5-bromoindazole(364 mg) and 2-benzyl-5-bromoindazole (302 mg).

1-Benzyl-5-bromoindazole (364 mg, 1.3 mmol) was converted to boronicacid 316 (126 mg, 40%) as a white solid using method 3 followed bymethod 5. [M−H]⁻=251.1 m/z. Activity: A.

Example 275

5-Borono-2-aminopyridine pinacol ester (250 mg, 1.1 mmol) and 94%—pure2-bromoacetophenone containing 2,2,-dibromoacetophenone (250 mg, 1.25mmol, 1.1 eq.) were combined in ethanol (2.5 mL) and subjected tomicrowave heating at a temperature of 130° C. for 30 min. The solventwas removed in vacuo and the pinacol ester cleaved using method 5.Purification using silica gel chromatography of the product (gradient of0→30% methanol/methylene chloride) afforded only one compound,brominated imidazopyridine boronic acid 317 (84 mg) as a yellowcrystalline solid. [M−H]⁻=317.0 m/z. Activity: A.

Example 276

1-Boc-4-(4-boronophenyl)piperazine pinacol ester (200 mg, 0.52 mmol) wasconverted, via method 5, to boronic acid 318 (121 mg, 77%) as a whitesolid. [M−H]⁻=305.1 m/z. Activity: B.

Example 277

A solution of 2-chloro-6-bromoquinoline (250 mg, 1.0 mmol) andbenzylnitrile (148 mg, 1.2 mmol, 1.2 eq.) in tetrahydrofuran (20 mL) wastreated with 1.0M NaHMDS in THF (2.6 mL, 2.6 mmol, 2.5 eq.) and stirredat ambient temperature overnight. LC/MS showed complete conversion tothe diarylacetonitrile intermediate. Saturated aqueous ammonium acetate(5 mL) and sodium peroxide (320 mg, 4.1 mmol, 4.0 eq.) were added andthe solution stirred at room temperature for 24 h. LC/MS indicatedincomplete conversion, about 40%. The reaction mixture was diluted withMTBE, washed with water and brine, dried over Na₂SO₄, treated withsilica gel, concentrated, and purified using silica gel chromatography(gradient of 0→8% ethyl acetate/hexanes), giving two products,2-(6-bromoquinoline-2-yl)-2-phenylacetonitrile (185 mg) and2-benzoyl-6-bromoquinoline (97 mg, 30%).

2-Benzoyl-6-bromoquinoline (97 mg, 0.31 mmol) was converted to boronicacid 319 (42 mg, 50%) as a brownish solid using method 3 followed bymethod 5. [M−H]⁻=276.1 m/z. Activity: A.

Example 278

Tert-butyl 3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl) propionate(0.313 g) was dissolved in 5 mL of methylene chloride. Trifluoroaceticacid was added (0.5 mL) and the reaction was allowed to stir overnightat room temperature. The solvent and acid were then removed under vacuumand the crude mixture was azeotroped using toluene (2×50 mL) to providecrude deprotected acid 320 which was used directly.

A portion of acid 320 (72 mg, 1.0 equiv) was dissolved in 1 mLN,N-dimethyl foramide, followed by the addition of PyBOP (190 mg, 1.0equiv) and phenethylamine (50 μL, 1.11 equiv). Triethylamine (150 μL,3.0 equiv) was then slowly added and the reaction was allowed to stir atroom temperature for 30 min. After this point the reaction wastransferred to a separatory funnel with excess water and ethyl acetate.The water layer was extracted with ethyl acetate (3×50 mL) and driedover Na₂SO₄ and concentrated. This residue was used directly to form thedesired boronic acid 321 using method 5 and was purified usingsemi-preparatory reverse phase liquid chromatography. [M−H]⁻=220.1 m/z.Activity: C.

Example 279

Boronic acid 322 was prepared using the analogous procedure as example278 except that 1-(benzyloxycarbonyl)piperazine was used in place ofphenethylamine. [M−H]⁻=319.2 m/z. Activity: B.

Example 280

Boronic acid 323 was prepared using the analogous procedure as example278 except that 1-Boc-piperazine was used in place of phenethylamine[M−H]⁻=285.2 m/z. Activity: C.

Example 281

3-(4-Boronophenyl)propanoic acid (102 mg, 1.0 equiv) was dissolved in 2mL N,N-dimethylforamide after which BOP (293 mg, 1.0 equiv), DIPEA (300μL, 3.2 equiv) and benzylamine (100 uL, 1.78 equiv) were added and thereaction was allowed to stir for 16 h at room temperature. After thispoint, 25 mL of water was added and the mixture was transferred to aseparatory funnel The water layer was extracted with ethyl acetate (2×50mL). The organics were combined, dried over MgSO₄, and concentrated toprovide crude material that was purified by silica gel chromatography(gradient 50% ethyl acetate/hexanes to 1% methanol/ethyl acetate toprovide 88 mg of boronic acid 324. [M−H]⁻=282.2 m/z. Activity: C

Example 282

4-Hydroxyphenylboronic acid (63 mg, 1.0 equiv) was suspended in 2 mL 5%sodium bicarbonate solution and a 12 mL of tetrahydrofuran/watersolution is added (1:1 v/v). 4-(Bromomethyl)phenylboronic acid (116 mg,1.2 equiv) was then added and the reaction was allowed to stir for 16 hat room temperature. After this point, the tetrahydrofuran was removedunder vacuum and the reaction was acidified to pH <2 with 1N HCl. Themixture was transferred to a separatory funnel and the water layer wasextracted with methylene chloride (2×75 mL). The organics were combined,dried over MgSO₄ and concentrated to provide crude material that waspurified by silica gel chromatography (gradient 50% ethylacetate/hexanes to 5% methanol/ethyl acetate to provide boronic acid325. [M−H]⁻=271.1 m/z. Activity: C

Example 283

3-Hydroxyphenylboronic acid (40 mg, 1.05 equiv) and4-(bromomethyl)phenylboronic acid (65 mg, 1.0 equiv) were dissolved in 6mL solution of tetrahydrofuran/N,N-dimethylforamide (1:1 v/v). Sodiumhydride (36 mg, 5.0 equiv) is added and the reaction is allowed to stirat room temperature overnight. Water (25 mL) is then added and thereaction is acidified to pH <2 with 1N HCl and transferred to aseparatory funnel. The water layer is washed with ethyl acetate (1×75mL) and diethyl ether (1×75 mL). The water layer is then concentratedunder vacuum to provide crude oil which is triturated withtetrahydrofuran and methanol to provide the desired boronic acid 326.[2M−3H₂O]⁻=488.0 m/z. Activity: A

Example 284

Part A

4-(1-Boc-piperidin-4-yl)-butanoic acid (6.45 g, 1.0 equiv) was dissolvedin 40 mL methylene chloride and cooled to 0° C. in an ice bath. Ethylchloroformate (2.9 mL, 1.28 equiv) was added followed, byN,N′-dimethylhydroxylamine hydrochloride (2.6 g, 1.1 equiv) andtriethylamine (10 mL, 3.0 equiv). The reaction was allowed to warm toroom temperature overnight during which time the was the formation ofsignificant amounts of white precipitate. The reaction was then dilutedwith water (50 mL) and extracted with methylene chloride (2×75 mL). Thecombined organics were combined, dried over MgSO₄, and concentrated toprovide crude 327 which was used directly in the next step.

Oxazole (710 mg, 1.3 equiv) was dissolved in 5 mL of tetra hydrofuranand cooled to −78° C. in a dry ice/acetone bath. Isopropyl magnesiumchloride (5.0 mL, 2.0 M in diethyl ether, 1.23 equiv) was added over 5minutes and the reaction was allowed to stir for 20 min at −20° C.during which time the solution turned orange. Weinreb amide 327 (2.56 g,1.0 equiv) dissolved in 5 mL tetrahydrofuran was then added and thereaction was allowed to warm to room temp overnight. After this point,40 nil, of saturated ammonium chloride was added after which thereaction was transferred to a reparatory funnel. The water layer waswashed with diethyl ether (2×100 mL). The organic layers were dried overMgSO₄, filtered and concentrated to provide crude material which waspurified using silica gel chromatography (gradient of 20-70% ethylacetate/hexanes) to provide 500 mg of ketooxazole 328.

Part B

Ketooxazole 328 was dissolved in 15 mL diethyl ether. Anhydrous HCl wasbubbled through the solution for a few seconds and allowed to stir for20 min after which point TLC analysis indicated that there was no morestarting material. The r×n was then concentrated and used directly.

4-(Bromomethyl)phenylboronic acid (125 mg, 1.03 equiv) and the HCl saltof 328 (146 mg, 1.0 equiv) were dissolved in 4 mL of methylene chloride.Hunig's base (300 μL) was added and the reaction was allowed to stirovernight with the formation of a significant amount of solid in theflask. The reaction is quenched with water and acidified to pH <2 with1N HCl. However in this case the product stayed in the water layer. Theorganic layer was removed and a 5% solution of sodium carbonate wasadded which caused the desired product to crash out the water layer toprovide boronic acid 329. [M−H]=355.1 m/z. Activity: C.

Example 285

TABLE A Other boronic acids tested

C

D

C

B

D

D

D

B

C

B

A

B

D

C

C

C

D

C

Biological Protocols Example 286 Inhibition of Rat and Human FAAH

The following assays may be used to determine the inhibition of FAAH bythe compounds of the present invention: (1) a fluorescence-based assayfor fatty acid amide hydrolase compatible with high-throughput screeningas described in Manjunath et al., Analytical Biochemistry (2005)343:143-151; and (2) a high-throughput screening for the discovery ofinhibitors of fatty acid amide hydrolase using a microsome-basedfluorescent assay. Wang et al., Biomolecular Screening (2006) 1-9.

Rat FAAH Preparation: Five rat livers were homogenized in five foldvolume with ice cold Tris (20 mM pH 8.0) and 0.32 M Sucrose solution viaan Ultra Turrax T25 homogenizer. All subsequent preparation steps werecarried out at 4° C. The homogenate was centrifuged at 6000 g, for 20minutes and the pellet, containing nuclear debris and mitochondria wasdiscarded. The supernatant was centrifuged at 40,000 g for 30 minutes.The supernatant was discarded and the pellet solubilized via a douncehomogenizer in resuspension buffer (20 mM Hepes pH 7.8, 10% v/vglycerol, 1 mM EDTA, 1% triton X-100) overnight at 4° C. to resolubilizemembrane bound FAAH. The solution was centrifuged at 40,000 g for 30minutes and the pellet discarded. The supernatant containing rat FAAHwas aliquoted and flash frozen with liquid nitrogen and stored for longterm usage at −80° C.

Human FAAH Preparation: COS-7 cells were split the day before, 1:5 into150 mm×25 mm cell culture dishes (Corning Inc., Cat. No. 430599).Transient transfection took place at 30-40% confluency according toFuGENE 6 Transfection Reagent (Roche, Cat. No. 11814 443 001).

Transfection Procedure: The FuGENE transfection 6 reagent (45 uL) wasadded to 1410 μL of media (DMEM, serum free without pen/strep) in a 15mL conical tube and incubated at room temp for 5 minutes, followed bythe addition of FAAH plasmid DNA (15 μg) (OriGene Cat. No. TC119221,Genbank Accession No. NM_(—)001441.1, 0.67 ug/uL) and a furtherincubation of 15 minutes at room temperature. The resulting solution wasadded into one dish of 30-40% confluent COS-7 cells in a drop-wisemanner. The COS-7 cell dish was subsequently incubated for 48 hours. Thecells are then harvested.

Harvest procedure: Media was aspirated from the dishes and the cellsrinsed with 10 mL PBS. The PBS was removed and 3 mL of PBS added to thedish. The dish was scraped to resuspend the cells, and the subsequentcell suspension collected into a 15 mL conical tube. The cells werepelleted by centrifugation at 1200 rpm for 5 minutes in a bench topcentrifuge. PBS was removed and the cell pellet snap frozen in liquidnitrogen and stored at −80° C.

COS-7 Cells—FAAH Purification:

-   -   (1) Fractionation: Frozen cell pellets from transient        transfections were thawed on ice and resuspended in 12.5 mM        Hepes pH 8.0, 100 mM NaCl, 1 mM EDTA (10 mL/0.2 g cell pellet).        The pellets were dounce homogenized and then sonicated to        produce cell extract. The cell extract was subsequently        centrifuged at 1000 g to remove cellular debris. The pellet was        discarded and the supernatant centrifuged at 13,000 g for 20        minutes. The pellet contained membrane bound FAAH. The        supernatant was discarded and the pellet resolubilized.    -   (2) Re-solubilization: The fraction of interest, (13,000 g,        membrane fraction) was re-suspended in 2.3 mL re-suspension        buffer (20 mM Hepes pH 7.8, 10% v/v Glycerol, 1 mM EDTA, 1%        Triton X-100) and the sample incubated on ice for 1 hour and        then centrifuged to remove any particulate matter. The        supernatant containing solubilized human FAAH was aliquoted and        snap frozen in liquid nitrogen and stored at −80° C. until use.    -   (3) Characterization: Protein Concentration determined by        Bradford assay.        -   SDS gel and Western blot to confirm presence of FAAH        -   FAAH activity assay        -   Km determination—96-well assay        -   Linear dependence—96-well assay        -   Standard compound Ki determination—384-well assay

Rat FAAH Biochemical Inhibition Assay; Materials and methods: Rat FAAHbiochemical assays were carried out in a 96 well flat bottom blacknon-treated polystyrene plates (Corning Costar Catalogue #3915). FAAHreaction buffer: 50 mM Hepes (pH 7.5), 1 mM EDTA, 0.2% Triton X-100.FAAH substrate—AMC Arachidonoyl Amide (Cayman Chemicals Company, Catalog#10005098). The reaction was read in an Envision microtiter plate reader[Excitation filter 355 nm (40 nm bandpass); Emmision filter 460 nm (25nm bandpass)]. The raw fluorescence was plotted on the y axis and theinhibitor concentration on the x axis to give a dose response inhibitioncurve. The data was fitted to a single site competitive inhibitionequation, fixing the Km for the rat and human enzyme to 12 μM and 9 μMrespectively.

Rat FAAH Biochemical Inhibition Assay; Experimental Protocol: Theprinciple of this assay was the hydrolysis of AMC-Arichodonoyl, afluorescent analogue of Anandamide, which results in the formation ofArachidonic acid and AMC. The formation of AMC results in an increase influorescence (see, for example, Manjunath et al., AnalyticalBiochemistry (2005) 343:143-151; and Wang et al., Biomolecular Screening(2006) 1-9). The inhibition of product formation and hence fluorescenceas a function of inhibitor concentration enables the determination of Kifor the compounds.

A 0.49 mg/ml Rat liver FAAH solution was made up in FAAH reactionbuffer, and 78 ul pipetted into a 96 well plate. To this was added 2 uLof a 3 fold serially diluted inhibitor from a DMSO stock solution. TheFAAH solution and inhibitor were incubated for 30 minutes at roomtemperature. The FAAH reaction was initiated by the addition of 80 μL of40 μM AMC Arachidonoyl Amide in FAAH reaction buffer, yielding a finalreaction FAAH rat liver preparation concentration of 0.25 mg,/mL andAMC-Arachidonoyl substrate concentration of 20 μM, reaction volume 160μL. The reaction was allowed to proceed for 4 hours at room temperature.The reaction was stopped by the addition of 80 μL 12 uMa-ketoheterocycle (Cayman Chemicals, catalogue #10435). The microtiterplate was read in the envision plate reader.

Human FAAH assay; Experimental Protocol: A 0.1 mg/mL Human FAAH solutionwas made up in FAAH reaction buffer, and 24 ul pipeted into a 384 wellplate. To this was added 1 μL of a 3 fold serially diluted inhibitorfrom a DMSO stock solution. The FAAH solution and inhibitor wereincubated for 30 minutes at room temperature. The FAAH reaction wasinitiated by the addition of 25 μL of 40 μM AMC Arachidonoyl Amide inFAAH reaction buffer, yielding a final reaction human FAAH preparationconcentration of 0.05 mg/ml and AMC-Arachidonoyl substrate concentrationof 20 μM, reaction volume 50 μL. The reaction was allowed to proceed for4 hours at room temperature. The reaction was stopped by the addition of25 μL 12 μM a-ketoheterocycle (Cayman Chemicals, catalogue #10435). Themicrotiter plate was read in the envision plate reader.

The raw fluorescence was plotted on the y axis and the inhibitorconcentration on the x axis to give a dose response inhibition curve.The data was fitted to a single site competitive inhibition equation,fixing the Km for the rat and human enzyme to 12 μM and 9 μMrespectively.

Example 287 Inhibition of FAAH in its Native Cellular Environment

Cellular FAAH inhibition assay: This assay measures the activity of FAAHin its native cellular environment. Radiolabelled anandamide, tritiatedon its ethanolamine component was added to a cell suspension. Anadamidediffuses into the cell, whereby the native cellular FAAH hydrolysesanandamide into arachdonic acid and ethanolamine. The cellular reactionwas quenched in a methanol/chloroform mixture. Ethanolamine partitionsinto the aqueous phase and was counted via a scintillation countergiving a measure of cellular FAAH activity Inhibition studies wereperformed by pre-incubating the cells with serially diluted inhibitor,followed by the addition of radiolabeled anandamide.

Cell preparation: RBL-2H3 and T-47D adherent cells were cultured via thestandard protocols. Cells were trypsinized and washed 3 times in RPMIbuffer plus 0.1% BSA. The cells were resuspended, counted and diluted toa final cell density of 1×10⁶ cells/mL. Human PBMC were isolated fromwhole blood and used at a final cell density of 4.5×10⁶ cells/mL in RPMIplus 0.1% BSA buffer.

Anandamide substrate solution: A 10 nM ³H anandamide substrate solutionwas prepared by diluting from a 16.7 μM (1 μCi/μL) stock in RPMI bufferplus 0.1% BSA, and incubated at room temperature for 90 minutes. Asubstrate-inhibitor solution was made by adding serially dilutedinhibitor from a DMSO stock solution to the desired concentration intothe substrate solution.

Assay: A 350 μL cell suspensions was incubated with serially dilutedinhibitor added from a DMSO stock and incubated for 30 minutes withconstant agitation. Cells were pelleted and the supernatant removed. Thecells were resuspended in 300 μL of 10 nM substrate+serially dilutedinhibitor, to maintain a constant free inhibitor concentration duringthe time-course of the reaction. The RBL-2H3 and T-47D cells wereincubated with the substrate—inhibitor for 5 minutes and PBMC for 15minutes. The reaction was quenched by the addition of 700 μL ofmethanol:chloroform (1:1 v/v), which lyses the cells and inactivatesFAAH. Sampled were vortexed and centrifuged to separate the aqueous andorganic solutions. ³H ethanolamine, the polar product of anandamidehydrolysis partitions into the aqueous phase and was counted via ascintillation counter.

Data Analysis: The radioactivity in the aqueous phase was plotted withrespect to inhibitor concentration to generate dose response inhibitioncurves, and the data fitted to determine the IC₅₀.

Example 288 FAAH Cell-Based Assay Protocol for Human and Rat Whole Blood

This assay measures the cellular activity of FAAH in whole blood via thehydrolysis of radiolabeled anandamide by the same methodology andprinciple used in the cell based assay described in Example 172. FAAH isfound to be expressed in the cells of the immune system.

Substrate Solution: ³H Anandamide (1 μC/μL, 16.7 μM stock) was added toa final concentration of 40 nM (4×) for the human whole blood assays and20 nM (2×) for rat whole blood assays to the RMPI buffer plus 0.1% BSA.The ³H anandamide stock solutions were incubated for 90 minutes at roomtemperature prior to use in the whole blood assay.

Human whole Blood Cellular FAAH assay: Human blood (262.5 μL) waspre-incubated with serially diluted inhibitor added from DMSO stocksolution for 30 minutes. The assay was initiated by the addition of 40nM ³H anandamide (87.5 μL) yielding a final assay volume of 350 μL and³H anandamide substrate concentration of 10 nM. The reaction mixture wasincubated for 30 minutes at room temperature, and the reaction stoppedby the addition of 700 μL of methanol: chloroform (1:1 v/v). This lysesthe cells and inactivates the FAAH. The solution was vortexed and ³Hethanolamine, the radiolabeled product of ³H anandamide hydrolysispartitioning into the aqueous phase, and was counted via a scintillationcounter.

Rat whole Blood Cellular FAAH assay: Rat blood (175 μL) waspre-incubated with serially diluted inhibitor added from DMSO stocksolution for 30 minutes. The assay was initiated by the addition of 20nM ³H anandamide (175 μL) yielding a final assay volume of 350 ul and ³Hanandamide substrate concentration of 10 nM. The reaction mixture wasincubated for 30 minutes at room temperature, and the reaction stoppedby the addition of 700 μL of methanol: chloroform (1:1 v/v). This lysesthe cells and inactivates the FAAH. The solution was vortexed and ³Hethanolamine, the radiolabeled product of ³H anandamide hydrolysispartitioning into the aqueous phase, and was counted via a scintillationcounter.

Data Analysis: The radioactivity in the aqueous phase was plotted withrespect to inhibitor concentration to generate dose response inhibitioncurves, and the data fitted to determine the IC₅₀.

Example 289 In Vivo Analysis of Boronic Acid and Boronic EsterDerivatives in a Pain Model

This assay may be used to evaluate the effect of the compounds of thepresent invention on the reflexive withdrawal of the rat from an acutenoxious stimulus (hot surface).

(1) Heat plate to testing temperature (Hot plate analgesia meter;Harvard Apparatus)—takes about 10-15 min (the actual surface temperatureis not reflected in the LED read out. The actual surface temperature is10° C. less than the read out indicates).

Read-out Surface temp 57° C. 47° C. 62° C. 52° C. 65° C. 55° C.

(2) Place plexi-glass cylinder on hot plate. Place rat within cylinderand start timer. When the rat either licks its hind paw or jumps, stopthe timer and remove from hot plate. Record the response latency (insec), usually 6-7 sec at 52° C. Measure baseline latencies for all rats.

(3) Inject drug or vehicle.

(4) Measure response 5, 15, 30, 60, 90, 120 min, etc. after druginjection. Cut-off time for 52° C. is 30 sec. A rat that does notrespond by 30 sec. is assigned a latency of 30 sec.

(5) Clean hot plate surface in between time points with water, dry withkimwipe and wait until temperature read out has returned to 57° C.

Data may be expressed as either latency or percent maximum possibleeffect [% MPE=(drug latency−baseline latency)/(cut-off−baselinelatency)×100].

Other temperatures may be used (e.g., 47° C., 55° C.). Cut-off timeshould be adjusted accordingly (e.g., 40 sec at 47° C.; 20 sec at 55°C.). Increased temperatures recruit myelinated afferents (Aδ-fibers)whereas lower temperatures involve unmyelinated afferents (c-fibers).Sensitivity to drug effects may be altered with different platetemperatures.

Example 290

Evidence for Covalent Complex Formation between Serine-241 of FAAH andBoronic Acid Inhibitors

Treatment of rat FAAH protein with the active site-directed irreversibleinhibitor methoxy arachidonyl fluorophosphonate results in a crystalstructure wherein methoxy arachidonyl phosphonate is covalently bound tothe side chain of Ser-241 (Bracey et al., Science (2002) 298:1793-1796).

Based on this data, it is hypothesized that the boronic acid compoundsprovided by the present invention form reversible covalent complexeswith the nucleophilic side chain of Ser-241. This hypothesis isconsistent with the kinetic data. Molecular modeling studies of arylboronic acid compounds provided herein indicates that the aryl ring canbe directed to bind either in the narrow hydrophobic channel of theenzyme near Ser241, which is confluent with the membrane portion and theacyl chain binding pocket, or alternatively bind toward the cytosolicportion.

To distinguish between these two binding modes, a mutant protein wascloned and expressed which was identical to the rat FAAH proteinsequence, except at four positions in the sequence: 1491V, V495M, L192F,and F194Y. These four residues line the narrow hydrophobic channel nearSer-241 in the rat x-ray structure. Starting from the published X-raycrystal structure of rat FAAH, a 3-D homology model was built of humanFAAH using the program DeepView (Nicolas Guex, Manuel Peitsch, TorstenSchwede Alexandre Diemand “DeepView/Swiss-Pdbviewer” (1995-2001)). Basedon this 3-D homology model of the human protein, mutation of these fourresidues to the corresponding amino acids in the human sequence waspredicted to significantly influence the binding of the aryl boronicacid compounds if the aryl ring is in close proximity to these residues.

The inhibition constant (K_(i)) was measured for a panel of elevenboronic acid-containing compounds differing in their ability to inhibitrat and human FAAH. Table B below summarizes the statistical analysisfor the panel of eleven compounds, comparing the ratio of inhibitionconstants for the wild-type rat and human enzymes (R/H) to ratio ofinhibition constants for the mutant rat and human enzymes (M/H). Thedata indicates that the compounds bind at Serine-241 with the aryl ringdirected toward the narrow hydrophobic channel.

TABLE B R/H M/H 11 11 nObs 2.99 1.08 Mean 3.45 0.48 StDev 0.02 0.49 Min11.86 1.8 Max

Equivalents

Those skilled in the art will recognize, or be able to ascertain usingno more than routine experimentation, many equivalents to the specificembodiments of the invention described herein. Such equivalents areintended to be encompassed by the following claims.

1.-73. (canceled)
 74. A compound of the following formula:

or a pharmaceutically acceptable salt or prodrug thereof; wherein: (i)Z¹ is —OH or —OR³ and Z² is —OH, —OR⁴, an optionally substituted C₁₋₈alkyl, optionally substituted C₂₋₈ alkenyl, optionally substituted C₂₋₈alkynyl, optionally substituted C₁₋₈ heteroalkyl, optionally substitutedC₂₋₈ heteroalkenyl, optionally substituted C₂₋₈ heteroalkynyl,optionally substituted C₃₋₁₀ carbocyclyl, optionally substituted 3-10membered heterocyclyl, optionally substituted C₆₋₁₀ aryl, or optionallysubstituted 5-10 membered heteroaryl; (ii) Z¹ and Z² taken together withthe boron atom to which they are bound, form a 5- to 8-membered ringhaving at least one O, S, N or NR⁵ atom directly bonded to the boronatom; or (iii) Z¹ is —OH or —OR³, and Z² and Ring A taken together forman optionally substituted 5- to 7-membered ring; W³ is C, CR¹⁵ or N; Xis a covalent bond, —O—, —N═N—, —C═N—, —NR⁶—, —C(NR⁶)—, —S—, —C(O)—,—S(O)—, —S(O)₂—, or optionally substituted C₁₋₆ alkylene, wherein one,two or three methylene units of the C₁₋₆ alkylene are optionally andindependently replaced with one or more groups selected from —O—, —N═N—,—C═N—, —NR⁶—, —C(NR⁶)—, —S—, —C(O)—, —S(O)—, and —S(O)₂—; each instanceof R¹ is, independently, halogen, —OR⁸, —CF₃, —CN, —NO₂, —SO₂R⁸, —SOR⁸,—C(O)R⁸, —CO₂R⁸, —C(O)N(R⁸)₂, —CHO, —N₃, —N₂R⁸, —N(R⁸)₂, —B(OH₂),optionally substituted C₁₋₈ alkyl, optionally substituted C₂₋₈ alkenyl,optionally substituted C₂₋₈ alkynyl, optionally substituted C₁₋₈heteroalkyl, optionally substituted C₂₋₈ heteroalkenyl, optionallysubstituted C₂₋₈ heteroalkynyl, optionally substituted C₃₋₁₀carbocyclyl, optionally substituted 3-10 membered heterocyclyl,optionally substituted C₆₋₁₀ aryl, or optionally substituted 5-10membered heteroaryl; each instance of R² is, independently, halogen,—OR⁹, —CF₃, —CN, —NO₂, —SO₂R⁹, —SOR⁹, —C(O)R⁹, —CO₂R⁹, —C(O)N(R⁹)₂, —N₃,—N₂R⁹, —N(R⁹)₂, optionally substituted C₁₋₈ alkyl, optionallysubstituted C₂₋₈ alkenyl, optionally substituted C₂₋₈ alkynyl,optionally substituted C₁₋₈ heteroalkyl, optionally substituted C₂₋₈heteroalkenyl, optionally substituted C₂₋₈ heteroalkynyl, optionallysubstituted C₃₋₁₀ carbocyclyl, optionally substituted 3-10 memberedheterocyclyl, optionally substituted C₆₋₁₀ aryl, or optionallysubstituted 5-10 membered heteroaryl; each instance of R³ and R⁴ is,independently, optionally substituted C₁₋₈ alkyl, optionally substitutedC₂₋₈ alkenyl, optionally substituted C₂₋₈ alkynyl, optionallysubstituted C₁₋₈ heteroalkyl, optionally substituted C₂₋₈ heteroalkenyl,optionally substituted C₂₋₈ heteroalkynyl, optionally substituted C₃₋₁₀carbocyclyl, optionally substituted 3-10 membered heterocyclyl,optionally substituted C₆₋₁₀ aryl, or optionally substituted 5-10membered heteroaryl; each instance of R⁵, R⁶, R⁸ and R⁹ is,independently, hydrogen, —SO₂R¹¹, —SOR¹¹, —C(O)R¹¹, —CO₂R¹¹,—C(O)N(R¹¹)₂, —C(O)NH(R¹¹), —C(O)NH₂, optionally substituted C₁₋₈ alkyl,optionally substituted C₂₋₈ alkenyl, optionally substituted C₂₋₈alkynyl, optionally substituted C₁₋₈ heteroalkyl, optionally substitutedC₂₋₈ heteroalkenyl, optionally substituted C₂₋₈ heteroalkynyl,optionally substituted C₃₋₁₀ carbocyclyl, optionally substituted 3-10membered heterocyclyl, optionally substituted C₆₋₁₀ aryl, or optionallysubstituted 5-10 membered heteroaryl; each instance of R¹¹ is,independently, optionally substituted C₁₋₈ alkyl, optionally substitutedC₂₋₈ alkenyl, optionally substituted C₂₋₈ alkynyl, optionallysubstituted C₁₋₈ heteroalkyl, optionally substituted C₂₋₈ heteroalkenyl,optionally substituted C₂₋₈ heteroalkynyl, optionally substituted C₃₋₁₀carbocyclyl, optionally substituted 3-10 membered heterocyclyl,optionally substituted C₆₋₁₀ aryl, or optionally substituted 5-10membered heteroaryl; R¹⁵ is hydrogen, halogen, —CF₃, optionallysubstituted C₁₋₈ alkyl, optionally substituted C₂₋₈ alkenyl, oroptionally substituted C₂₋₈ alkynyl; n is 0, 1, 2 or 3; and with theproviso that the following compounds are excluded:


75. The compound of claim 74, wherein W³ is C or CR¹⁵.
 76. The compoundof claim 74, wherein W³ is N.
 77. The compound of claim 74, wherein X isa covalent bond, —O—, —(CH═CH)— or —(CH₂)—.
 78. The compound of claim74, wherein Z¹ and Z² are both OH.
 79. The compound of claim 78, whereinn is
 0. 80. The compound of claim 79, wherein R² is optionallysubstituted C₁₋₈ alkyl.
 81. The compound of claim 80, wherein the C₁₋₈alkyl is substituted with optionally substituted phenyl.
 82. Thecompound of claim 80, wherein the C₁₋₈ alkyl is substituted with —CF₃ or—CF₂CF₃.
 83. The compound of claim 80, wherein the C₁₋₈ alkyl issubstituted with an optionally substituted 5- or 6-membered ring having0-4 heteroatoms selected from N, O or S.
 84. The compound of claim 80,wherein the C₁₋₈ alkyl is substituted with) —N(R⁰)C(O)OR⁰, wherein eachR⁰ is independently hydrogen or C₁₋₈ alkyl.
 85. The compound of claim79, wherein R² is optionally substituted C₆₋₁₀ aryl or optionallysubstituted 5 to 10 membered heteroaryl.
 86. The compound of claim 74,wherein n is
 1. 87. The compound of claim 86, wherein R¹ is a halogen or—CF₃.
 88. The compound of claim 86, wherein R² is optionally substitutedC₆₋₁₀ aryl.
 89. The compound of claim 74, which is:

or a pharmaceutically acceptable salt or prodrug thereof.
 90. Apharmaceutical composition comprising a compound, or a pharmaceuticallyacceptable salt or prodrug thereof, of claim 74, and a pharmaceuticallyacceptable excipient, medium, or carrier.
 91. A method of treating anFAAH-mediated disease, disorder or condition comprising administering toa patient a therapeutically effective amount of a compound of claim 74,or a pharmaceutically acceptable composition thereof.
 92. The method ofclaim 91, wherein the FAAH-mediated disease, disorder or condition ispainful condition, disease or disorder, inflammatory disorders, immunedisorders, depression, anxiety, anxiety-related disorders, sleepdisorders, feeding behaviors, movement disorders, glaucoma,neuroprotection or cardiovascular disease.